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Exploring the interaction between asymmetric phosphonates and acetylcholinesterase.  
Probing the gorge and P-site via customized covalent modification. 
 
Chairperson:  Charles M. Thompson 
 
  Organophosphates (OPs) react with acetylcholinesterases (AChEs) to form a covalent 
bond at a specific serine residue in the active gorge, thereby providing a highly precise 
modification of this enzyme and an opportunity to explore protein structure, function and 
mechanism.  The goal of this study is: 1) to show how covalent modification of AChEs 
by chromophore-linked OPs can be used to probe the active and peripheral sites of the 
protein and its local environment; 2) to differentiate AChE stereoselectivity with 
asymmetric phosphonothiolates. 
  Click chemistry was used as a key transformation method to prepare an array of 
chromophores linked to a reactive fluorophosphonate (FP) head group.  Chromophore-
linked FPs varying in length and chromophore were synthesized and computer-modeled 
to visualize and calculate positioning of the chromophore-FP-AChE relative to the 
protein active gorge.  The inhibition rates of chromophore-FPs against recombinant 
mouse AChE (rMAChE) and electric eel AChE (EEAChE) were determined via 
colorimetric assay and the dansyl containing FPs were demonstrated to be the most 
potent.  In addition, the binding effects of the chromophore and FP moiety to protein 
were evaluated and results demonstrated that the size and structure of chromophore and 
the length of the ligands mutually affect the inhibition potency.  Dansyl, dabsyl and 
pyrene were the best chromophores with least interaction with AChEs.  
  To examine the interactions of asymmetric analogs of the OP compounds within the 
steric confines of AChEs, the synthesis of phosphonothiolate enantiomers as anti-AChEs 
was conducted using a chiral auxiliary for separation.  X-ray analysis and 31P NMR were 
used to show an exclusively separation of the two diastereomers.  The kinetic parameters 
ki and KD for the inhibition of recombinant human AChE (rHuAChE) were determined.  
A 4-fold difference in anti-AChE potency was observed between Sp (ki = 1.7 x 103 M-
1min-1) and Rp (ki = 9.0 x 103 M-1min-1).  These enantiomers link to the chromophores via 
click reaction to form chromophore-linked asymmetric phosphonothiolates (CLAPs), 
which can be used to study AChE stereospecificity.  
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CHAPTER 1 
 
 
INTRODUCTION 
 
This research attempts to study how covalent modification of 
acetylcholinesterases (AChEs) by organophosphonates (OPs) can be used to probe 
structure and differentiate between enzymes and their mechanisms.  Specifically, the 
objectives include: 1) syntheses of a panel of customized, racemic OP probes of AChE 
bearing reactive moieties and reporter groups, 2) covalent inactivation of AChEs by 
custom OP probes to seat a tethered chromophore at a predictable depth within the 
protein to determine the interaction between the ligand and the enzyme; 3) syntheses and 
anti-AChEs analysis of asymmetric OP custom probes to elucidate the stereospecificity 
of AChEs. 
The broader impact of this study is that AChEs are essential to neuromuscular and 
brain function through the breakdown of neurotransmitter (NT) and other esters.  OP 
compounds impose a majority of their toxic action through biochemical interactions with 
AChEs.  Health concerns originating from the high toxicity of OP nerve gases, and more 
importantly the use of OP insecticides make the understanding of mechanism of OP-
AChE interaction an imminent task. 
Acetylcholinesterases (AChEs) are ideal enzymes for mechanistic studies and 
method development due to a rich database about their structure, catalytic mechanism, 
 2 
and functional knowledge of their active sites (Taylor, 1994; 1995).  Chapter 2 of this 
thesis discusses the AChE background in greater details, explicating the two interaction 
sites on the protein: the catalytic active site and the peripheral active site.  The catalytic 
active site (A-site) responsible for hydrolysis of acetylcholine (ACh) is comprised of a 
catalytic triad (His-Glu-Ser) located halfway through the protein at the bottom of a 20Å 
gorge that connects to the protein surface.  The peripheral site (P-site) located on the 
entrance of the gorge attracts cation substrates that transiently bind prior to gorge entry 
and eventually arrive at the A-site.  AChE activity can be suppressed by introducing 
interacting molecules at the A-site, at the P-site, or both.   
Typically, OP compounds block the A-site at the catalytic serine of AChE by a 
covalent modification.  Certain cation ligands like propidium inhibit AChE via P-site 
binding in a process termed ‘steric blockage’ (Johnson, 2003; Roseberry, 1999; 
Mallender, 1999).  The most potent inhibitor was recently manufactured by taking the 
advantage of dual binding to both the A- and P-sites while using the gorge to connect the 
two inhibitor pieces (Lewis, 2002).  To investigate the P-site mechanism 
spectroscopically, and optimize the dual binding opportunity, various types of 
chromophores are envisioned as potential P-site inhibitors.  Their-linked OP moieties are 
designed to covalently modify the A-site to place the chromophore at the P-site to probe 
the interaction with the enzyme.  Chapter 4 centers on the design and synthesis of a panel 
of chromophore-linked fluorophosphonates (FPs) that vary in the ligand length and 
chromophore structure to optimize this dual binding effect.   
The inhibition rate (ki) is a general measurement of the anti-AChE potency of OP 
and therefore, FP compounds.  In Chapter 5, a comparison between chromophore-FPs 
 3 
and a control containing only FP moiety in the inhibition potency is discussed and 
demonstrates that the size and structure of chromophore and the length of the ligands 
mutually affect the inhibition potency.  To visualize and calculate positioning of the 
chromophore-FP-AChE relative to the protein active site/gorge/peripheral site, molecular 
modeling of the chromophore-FP:AChE complex are also presented in Chapter 5.  The 
docking results further explained the steric blockage effect of the big chromophores.  
Although the A-site of AChE has been the principle target for researchers to 
investigate and known for its highly conserved and sterically constrained structure, the 
stereoselectivity of OP-AChE interaction in phosphorylation and dephosphorylation 
processes remains unclear and recently emerged as a hot topic.  Previous studies have 
shown that phosphorus stereochemistry dictates the extent and the rate of inhibition and 
reactivation of AChE (Doorn, 2000, 2001; Ryu, 1991; Berkman, 1993).  To address the 
stereospecificity of AChEs and other OP-reactive proteins in a greater detail, more 
available and generally applicable asymmetric phosphorus compounds are desired.   
Different methods to synthesize asymmetric phosphonothiolates are discussed in 
this study and a reliable and flexible synthetic route for preparation of asymmetric 
phosphonothiolates is proposed (details in Chapter 4).  The phosphonothiolates 
enantiomers are prepared with an attached propylazo group as the building blocks for the 
‘click’ reaction, providing our study in the immediate future a specific opportunity to 
construct the chromophore-linked asymmetric phosphonothiolates (CLAPs) via click 
reaction and observe this stereospecificity spectrally and quantitatively. 
The phosphonothiolate enantiomers undergo reactions with AChE with ejection 
of a thiol group to generate stereoselectively-modified AChE that can be examined by 
 4 
various means.   In Chapter 5, the kinetic parameters ki (inhibition rate constant) and KD 
(dissociation constant) of the phosphonothiolate enantiomers for the inhibition of 
recombinant human AChE (rHuAChE) were examined to demonstrate differences in anti-
AChE potency between Sp and Rp - isomers.   
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CHAPTER 2 
 
 
BACKGROUND 
 
2.1 ACh, AChE and the Cholinergic System 
 
Acetylcholine (ACh) is one of the oldest and best understood neurotransmitters in 
the mammalian central nervous system (CNS).  ACh is synthesized in and released from 
cholinergic neurons, which are localized in various parts of the CNS.  Cholinergic 
neurons projecting from basal forebrain nuclei play important roles in cognitive processes 
such as learning and memory.  Cholinergic neurons in striatum are involved in 
movements and motor functions.  Degeneration and dysfunction of cholinergic neurons 
are related to several neurodegenerative diseases such as Alzheimer’s disease (Evans, 
1989; Kihara, 2004) and Huntington’s disease (Pisani, 2001; Growdon, 1977). 
In presynaptic cholinergic neurons, ACh is synthesized from choline and acetyl 
CoA through the action of choline O-acetyltransferase (ChAT) (Parsons, 1993) (Scheme 
2.1).  
 
+ H3C
O
S
CoA
Choline 
acetyltransferase
CH3
N+H3C
H3C
OH
CH3
N+H3C
H3C
O
O
CH3
+ HS CoA
Choline Acetyl CoA Acetylcholine Coenzyme A  
Scheme 2.1. Synthesis of acetylcholine. 
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Dietary choline and phosphatidylcholine serve as the sources of free choline for 
ACh synthesis.  Acetyl CoA is derived during the metabolism of glucose.  Newly 
synthesized ACh is translocated into synaptic vesicles by the vesicular ACh transporter 
(VAChT).  When the nerve impulse reaches the synapse, triggered by calcium gradient, 
synaptic vesicles containing ACh fuse with presynaptic membrane (exocytosis) and 
release ACh into the synaptic cleft (Fig 2.1).   
 
 
Figure 2.1. Cholinergic synapse (adapted from Feldman 1984). 
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A single motor-nerve terminal contains 300,000 or more vesicles (Katz, 1965) 
and single synaptic vesicles are estimated to contain from 1,000 to over 5,000 ACh 
molecules each.  When released into synaptic cleft, ACh activates cholinergic receptors 
on membranes of postsynaptic neuron and proximal glia (Aschner, 2000).  There are two 
major types of cholinergic receptors: nicotinic receptor and muscarinic receptor.  The 
nicotinic receptor is a ligand-gated channel composed of five subunits.  The activation of 
nicotinic receptor results in a rapid membrane depolarization caused by the influx of Na+ 
and Ca2+ and excitation.  Nicotinic receptors are primarily responsible for the peripheral 
effects of ACh at the autonomic ganglia and the neuromuscular junction (Itier, 2001).  
Muscarinic receptors belong to a big family of G-protein coupled receptors (GPCRs).  
The activation of muscarinic receptor involves the binding of GTP to the receptor and 
initiation of second messenger systems, which lead to a cascade of intercellular pathways.  
Muscarinic responses are slower, compared with nicotinic receptor, and may produce 
excitation or inhibition (Eglen, 2006). 
Following the repolarization of postsynaptic neurons, ACh left in the synaptic 
cleft must be removed immediately to avoid hyperpolarization.  This is achieved by 
enzyme-catalyzed hydrolysis of ACh.  The enzyme involved in this process is called 
acetylcholinesterase (AChE).  
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2.2 Structural and Mechanistic Features of AChE 
 
Acetylcholinesterase (AChE) is a 60 KDa protein belonging to the alpha/beta 
hydrolase family.  Depending on the functions, AChE exists in several forms and is 
localized both intracellularly and extracellularly.  Cytosolic AChE is responsible for 
breaking down excess intracellular ACh and AChE in the synaptic cleft or the 
neuromuscular junction clears extracellular ACh.   
Structurally, the Torpedo California AChE (TcAChE) is similar to most 
alpha/beta hydrolases, with 12 beta sheets surrounded by 14 alpha helices (Sussman, 
1991).  The x-ray crystal structure of TcAChE demonstrated the presence of a long and 
narrow gorge, approximately 20 Å deep leading to the active site.  The gorge is lined with 
conserved aromatic residues and only approximately 5 Å wide defined by Tyr121 and 
Phe330 residues.  Because the diameter of the quaternary portion of ACh is 6.4 Å, 
substantial conformational change of the gorge must be involved in the translocation of 
the substrate molecules (Colletier, 2006).   
The kinetic models for AChE (Marcel, 1998; Johnson, 2003) suggest that there 
are at least two substrate-binding sites, the active site, at the bottom of the active-gorge, 
and the peripheral anionic site (PAS), near the entrance of the gorge (Figure 2.2).  
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Figure 2.2. Structure of Torpedo AChE with the surface of the gorge outlined as a purple 
surface (Adapted from Silman, 2005).  
 
 
The active site is composed of two subsites:  the esteratic subsite and the catalytic 
anionic subsite (CAS).  The esteratic subsite in AChE (Figure 2.3) contains a typical 
serine-hydrolase catalytic triad, Ser200-His440-Glu327 in TcAChE (in mammalian 
AChE, Ser203-His447-Glu334) (Harel, 1993; Sussman, 1991).  A few important 
structure components with contribution to ACh binding in the active site have been 
identified over the years, including the oxyanion hole formed by residues Gly118, 
Gly119 and Ala201, the acyl-pocket formed by Trp233, Phe288, Phe290 and Phe331 
(Harel, 1996).  The CAS contains no negative charged residues, but the indole ring of 
Trp84, and Glu199 and Phe330, which makes a cation-π interaction with the quaternary 
group of ACh (Sussman, 1991). 
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The active site inhibitors inactivate AChE and prevent the substrate molecule 
from binding, either by interacting with the active site with high affinity and occupying 
the site (such as tacrine, Wlodek, 1996) or by reacting irreversibly with the active site 
(such as organophosphates and carbamates, Bartolucci, 1999).  
 
 
Figure 2.3. Important residues in the 
esteratic subsite (Harel, 1993; 
Sussman, 1991). 
 
Figure 2.4. The catalytic anionic subsite 
(Harel, 1993; Sussman, 1991). 
 
 
 
Site-directed mutagenesis studies and binding studies of inhibitors such as 
propidium, BW284C51, d-tubocurarine (Fig 2.6), the mamba venom toxin, and fasciculin 
(Radić, 1991, 1994; Barak, 1994), revealed that three essential amino acids, Trp279, 
Tyr70 and Asp72 (Figure 2.5), form the peripheral anionic site (PAS) (Johnson, 2006).  
The solution of the 3D structures of above AChE-inhibitor complexes further supported 
the hypothesis (Harel, 1993; Bourne, 1999; 2003).   
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Figure 2.5. Structure of Torpedo AChE showing the PAS-associated residues (shown in 
space filling mode): Tyr 70, Asp 72, Trp 279, Tyr 121 and Tyr 334 (Adapted from 
Johnson, 2006). 
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Figure 2.6. Structures of propidium, BW284C51 and d-tubocurarine. 
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The PAS has been demonstrated to be involved in catching and guiding substrate 
molecules into the active site, and likely gives rise to allosteric modulation of the 
enzymes activity (Zhou, 1998).  Inhibition of the PAS can inactivate the enzyme activity 
because of the resulting conformational changes.  It has also been proposed that the 
substrate binding to the PAS prevents the hydrolyzed choline from leaving the active site 
(Rosenberry, 1999; Johnson, 2003, Stojan, 2004).   
Bis-quaternary cation inhibitors such as decamethonium, simultaneously bind to 
the active and peripheral sites, thus occupying the entire catalytic gorge, which is known 
as ‘dual-site binding’ (Harel, 1993). 
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2.3 AChE Hydrolysis of ACh 
 
AChE is a serine hydrolase that belongs to the esterase family within higher 
eukaryotes.  This family acts on different types of carboxylic esters.  The primary 
biological role of AChE is the rapid termination of the neuronal impulse that occurs when 
ACh is released into the synaptic cleft.  Following the production of an end-plate 
potential at the motor end plates of skeletal muscle or the polarization of the postsynaptic 
neurons, AChE removes ACh from the synaptic cleft by catalyzing its hydrolysis to 
acetate and choline (Scheme 2.2, Schumacher, 1986). 
 
H3C
N+H3C
H3C
OH
CH3
N+H3C
H3C
O
O
CH3
+
cholineacetylcholine
AChE
H3C
O
O
acetic acid  
Scheme 2.2. Hydrolysis of acetylcholine by acetylcholinesterase. 
 
AChE hydrolysis of ACh demonstrates the hallmark elements of an acid-base 
catalyzed reaction, including both acetylation and deacetylation processes.  Acetylation 
of the serine hydroxyl (Ser 200) within the esteric subsite is catalyzed by the basic 
imidazole moiety in His440 and the acidic moiety in Glu327.  Free AChE is regenerated 
by a deacetylation step assisted by water.  A simplistic representation of the AChE active 
site for the hydrolysis of ACh is outlined in Scheme 2.3.  In addition to the regions shown 
in the scheme, it has also been proposed that the PAS facilitates initial association and 
alignment of ACh (Zhou, 1998) and the quaternary trimethylammonium choline moiety 
of ACh is stabilized principally via a cation-π interaction with Trp84, Glu199 and Phe330 
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in the CAS (Sussman, 1991).  It is emphasized that AChE is a highly complex and 
dynamic protein, and consequently, there are a number of hydrophobic/hydrophilic 
regions in the active gorge that may be involved in allosteric modulation of the hydrolysis 
activity.  
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Scheme 2.3. Mechanism of ACh hydrolysis by AChE. 
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2.4 Organophosphorus Compounds (OPs) 
 
Organophosphorus (OP) compounds are derived from phosphoric, phosphonic or 
phosphinic acids and the phosphorus-linked oxygens are substituted by sulfur or nitrogen 
atoms.  General structures of several OP compound types are shown in Figure 2.7.   
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Figure 2.7. Nomenclature of OP compounds. 
 
Organophosphorus compounds are used primarily as pesticides, drugs and nerve 
agents imposing their toxicity through the inhibition of AChE.  It is a requirement for 
anti-AChE activity that one of the ligands attached to the phosphorus atom must be a 
good leaving group.  Fluoro(-F), thiol (-SR), phenoxy (-OPhNO2) and cyano (-CN) 
groups are some among the common but better leaving groups.  A few well-known OP 
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insecticides and chemical warfare agents are listed in Figure 2.8.  The majority of 
organophosphorus insecticides are phosphorothioates; nerve agents are phosphonates or 
phosphonothioates whereas industrial chemicals are typically organophosphates.  
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Figure 2.8. OP insecticides and their metabolites, chemical warfare agents, and designed 
compounds for potency or selectivity.  
 
 
Most fluorophosphonates, especially those with short branched-chain alkyl groups, 
have shown a powerful inhibitory action on acetylcholinesterase (Saltmarsh, 2000; 
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Steinberg, 1989).  Fluorophosphonates (FPs) bearing a chromophore have been used as 
probes for the active site of AChE (Saltmarsh, 2000; Steinberg, 1989; Amitai, 1982; 
Berman, 1978).  This aspect of OP reactivity will be discussed in greater detail in the 
following sections. 
A thiol (-SR) leaving group is preferred in many studies towards AChE 
stereospecificity.  A phosphonothionate compound is prone to undergo thiono-thiolo 
rearrangements to offer a phosphonothiolate, which is an OP compound with a thiolate 
ester leaving group (Scheme 2.4).  This isomerization process can be induced by thermal 
and chemical means (Eto, 1974; Metcalf, 1953).  
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Scheme 2.4. Thiono-thiolo rearrangement. 
 
The thiono-thiolo rearrangement can be triggered by reaction of a 
phosphonothionate with an alkyl iodide to form S-alkyl isomer by alkylating the thionate, 
following with dealkylation.  Intermolecular or self-isomerization occurs primarily at 
elevated temperatures when one phosphonothionate is dealkylated to produce an ambient 
 18 
ion pair that realkylates at the more nucleophilic sulfur atom (Scheme 2.4).  The 
rearrangement of OP compounds with thiolate esters as leaving groups is studied in more 
detail in Chapter 4.   
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2.5 Mechanism and Kinetics of AChE Inactivation by OPs 
 
The inhibition of AChE can be categorized into two classes based on their 
inhibition mechanisms.  The first class of inhibitors acts to competitively impede 
hydrolysis without reacting with the enzyme (discussed in Section 2.8).  Others inhibit 
AChE by interacting with the serine in the active site and the resulting inhibitor-AChE 
adduct is more stable than acetate and resistant to hydrolysis. 
Organophosphorus compounds inactivate AChE by phosphorylating the active 
site serine hydroxyl where one ligand of phosphorus is displaced as the leaving group 
(Scheme 2.5).  This produces a covalently modified AChE which is catalytically inactive.  
The first step in the inactivation of AChE involves the reversible formation of an 
enzyme-inhibitor complex and is represented by the equilibrium constant, KD (the 
quotient of dissociation rate constant: association rate constant) (Main, 1964).  KD  is 
generally considered as a measure of an OP’s affinity for the enzyme active site  (Fukuto, 
1990).  The second step of inhibition leads to the irreversible phosphorylation of AChE 
by forming a covalent bond.  The chemical covalent modification of the serine hydroxyl 
is responsible for the ultimate loss in the enzyme activity of hydrolyzing ACh.  The 
phosphorylation rate constant kp is a measure of the reactivity of the enzyme-inhibitor 
complex (Main, 1964; Fukuto, 1990).  The overall rate of inhibition is presented as the 
bimolecular reaction (or rate) constant, ki.  This parameter is a function of both KD and kp 
(ki = kp/KD) and is a measure of the inhibition potency of an OP inhibitor.   
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Scheme 2.5. Mechanistic and kinetic description of AChE inactivation by an OP. 
 
The bimolecular reaction constant ki, dissociation constant KD, and 
phosphorylation constant kp can be determined by a concentration-dependent method, 
using Equations 2.1 and 2.2 as defined by Main (Main, 1964): 
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  [i] is the concentration of inhibitor; 
∆t is the time of incubation; 
v
v
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in which: 
v0 is the control rate of enzyme; 
v is the rate for sample with inhibitor; 
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Typically, 1/[i] is plotted against ∆t/∆lnv and the slope of the resulting straight 
line is ki and the inverse of the intercept is KD.  The phosphorylation rate constant kp is 
deduced from the equation: kp = ki x KD. 
 When the dissociation constant (KD) is much greater than the inhibitor 
concentration and the reversible step of inhibition can be disregarded, inhibitory 
potencies (ki) can also be determined experimentally by a time-dependent manner 
(Equations 2.3 and 2.4): 
ikv
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∆
∆
=
ln][
1  (2.3) 
tikv i ∆=∆ ][ln  (2.4) 
where the time dependent loss of enzyme activity is monitored in the presence of a 
specific concentration of OP inhibitor (Aldridge 1950).  This equation is more convenient 
to work with as it requires a single concentration of the inhibitor.  However, it is most 
applicable when 1/KD is insignificant.  The comparison of inhibitory potencies with this 
method may require using same inhibitor concentration. 
 The inhibition potency, ki, can also be expressed in terms of IC50 value.  IC50 is a 
parameter that represents the molar concentration of inhibitor that causes a 50% reduction 
of enzyme activity during a discrete period of incubation with the inhibitor.  
Consequently, the IC50 value of an OP inhibitor against AChE can be determined by 
Equation 2.5 (Eto, 1974). 
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2.6 Post-inhibition Phase of AChE Inhibited by OPs 
 
Upon phosphorylation, there are three post-inhibition routes that an AChE can 
possibly undertake: (a) reactivation, in which the phosphoester-serine bond is broken 
either spontaneously (water) or mediated by oxime antidotes, (b) “aging”, in which a 
phosphate oxyanion is produced by the cleavage of a phosphoester bond other than the 
phosphoserine, or (c) non-reactivation, in which the enzyme is unable to recover its 
activity by mechanisms other than aging (Eto 1974, Westheimer 1987).   
These post-inhibition fates are discussed in detail in the following sections. 
 
2.6.1 Spontaneous Reactivation 
Phosphorylated AChE can spontaneously recover its enzymatic activity if the 
serine-phosphate bond is cleaved via hydrolysis to regenerate an active serine residue 
(Scheme 2.6).  The mechanism of spontaneous reactivation is similar to the second step 
of the AChE-catalyzed hydrolysis of ACh (in Scheme 2.3).  However, the rate of 
spontaneous reactivation (k0) of AChE inactivated by an OP is far slower than the 
turnover rate for the natural substrate, ACh (Eto 1974). 
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Scheme 2.6. Spontaneous reactivation of AChE inhibited by an OP. 
 
The spontaneous reactivation of inactivated AChE by an OP inhibitor is 
dependent upon a number of factors including the enzyme source, pH, ionic strength, and 
temperature (Lieske 1980, 1990; Lanks 1981; Fisher 2000).  In addition, the rate at which 
AChE recovers from OP inhibition is also dependent upon the nature and reactivity of the 
appended phosphoryl groups.  The rate of spontaneous reactivation is greatest when less 
bulky ligands (R1 and R2) are used in OP diester compounds because of less steric 
hindrance (Lotti, 1991). 
 
2.6.2 Oxime-Mediated Reactivation  
 The observation that phosphorylated AChE can be reactivated by the nucleophilic 
attack of a weak nucleophile, water, has led to exploration of the possibility of AChE 
reactivation promoted by use of stronger nucleophiles such as oximes (Wilson 1955, 
1958).  It has since been found that reactivation process of AChE is affected by several 
factors including the relative strength of the nucleophile, the orientation of the 
nucleophile with respect to the OP-AChE conjugate, and the prevention of aging.  These 
considerations have led to the development of various oximes as potential antidotes to 
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AChE poisoning (Froede, 1971; Wilson 1992).  The structures of generally used oximes 
are illustrated in Figure 2.9. 
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Figure 2.9. Oxime reactivation agents. 
 
 Oxime-mediated nucleophilic reactivation of OP inhibited AChE was proposed to 
proceed via the similar mechanism as scheme 2.6 (Scheme 2.7) (Aldridge 1975; Luo 
1999).   
 
O
Ser
AChE
P
O
R2
R1
B
oxime-mediated
reactivation
O
Ser
AChE
B
H
+ R2
P
O
O
R1
Enz-OP(O)R1R2
k3
Enz-OH + R-CH=NOP(O)R1R2
N OR
N
R
 
Scheme 2.7. Oxime-mediated reactivation of AChE inhibited by an OP. 
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There are a lot of similarities between this mechanism and that of spontaneous 
reactivation.  The displacement of the OP moiety is dependent on the nature of the 
ligands linked to the phosphorus atom in both reactivation processes (Lotti, 1991), and 
smaller ligands are displaced with greater efficacy than compounds with bulkier groups.  
It has been suggested that this trend is due in part to the dimensional constraints imposed 
by the gorge structure obstructing oxime access (Wong, 2000), and competing aging 
mechanisms that are favored by bulkier groups. 
 
2.6.3 Aging and Non-reactivation 
 Some OP-enzyme adducts undergo post-inhibitory reactions such as secondary 
dealkylation of the conjugated OP to produce an anionic phosphylated conjugate that is 
particularly resistant to all forms of reactivation, a process known as ‘aging’ (Scheme 
2.8). 
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Scheme 2.8. Aging of AChE inhibited by an OP. 
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The negative charge introduced by the loss of an alkyl group during the aging 
process causes a significant charge repulsion barrier to dephosphylation because the 
inherent anionic phosphoester is resistant to nucleophilic attack (Westheimer 1987). 
Aging is not the only phenomenon that results in non-reactivable AChEs.  Non-
reactivation can also be caused by a number of factors, including possible modification of 
the enzymes’ tertiary structure resulting in loss of normal enzyme function (Morel, 1999; 
Sentjurc, 1999), steric occlusion of the phosphorylated active site that restricts the access 
of reactivating nucleophiles (Wong, 2000), and covalent modification of a residue other 
than serine in the active site (Mullner, 1980).  These post-inhibitory processes also result 
in a time-dependent loss of the enzyme’s ability to reactivate but do not involve a 
secondary dealkylation of the OP-AChE adduct, which is unique in aging. 
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2.7 Stereochemical Aspects of Organophosphorus Compounds 
 
One of the most important structural features about OP compounds is their 
stereochemistry.  The sp3-tetracoordinated phosphorus atom becomes an asymmetric 
center when four ligands attached are non-identical.  Chiral nonracemic phosphorus 
compounds are ubiquitous in asymmetric synthesis, both as ligands in metal-based 
processes and more importantly, as designed asymmetric inhibitors against AChE.  
Although P-stereogenic ligands have proven to be effective stereoselective inhibitors 
(Berkman, 1993), only a few have been made because of the difficulties in their synthesis.  
Synthesis is mostly based on resolution and the generation of a mixture of diastereomers 
(Valentine, 1984; Berkman, 1993; Wu, 1994; Reddy, 2002), which is discussed in greater 
details in Chapter 4. 
Because the phosphorus atom is directly involved in the covalent modification to 
the active site of AChE, the chirality of an OP compound presumably affects mostly the 
inhibitory and post-inhibitory processes.  The mechanism of stereoselective inhibition of 
AChE by OP-inhibitors has been suggested to be steric limitations within binding 
domains of the active site (Jarv, 1984).  A 4,200-fold difference in inhibitory potency has 
been observed for the enantiomers of sarin (Figure 2.8). 
Previous studies have suggested the classification of three binding domains (D1,  
D2 and D3 in Scheme 2.9) that precisely complement the three groups on phosphorus 
after the oxygen's position is fixed by the H-bond with the acidic residue (Jarv, 1984). 
Structural studies indicate that domain D3 (pointing to the gorge entrance) probably 
accommodates the leaving group, while domains D1 and D2 are responsible for 
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recognizing the ligands that remain attached to phosphorus after phosphorylation 
(Scheme 2.9) (Jarv, 1984).   
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Scheme 2.9. Stereoisomeric forms of AChE inhibited by an asymmetric OP. 
 
 If the positions of the leaving group and the phosphoryl oxygen are held by D3 
and acidic residue respectively, the molecular recognition between the binding pocket 
and the remaining two ligands (R1 and OR2) is highly dependent on the absolute 
configurations of the chiral center.  Therefore, enantiomeric OPs have different inhibition 
rates.   
Additionally, chiral preferences have also been observed in post-inhibition 
(reactivation or aging) kinetics experiments.  The reactivation rates of stereoisomeric 
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phosphorylated AChE (OP-AChE conjugate) are so different that one OP-AChE is 
irreversibly inhibited (Wong, 2000; Doorn, 2000).   
Phosphorothiolates are one general type of AChE-reactive molecules that have 
been shown to react with AChE in high stereoselectivity manner with ejection of thiol 
group (Ryu, 1991; Berkman, 1993; Thompson, 1996; Doorn, 2000).  They become 
acknowledged mostly because of the success of their synthesis strategies and flexibility in 
design.   
Phosphonothiolates bearing an asymmetric phosphorus atom have similar 
inhibition mechanism and activity as phosphorothiolate.  However, few stereospecificity 
studies have been reported for phosphonothiolates mostly due to the limitation in their 
synthesis.  In this study, asymmetric phosphonothiolates are successfully synthesized 
(Chapter 4) in an attempt to explore the stereoselectivity of the binding process. 
 
 31 
2.8 Mechanism and Kinetics of AChE Inactivation by Reversible Inhibitors 
 
In contrast to the irreversible organophosphorus inhibitors, reversible inhibitors 
can only transiently bind to AChE without covalent modifications.  Weak interactions 
such as hydrogen bonds, hydrophobic interactions and ionic bonds involved in binding to 
AChE, can be easily removed.  Various types of compounds have been discovered as 
reversible inhibitors against AChE (Fig 2.10). 
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Figure 2.10. Examples of reversible acetylcholinesterase inhibitors. 
 
 Generally, reversible inhibitors are classified into competitive, noncompetitive 
and mixed-type inhibitors according to the changes of inhibition efficiency while varying 
the concentration of the substrate (Berg, 2002).   Competitive inhibitors and the substrate 
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have affinity to the same active site of the enzyme therefore cannot bind simultaneously.  
Non-competitive inhibitors reduce enzyme’s activity but do not interfere with substrate’s 
binding to the active site, resulting in the inhibition depends only on the concentration of 
the inhibitor.  In mixed-type inhibition, the inhibitor and the enzyme’s substrate bind to 
the enzyme at the same time, however, the two binding processes affect each other.  
The binding of reversible inhibitors to the enzyme can be quantitatively described 
as Figure 2.11.  The enzyme-substrate complex ES is formed reversibly through the 
bimolecular reaction between enzyme E and substrate S.  After catalysis, enzyme E and 
product P are released and free enzyme is regenerated.  Dissociation constants Ki or Ki' 
describe the binding of inhibitor (I) to E and ES. 
 
E +  S ES E +  P
+
I
EI ESI
+
I
E: enzyme
S: substrate
I: reversible inhibitor
P: product from substrate and enzyme
Ki Ki'
 
Figure 2.11. Kinetic description of reversible enzyme inhibitors. 
 
The three types of inhibitors have different affinities to free enzyme E and 
enzyme-substrate complex ES.  Competitive inhibitors only bind to free enzyme (E) but 
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not to ES; non-competitive inhibitors bind to both E and ES with same affinity (Ki = Ki'); 
and mixed-type inhibitors bind to both E and ES, but with different affinities.   
The dissociation constants (Ki and Ki') of a reversible inhibitor can be determined 
by fitting the kinetic data to a Lineweaver-Burk plot (Burk, 1934) according to a 
modified Michaelis–Menten kinetic equation (equation 2.6) based on the quasi steady 
state approximation (Briggs, 1925):  
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where the modifying factors α and α' are defined by the concentration of an inhibitor and 
its two dissociation constants: 
iK
I ][1+=α   (2.7)  
'
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I
+=α   (2.8) 
V is the reaction velocity (the reaction rate),  
Km is the Michaelis-Menten constant,  
Vmax is the maximum reaction velocity, and [S] is the substrate concentration. 
 
The Lineweaver-Burk plot of 1/V versus 1/[S] is used to determine the types of 
inhibitors based on the slopes and intercepts.  When the Lineweaver-Burk plots of 
different [I] have the same y-intercept as uninhibited enzyme but different slopes and x-
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intercepts (α’ is a constant), the inhibitor is a competitive inhibitor since Vmax is 
unaffected by competitive inhibitors.  Noncompetitive inhibition generates plots with the 
same x-intercept (Km is a constant) but different slopes and y-intercepts (α is unchanged).  
Mixed inhibition causes different intercepts on both the y- and x-axes and different slopes 
(Fig 2.12). 
 
 
Figure 2.12.  Lineweaver-Burk plots of different types of reversible enzyme inhibitors 
(http://en.wikipedia.org/wiki/Image:Inhibition_diagrams.png). 
 
 
Based on equation 2.9, the competitive inhibition constant Ki is obtained by 
secondary plot of the slope versus the inhibitor concentration and the resulting x-axis 
intercept represents -Ki of the inhibitor.  The noncompetitive inhibition constant Ki’ is 
obtained by secondary plot of the y-intercept versus the inhibitor concentration and the 
resulting x-axis intercept represents -Ki’. 
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2.9 OP-Tethered Reporter Groups 
 
We and other groups have shown that OP inhibitors of AChE bearing a reporter 
group (chromophore) can be used to probe the enzyme activity (Liu, 1999; Cravatt, 2000; 
Saltmarsh, 2000).  This strategy is to seat a reporter group (chromophore probe) into the 
gorge of AChE, to elucidate the environment at a given depth within the protein.  The 
general architecture of a molecular probe is illustrated in Figure 2.13. 
 
 
spacer C
H2
P
O
LG
ORC
20 Å
C = chromophore
LG = leaving group
R = aliphatic
spacer = linear chain of known length  
Figure 2.13. General design of the OP probes. 
 
An organophosphate (OP) group is selected to covalently modify the active site of 
AChE, thereby placing the probe in the gorge region but removed from the immediate 
vicinity of the catalytic serine.  Spacer groups were used to position the reactive 
phosphorus atom 16~20 Å from the further edge of the chromophore moiety.  This length 
reporter 
group 
spacer OP
~20 Å
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is to assure that the reporter group is placed at the entrance of the gorge when the 
phosphorus group binds to the active site.  
Numerous applications in protein chemistry are rapidly shifting towards the use of 
fluorescent-based detection methods.  The most important reasons for this shift are the 
availability of numerous spectrally distinct fluorescent labels and their wide variety of 
uses to replace the radioactive compounds.  Consequently, reporter groups in this study 
are also chosen from different types of chromophores. 
The major factors affecting chromophore performance are considered to make 
intelligent choice in chromophore selection: 
(1) Molar extinction coefficient (ε). 
Defined by A = ε x b x C, in which A is the amount of light absorbed by a 
chromophore, ε is molar extinction coefficient in M-1cm-1, b is light path in centimeters, 
and C is the molar concentration of the chromophore.  The molar extinction coefficient ε 
is a direct measure of a chromophore’s ability to absorb light (Singer, 1996).  This 
capability is essential to determine the amount of light that a molecule can generate via 
fluorescence emission.  Most chromophores in common use have molar extinction 
coefficients at their wavelength of maximal absorption ranging between 5000 and 
200,000 M-1cm-1 (Haugland, 1996).  A larger ε value provides more convenience in UV-
Vis and fluorescence emission spectrum analyses.  However, determination of the 
inhibition rate of chromophore-linked OPs against AChE by Ellman method (Ellman, 
1961) has to be conducted at 412 nm by observing the absorbance changes; thus, a 
chromophore with a large ε (strong color) may block the readings of spectrophotometer, 
especially when the absorbance of the chromophore is close to 412 nm.  
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(2) Absorption wavelength (Abs). 
The longest wavelength absorption maximum in nanometers is expressed as Abs.  
In order to distinguish different chromophore-linked OPs in the future, chromophores 
with different Abs are desired.  However, it is worth noting that a chromophore with a 
broad Abs is out of favor because of the potential overlapped spectrum.  Also as 
mentioned earlier, chromophores with λmax of approximately 412 nm absorbance should 
be avoided.  
(3) Structure. 
Different types of chromophores are available commercially.  Considering the 
features of the peripheral anionic site of AChE, positively charged chromophores may 
bind to the peripheral anionic site on the gorge, while uncharged chromophores may not.  
Large chromophores can possibly block the entrance to the gorge, and small ones may 
slip into the gorge easily.  Chromophores with a lot of aromatic rings may bind with 
aromatic residues in AChE, but attention needs to be paid in preparation because of the 
poor solubility of large, uncharged groups.   
(4) Availability and price. 
Some chromophores are too expensive therefore seldomly used by researchers 
and only available in the mixture of isomers, while some are inexpensive, commonly-
used and well-characterized.  Amine-reactive probes are widely used to probe proteins 
mostly because of the stability of the resulting chemical bond in biophysiological 
conditions.  They are selected in this study to facilitate the linkage between the 
chromophore and OP moiety in the synthesis scheme in the future.  Amine-reactive 
chromophores are mostly acylating reagents that from carboxyamides, sulfonamides, 
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ureas, and thioureas upon reaction with amines.  Sulfonyl chlorides, including the dansyl, 
pyrene, Lissamine rhodamine B and Texas Red derivatives, are highly reactive and the 
resulting sulfonamides are extremely stable.  Succinimidyl esters and carboxylic acids are 
also excellent reagents for amine modifications because of both stability and availability.     
Considering all the factors above, the following chromophores are chosen (Table 
2.1) based on molecule size, functionality, structure, absorbance (Abs), emission 
maximum spectrum (EM) and molar extinction coefficient (ε). 
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Table 2.1: Structure and properties of chromophores. 
Structure Name Abs ε: M-1cm-1 EM
SO2Cl
N(CH3)2
 
5-dimethylamino
naphthalene-1-
sulfonyl chloride 
(dansyl chloride)
372 3900 none
ClO2S
 
1-pyrenesulfonyl 
chloride 350 28,000 380
N
N(H3C)2N
SO2Cl
4-dimethylamino
azobenzene-4'-
sulfonyl chloride 
(dabsyl chloride)
466 33,000 none
OO
N(C2H5)2
O
HO
 
7-diethylamino 
coumarin-3-
carboxylic acid 
409 33,000 473
C
O
OO
OCH3
HO
 
7-methoxyl 
coumarin-3-
carboxylic acid 
336 20,000 402 
SO2Cl
-O3S
O+(C2H5)2N N(C2H5)2
Lissamine™ 
(rhodamine B 
sulfonyl chloride)
568 88,000 583
SO2Cl
-O3S
ON+ N
Texas Red 
sulfonyl chloride 588 84,000 601
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The chemical properties of the selected chromophores are obtained from 
Molecular Probes Handbook (Haugland, 1996) and all of them are amine-reactive 
chromophores.   
Dansyl chloride is one of the most commonly used amine-reactive chromophores, 
however, it is nonfluorescent until reacting with amines.  The resulting dansyl amides are 
environmentally sensitive, indicating that their fluorescence quantum yields and emission 
spectral respond with changes of their local surroundings.  The absorptivity of dansyl 
derivatives is weak compared with that of the more strongly UV light-absorbing 
chromophores such as pyrenesulfonyl chloride.  Pyrenesulfonyl chloride derivatives have 
extremely long fluorescence lifetime (>100 ns), which is widely used in fluorescence 
anisotropy measurements.  Dabsyl chloride derivatives have broad and intense visible 
absorption but no fluorescent signal, making them useful as acceptors in fluorescence 
resonance energy transfer (FRET) applications to study the interactions between two 
chromophores. 
Coumarin derivatives are shorter wavelength reactive dyes for preparing the 
brighter fluorescent chromophores.  The carboxylic acid groups in coumarins make them 
amine-reactive.  Derivatives of 7-aminocoumarins have been widely applied in protein 
chemistry as labeling reagents and the methoxycoumarins have been used to achieve 
stable signal in solutions because they are pH-insensitive. 
Lissamine rhodamine B and Texas Red sulfonyl chlorides have larger size than 
other chromophores and both are positively charged.  They are long-wavelength light-
emitting dyes and only available as mixtures of isomeric sulfonyl chlorides.  Lissamine 
rhodamine B sulfonyl chloride is much less expensive and emits a shorter wavelength 
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than Texas Red sulfonyl chloride.  Among all the rhodamines, the Texas Red 
chromophores exhibit very little spectral overlap with other chromophores since it has the 
longest emission spectrum.  Moreover, the fluorescence quantum yield of Texas Red is 
usually higher than that of Lissamine rhodamine B sulfonyl chloride.  It is worth noting 
that Texas Red sulfonyl chloride is highly unstable in water, however, the corresponding 
sulfonamides are extremely stable (Haugland, 1996).  
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2.10 Click Chemistry 
 
With the growth of drug discovery and combinatorial synthesis in the past two 
decades, the generation of lead compounds, and consequently, the reliability of the 
individual reaction to link the building blocks is required for high-throughput screening.  
Click chemistry is one of these approaches to the synthesis of drug-like molecules 
constructed by reactive building blocks to accelerate the drug discovery.   
Sharpless and his coworkers defined click chemistry as a “modular, wide in scope, 
stereospecific” chemistry reaction, which gives “very high yield in simple reaction 
conditions, and generates only inoffensive byproducts” (Kolb, 2001).  Of these reactions, 
a best ‘click reaction’ is the “Huisgen 1,3-dipolar cycloaddition of alkynes to azides to 
form 1,4-disubsituted-1,2,3-triazoles (anti) or 1,5-disubsituted-1,2,3-triazoles (syn)” 
(Scheme 2.10).   
The click reaction is a slow kinetic process at room temperature without a catalyst 
and results in the mixture of regio-isomers.  It has been demonstrated that the catalysis of 
this reaction by Cu(I) yields exclusively a 1,4-disubstituted triazole with a much faster 
rate (Rostovtsev, 2002).  The reaction is mild and very efficient, requiring no purification 
in many cases (Rostovtsev, 2002).  The formation of 1,5-disubstituted triazoles has been 
regioselectively mediated by ruthenium complexes (Krasinski, 2004; Tam, 2007), 
stereoelectronic effects (Coats, 2005) or biological selection (Krasinski, 2005; Manetsch, 
2004).  
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Scheme 2.10. Click chemistry. 
 
The azide and alkyne groups are insensitive to most biological functional groups 
and aqueous environments, which allows the wide use of the click reaction in target 
guided synthesis (Manetsch, 2004).  The resulting triazole ring has similarities to the 
ubiquitous amide moiety, but is not susceptible to hydrolysis and cleavage.  
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2.11 Single Molecule Docking and FlexX 
 
Given a protein and an arbitrary small molecule, docking predicts whether the 
small molecule will bind to the protein and how the geometry of the binding is.  Ligand-
protein docking predictions determine the structure of the ligand-protein complex given 
the protein atomic coordinates.  In certain cases, both protein and ligand are considered as 
rigid bodies to make an easier prediction of the interactions; in other cases, it might be 
necessary to consider either the ligand, or the protein or both molecules as completely or 
partially flexible when necessary conformational changes are considered in the binding 
process.  The basic theory of docking program is that the configuration of the system 
(protein-ligand complex) has the minimum of free energy (potential energy + entropy). 
As a relatively new approach to drug design, docking is largely dependent on the 
number of available protein crystal structures, which is increasing exponentially.  The 
fast advancement in computer technology in the past few years has led to the 
development of several ligand-protein docking and drug-design tools (Joseph-McCarthy, 
1999; Tao, 2001; Pei, 2004).   
Some of the most commonly-used docking programs include AutoDock 
(Goodsell, 1990; Morris, 1996; Olson, 1998), DOCK (Kuntz, 2005), FADE (Fast Atomic 
Density Evaluator) and PADRE (Pairwise Atomic Density Reverse Engineering) 
programs (Mitchell, 2001; Law, 2003), Glide (Friesner, 2004; Halgren, 2004) and FlexX 
(Kramer, 1999).  These docking programs use different construction algorithm and have 
various applications in molecular modeling studies, such as FADE and PADRE programs 
are used to rapidly discover the reactive regions of a protein and illuminate its interesting 
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structural features, AutoDock, FlexX and Glide are designed to predict interactions 
between small molecules (such as substrates and drug molecules) and proteins with 
known x-ray structure, and DOCK is mainly used to examine possible binding 
orientations of protein-protein and protein-DNA complexes.    
Among these docking programs, FlexX was chosen to predict protein-ligand 
interactions in this study because of its fast rate, steadiness and flexibility.  An overriding 
advantage of FlexX is that FlexX-Pharm in FlexX allows us to include pharmacophore 
type constraints in the docking calculation, which satisfies the requirement of the 
covalent modification between OP compounds and AChE in this study.  A chemical 
reaction generally occurs only when the distance between the two reactive groups is less 
than 2.5 Å and a new chemical bond is formed after the reaction.  To ensure a covalent 
modification of AChE, a 2.5 Å distance between the phosphorus atom of the ligand and 
the hydroxyl group of the active serine is defined in FlexX-Pharm as a necessary 
constraint, consequently, the protein with configurations in the resulting docking 
resolutions presumably can be irreversibly modified by the ligand.  This will be discussed 
in detail in experimental section. 
By using an incremental construction algorithm (Kramer, 1999), FlexX finds the 
most favorable position of the fragments in the active site by calculating torsion angles 
(intramolecular energy) and protein-ligand interactions (intermolecular energy).  Besides 
defining a constraint, a reference ligand file and a protein file also need to be constructed 
before docking.  The reference ligand provides the proper structure of ligand before being 
docked into the active site.  The preparation of ligand converts data into readable format 
so that SYBYL can read and build proper structure of the ligand.  Protein properties, such 
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as active site, ionization stage, and acceptable torsions, are defined in the protein 
preparation step.  After docking, FlexX ranks a series of possible protein-ligand 
complexes based on various scoring systems. 
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CHAPTER 3 
 
 
OBJECTIVES 
 
1. To prepare a panel of chromophores linked to a reactive fluorophosphonate (FPs) 
head group and address a variety of chromophore-linked FPs different in 
chromophore structure and length.   
 
2. To determine the inhibition potency (inhibition rate ki) of chromophore-FPs against 
purified recombinant mouse AChE (rMAChE) and commercial electric eel AChE 
(EEAChE) and evaluate the binding effects of the chromophore and FP moiety to 
protein.   
 
3. To visualize and calculate positioning of the chromophore-FP-AChE relative to the 
protein active site/gorge/peripheral site by molecular modeling. 
   
4. To synthesize the asymmetric phosphonothiolates as anti-AChE inhibitors. 
   
5. To examine the AChE stereospecificity by studying the anti-AChE potency of Sp- and 
Rp- phosphonothiolate enantiomers. 
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CHAPTER 4 
 
 
SYNTHESIS 
 
4.1 Chromophore-linked Fluorophosphonates (FPs) 
 
A panel of chromophore-FPs was synthesized to ensure: 1) the synthetic routes to 
chromophore-linked OPs were functional; 2) the designed chromophore-linked OPs were 
still inhibitors against AChEs, which means that the added linker and chromophores did 
not impede inhibition; and 3) the chromophore and OP parts were positioned at the P-site 
and A-site, respectively, in the active gorge.  In addition, the role of the chromophore in 
binding to AChEs could be evaluated by using a fluorophosphonate analog holding the 
tether constant (Saltmarsh, 2000).  The fluoro atom has been chosen as an excellent 
leaving group and the phosphorus stereochemistry is not being discussed in this section.  
The overall strategy was to synthesize a reactive phosphorus group containing an 
azo group and a chromophore part containing acetylene group and to use click chemistry 
to link the two building blocks together via a triazole ring.  Fluoro groups would be 
added to phosphorus in the last step to ensure effective phosphorylation. 
Considering the depth of the AChE gorge is 20 Å, the length of the target 
synthesized FPs was adjusted to approximately 16 Å (chromophore excluded) to optimize 
the inhibition ability (Scheme 4.1).  With counting the length of triazole ring linker and 
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chromophore, three methylene (3-CH2, n = 3) or four methylene (4-CH2, n = 4) units 
between phosphorus and azo group were desired. 
 
 
SO2Cl
H2N
SO2
NH
PN3
O
F
OCH3
P
O
F
OCH3
SO2
NH
N
N N
n = 3 or 4
C C C
C = chromophore
(CH2)n
(CH2)n
 
Scheme 4.1. Design of chromophore-linked FPs (chromophore is not included in distance 
calculation). 
 
4.1.1 Dansyl-linked Fluorophosphonates (FPs) 
5-Dimethylaminonaphthalene-1-sulfonyl chloride (dansyl chloride) (Gray, 1972) 
is a very stable chromophore with a strong color (large ε), good solubility, and ease of 
reaction with amines.  These factors combined with the availability and inexpensive price 
of this source have made it the chromophore of choice for conducting preliminary 
synthesis studies.  
 The synthesis of dansyl-linked FPs is outlined in Scheme 4.2.  Trimethyl 
phosphite was used as the starting material, followed by Arbuzov reaction with 1,3-
dibromopropane (3-CH2) or 1,4-diromobutane (4-CH2) to produce O,O-dimethyl, bromo 
propyl/butyl phosphonate 1a/1b (Maguire, 2001).  Four equivalents of the dibromo 
compounds were used to reduce any double addition by-product.  31P NMR showed that 
16 Å
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the reaction was complete (from 140 ppm to 34 ppm) after refluxing at 140 ºC for 4 h.  
The desired products were bulb-to-bulb distilled into the cold trap under reduced pressure 
(0.5 mmHg) at a temperature of 90 °C to 130 °C.  Substitution of a bromine atom with an 
azo group using sodium azide produced O,O-dimethyl, azo propyl/butyl phosphonate 
2a/2b.  Various organic solvents including dimethylformamide (DMF), methanol, 
acetonitrile, and acetone were examined with 10% DI water as co-solvent and we found 
that DMF was the best solvent, which could facilitate a complete conversion in 12 h with 
best yield and purity.  Catalysis of the reaction with sodium iodide (NaI) in acetone was 
also attempted, however, more by-products made the purification process more 
complicated and lower yield.   
For the chromophore part, dansyl chloride was coupled with propargyl amine, 
thus adding an acetylene group to the amine-reactive chromophore (Bolletta, 1996).  The 
reaction went from a bright yellow sulfonyl chloride to a florescent sulfonamide.  After 
quenching with phosphate buffer (pH = 7) and extraction with CH2Cl2, sulfonamide 3 
was obtained as a yellow solid in a quantitative yield.  Click chemistry was conducted 
between the acetylene 3 and azo groups of 2a/2b in co-solvents of t-butanol (t-BuOH) 
and water and afforded a robust triazole ring (Kolb, 2001) to form compound 4a/4b.  The 
quantitative yield and high reaction rate of click reaction under Cu(I) catalysis provided a 
new, easy, efficient way to link the two building blocks and form chromophore-linked 
OPs.   
Dansyl-linked O,O-dimethyl phosphonate 4a/4b was hydrolyzed at a single P-
OCH3 with sodium hydroxide (NaOH, 2 N, reflux) to afford phosphorus monoacid 5a/5b 
and was converted to the corresponding fluorophosphonate (FP) 6a/6a’ with cyanuric 
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fluoride (C3N3F3) in CH2Cl2 (Kokotos, 1996).  Diethylamino sulfur trifluoride (DAST) 
was also examined as a reagent to introduce the P-F bond but did not work with our 
phosphonic acids.  The conversion of the phosphonic acids to FPs was monitored by 31P 
NMR: the 3 ppm upfield shift from the diester P(OCH3)2 (33.9 ppm) to the phosphorus 
monoacid (30.6 ppm) and finally, formation of the characteristic P-F coupling constant 
(JP-F = 1072 Hz), which was centered at 31.6 ppm. 
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Scheme 4.2. Synthesis of dansyl-linked FPs. 
 
In addition, the synthesis of azo-FPs 8a/8b was undertaken in an effort to provide 
a control molecule of the FP part without attaching chromophores.  Compounds 8a/8b 
would enable the study of the OP portion without the chromophore as an AChE inhibitor.  
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Similar hydrolysis and FP conversion methods were applied to compound 2a/2b (Scheme 
4.3) and again, the reaction sequence was monitored by 31P NMR.     
 
1. NaOH, 70oC
2. H+
(CH2)n
O
PH3CO
H3CO
2a: n = 3
2b: n = 4
N3 (CH2)n
O
PH3CO
HO
N3 (CH2)n
O
PH3CO
F
N3
7a: n = 3
7b: n = 4
8a: n = 3
8b: n = 4
C3F3N3
CH2Cl2
 
Scheme 4.3. Synthesis of azo-FPs. 
 
 
31P NMR data is shown in Table 4.1 and illustrates what a powerful tool it can be.  
As there is considerable difference in the chemical shift as one goes from P-OCH3 to P-
OH to P-F, it is easy to follow the course of reactions.  It is worth noting that the unique 
phosphorus-fluoro (P-F) coupling constant is an identity unique to FP compounds.   
Furthermore, as each phosphorus atom in a molecule produces only one sharp 
definitive peak with a chemical shift (as listed in Table 4.1) that is directly related to the 
phosphorus atom’s immediate environment, compounds containing impurities are easily 
spotted.  To simplify discussion, only compounds with 3-CH2 units (n = 3) were 
presented and 4-CH2 (n = 4) analogs have very similar properties. 
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Table 4.1: 31P NMR chemical shifts of FPs. 
compounds 31P NMR (δ) ppm 
P(OCH3)3 140.0 
(H3CO)2P(O)(CH2)3-Br (1a) 34.3 
(H3CO)2P(O)(CH2)3-N3 (2a) 34.5 
(H3CO)2P(O)(CH2)3-(triazole)-CH2SO2-dansyl (4a) 33.9 
(H3CO)(HO) P(O)(CH2)3-(triazole)-CH2SO2- dansyl (5a) 30.6 
(H3CO)(F) P(O)(CH2)3-(triazole)-CH2SO2-dansyl (6a) 31.6 (d, J = 1072 Hz)
(H3CO)(HO)P(O)(CH2)3-N3 (7a) 31.2 
(H3CO)(F)P(O)(CH2)3-N3 (8a) 32.2 (d, J = 1075 Hz)
Triazole: 1,4-substituted, 1,2,3-triazole ring. 
 
4.1.2 Other Chromophore-linked FPs 
Since many amine-reactive chromophores are commercially available as sulfonyl 
chlorides or carboxylic acids, the synthesis approach in Scheme 4.2 was rationalized to 
be the most applicable and general to a panel of structures.   
Using a similar scheme described above, FPs with either 3 methylene (n = 3) or 4 
methylene (n = 4) units were prepared bearing different chromophore groups, thereby 
expanding the structure and chromophore diversity.  Seven chromophores (Table 2.1) 
were selected and coupled with propargyl amine to form compounds 3a-3f (Table 4.2).  
Their corresponding chromophore-linked FPs were synthesized from 3a-3f and 2a-2b in 
collaboration with Dr. Alirica Suarez.  Fourteen chromophore-linked FPs (Table 4.3) and 
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two azo-linked FPs (controls) were prepared as inhibitors against AChE, and as potential 
probes of other protein targets. 
In order to know exactly which part of chromophore-linked FP contributes to the 
inhibition of AChE, seven acetylene-containing chromophores (3a - 3g, Table 4.2) were 
also prepared for inhibition studies against AChEs. 
 
Table 4.2: Synthesized chromophore amides. 
H
N chromophore
 
chromophore  compounds 
dansyl 3a 
pyrene 3b 
dabsyl 3c 
diethylamino coumarin 3d 
methoxycoumarin 
 3e 
Lissamine rhodamine B 3f 
Texas Red 3g 
Note: Chromophore structures are drawn in Table 4.3.
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Table 4.3: All chromophore-linked fluorophosphonates synthesized. 
H
N
N
N
N
(CH2)n
O
PH3CO
F chromophore
(n = 3, 4)  
chromophore n = 3 n = 4 
dansyl 
SO2
N(CH3)2  
6a 6a’ 
pyrene 
SO2
 
6b 6b’ 
dabsyl 
N
N N(CH3)2
S
O2 6c 6c’ 
diethylamino 
coumarin 
OO
N(C2H5)2
O  
6d 6d’ 
methoxy 
coumarin 
 
O
OO
OCH3
 
6e 6e’ 
Lissamine 
rhodamine B 
O2
S
-O3S
O+(C2H5)2N N(C2H5)2  
6f 6f’ 
Texas Red 
O2
S
-O3S
ON+ N
 
6g 6g’ 
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4.2 Dansyl-linked Phosphonothiolates 
 
Phosphonothioates are AChE-reactive molecules that typically contain an 
asymmetric phosphorus atom.  It was established that asymmetric phosphonothiolates 
undergo reactions with AChE with high stereoselectivity concomitant with ejection of a 
thiol group (Doorn, 2000; Ryu, 1991).  
A model compound, dansyl-linked O,S-dimethyl phosphonate (Fig 4.1) as a 
racemate was first studied to ensure the success of the synthetic steps and to estimate the 
inhibition potency of phosphonothioates.  For comparison, dansyl-linked O-methyl, S-
choline phosphonate (Fig 4.1) was synthesized because of the structural similarity to 
acetylcholine, the AChE’s endogenous substrate.  The synthesis of the 
phosphonothiolates were undertaken with three methylene units (n = 3) only. 
 
 
N(CH3)3
thiol-choline
S N(CH3)2
O
O
H
N
N
N
N
(CH2)3
O
PH3CO
H3CS
S N(CH3)2
O
O
H
N
N
N
N
(CH2)3
O
PH3CO
S
Dansyl-linked O,S-dimethyl phosphonate
Dansyl-linked O-methyl,S-choline phosphonate  
Figure 4.1. Structures of the target dansyl-linked phosphonothiolates. 
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4.2.1 Synthetic Approach A: Conversion of P=O to P=S in 4a with Lawesson 
Reagent (LR) 
Lawesson reagent (LR) (Figure 4.2) is a widely-used reagent to transform P=O to 
P=S (Horner, 1982; Lecher, 1956).   
 
P
S
S
PS
S
OCH3
H3CO
 
Figure 4.2. Structure of Lawesson reagent (LR). 
 
The most straightforward strategy to synthesize the desired dansyl-linked 
phosphonothiolates is to first modify the already synthesized dimethyl phosphonate 4a to 
dimethyl phosphonothionate by converting the P=O (oxon) to P=S (thionate).  The target 
dimethyl phosphonothionates can be dealkylated and realkylated on sulfur over oxygen to 
give O-methyl, S-alkyl phosphonates (Scheme 4.4). 
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Lawesson reagent
S N(CH3)2
O
O
H
N
N
N
N
4a
(CH2)3
O
PH3CO
H3CO
S N(CH3)2
O
O
H
N
N
N
N
(CH2)3
S
PH3CO
H3CO
S N(CH3)2
O
O
H
N
N
N
N
(CH2)3
O
PH3CO
RS
1. dealkylation
2. alkylation with R-I
R = CH3 or CH2CH2N+(CH3)3
 
Scheme 4.4. Attempted synthesis of dansyl-linked phosphonothioates with LR. 
 
The reaction between 4a and LR was monitored by 31P NMR.  The starting 
material 4a was consumed completely, however, no desired product was obtained.  
Experiments showed that LR also decomposed either the triazole ring or other functional 
groups in the molecule.  So, compounds synthesized prior to click chemistry, 1a or 2a, 
would be reacted with LR to attempt converting the phosphonyl to a thiophosphonyl 
without the triazole or chromophore present (next section).  
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4.2.2 Synthetic Approach B: Reacting Bromo/Azo-phosphonates (Compound 1a or 
2a) with LR 
From the observations of synthetic approach A, it was decided to conduct the 
P=O to P=S conversion before click chemistry so that LR would not react with the 
triazole ring or the chromophore (Scheme 4.5).  Both bromo-phosphonate (1a) and azo-
phosphonate (2a) were examined in reaction with LR, and it was shown that both bromo- 
and azo- groups were reactive toward LR.  However, it is worth noting that a lot of peaks 
in 31P NMR originated from the decomposition of LR, which brought trouble in keeping 
track of the reaction progress using 31P NMR.  Moreover, it was not clear in spectral 
monitoring that we were seeing desired formation of the thionates. 
 
NaN3
DMF
1a
70oC
2a
Lawesson
reagent
(CH2)3 Br
O
PH3CO
H3CO
(CH2)3 N3
O
PH3CO
H3CO
(CH2)3 Br
S
PH3CO
H3CO (CH2)3 N3
S
PH3CO
H3CO
Lawesson 
reagent
 
Scheme 4.5. Attempted synthesis of bromo-/azo- phosphonothionates with LR. 
 
 
4.2.3 Synthetic Approach C: Using Sodium Hydrosulfide (NaSH) As a Nucleophile 
to Produce Phosphonothioic Acids [P(O)SH] 
Because of the complexity of using LR in our studies, sodium hydrosulfide 
(NaSH) was selected to react with azo-phosphonate 2a and dansyl-linked phosphonate 4a 
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to prepare a phosphonothioic acid.  The displacement of a methoxy ester by –SH group 
was not observed under reflux after 48 h.  The reaction with NaSH was also studied with 
the reactive FP compounds 6a and 8a.  A reaction occurred but no desired product was 
observed in either reaction according to 31P NMR.  In these experiments, either a side 
reaction was predominating (e.g. dealkylation) or the product was decomposing upon 
formation as some thioic acids are known to do. 
 
4.2.4 Synthetic Approach D: Using a New Synthesis Strategy Starting with 
Dimethyl Thiophosphite 
With the difficulties of adding sulfur to phosphorus on the previously synthesized 
compounds, a new synthetic scheme starting with dimethyl thiophosphite (DMTP) was 
designed (Scheme 4.6).   
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Br (CH2)3 Br
DMTP
NaN3, DMF/H2O
t-BuOH/H2O
S
N(CH3)2
OO
NH
H2
C
R-Z
10
Lawesson reagent
benzene, 90 oC
sodium ascorbate
CuSO4.5H2O
+
3
9
1. TEA,acetone
2. H+
Na, CH3OH
DMP
O
PH3CO
H3CO
H
S
PH3CO
H3CO
H
(CH2)3 Br
S
PH3CO
H3CO
(CH2)3 N3
S
PH3CO
H3CO
SO2
N(CH3)2
H
N
N
N
N
(CH2)3
X
PH3CO
Y
11: X = S, Y = OCH3
12: X = S, Y = OH or X = O, Y = SH
13: X = O, Y = R = SCH3, Z = I
14: X = O, Y = R = SCH2CH2N(CH3)2, Z = ClCH3I
15: X = O, Y =  SCH2CH2N+(CH3)3  
Scheme 4.6. Synthesis of dansyl-linked phosphonothiolates. 
 
Commercially available DMTP gets oxidized easily and commonly contains 
impurities, so freshly synthesized DMTP is preferred.  Dimethyl thiophosphite (DMTP) 
was prepared from dimethyl phosphate (DMP) using LR (Tongcharoensirikul, 2004).  
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The reaction was heated at 90 – 100 ºC for 2 h and 31P NMR showed complete 
conversion (from 11.5 ppm to 74.9 ppm).  Sulfur- and phosphorus-containing by-
products were precipitated with adding hexane and filtered off.  The solution was 
concentrated and distilled under reduced pressure to give high purity DMTP.   
A solution of sodium dimethyl thiophosphonate (prepared from DMTP and an 
equivalent sodium in anhydrous methanol) was added dropwise to 1,3-dibromopropane to 
afford O,O-dimethyl (3-bromopropyl) thiophosphonate 9.  Bromine substitution of 9 with 
sodium azide provided O,O-dimethyl (3-azopropyl) thiophosphonate 10, which is now 
ready for the click reaction with compound 3, which proceeded without problem to afford.  
Dansyl-linked phosphonothionate 11 after click reaction was purified by a flash 
chromatography.  The synthesis of phosphonothionates (9, 10, and 11) was similar to the 
synthesis of the corresponding phosphonates (1a, 2a, and 4a) in section 4.1, however, 
inert argon gas was mandatory for each step of the synthesis, purification and storage 
processes to prevent oxidization of phosphonothionates by air or moisture.  
Dealkylation of phosphonothionate 11 was achieved by triethylamine and the 
resulting solution was acidified (pH = 1) to obtain the phosphonothioic acid (P-SH) 12.  
Tautomerization of 12 was equilibrated between P-SH and P-OH products, which 
produced two corresponding peaks in 31P NMR spectrum (93.1 and 49.7 ppm).  
Alkylation of 12 was achieved by reaction with the methyl iodide and 2-chloro-N,N-
dimethylethylamine and the target phosphonothiolates 13 and 14 were synthesized.  To a 
solution of compound 14 in chloroform, methyl iodide was added to obtain dansyl-linked 
O-methyl, S-choline phosphonate 15. 
Again, as a simple and straightforward analytical method, 31P NMR analysis was 
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used to follow the course of reactions.  Data associated with the synthesis of 
phosphonothioates are listed in Table 4.4.  Compared with phosphonate compounds (P=O) 
listed in Table 4.1, phosphonothionates (P=S) have higher or downfield chemical shifts.  
In addition, phosphonothiolate 13 changes ~ 40 ppm downfield from phosphonothionates 
11. All the data were collected with reference to 85% H3PO4 as an external standard. 
 
Table 4.4: 31P NMR chemical shifts of phosphonothioates. 
compounds 
31P NMR 
(δ) ppm 
(CH3O)2P(O)H 11.5 
(CH3O)2P(S)H 74.9 
(CH3O)2P(S)(CH2)3-Br (9) 102.7 
(CH3O)2P(S)(CH2)3-N3 (10) 103.2 
(CH3O)2P(S)(CH2)3-(triazole)-CH2SO2-dansyl (11) 102.1 
(CH3O)(HO)P(S)(CH2)3-(triazole)-CH2SO2-dansyl or 
(CH3O)(HS)P(O)(CH2)3-(triazole)-CH2SO2-dansyl (12)  
93.1 & 49.7
(CH3O)(CH3S)P(O)(CH2)3-(triazole)-CH2SO2-dansyl (13) 59.1 
(CH3O)[(CH3)2NCH2CH2S]P(O)(CH2)3-(triazole)-CH2SO2-dansyl (14) 59.0 
(CH3O)[(CH3)3N+CH2CH2S]P(O)(CH2)3-(triazole)-CH2SO2-dansyl (15) 58.8 
Triazole: 1,4-substituted, 1,2,3-triazole ring. 
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4.2.5 Summary 
Different approaches to the synthesis of the target phosphonothiolates were 
attempted and a robust, uncomplicated, and practical way was discovered (in section 
4.2.4).  The two designed dansyl-linked phosphonothiolates were successfully 
synthesized and their inhibition potency against AChEs was studied (in chapter 5).  It is 
worth noting that the phosphonothiolates and phosphonothionates are sensitive to 
air/water and thus have to be stored in an inert atmosphere to prevent oxidization. 
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4.3 Asymmetric Phosphonothiolates 
 
 The model phosphonothiolates 13/14/15 synthesized previously are actually a 1:1 
mixture of two enantiomers.  To study their stereoselective interaction with AChEs, 
enantiopure isomers need to be synthesized.  In general, enantiomers of smaller 
molecules are easier to be resolved, so asymmetric phosphonothionates with an azo- 
group (before click reaction) were prepared first in this section and then reacted with 
different alkyne-based chromophores to form CLAPs bearing an asymmetric phosphorus.   
Basically, there were two synthetic routes to obtain the asymmetric 
phosphonothiolates: 1) The first method involves dealkylation with an alkaloid to form 
two alkaloid salts of phosphonothioic acids (Rp and Sp).  Repeated fractional 
crystallization of the resulting diastereomeric mixtures results in separation of the 
individual, “resolved” diastereomers.  The individual phosphonothioic salts were then 
converted to each isomer of phosphonothiolates by removal of alkaloid.  This method has 
been used in the synthesis of asymmetric phosphonothiolates (Valentine, 1984; Aaron, 
1960; Berkman, 1993).  2) The second pathway uses a chiral auxiliary instead of the 
alkaloid to resolve the phosphorus stereocenter.  A covalent bond is formed between an 
amine enantiomer and one more chiral center was added to phosphonothioates.  The 
resulting two diastereomers were separated by HPLC and the added chiral center is 
removed to offer two enantiopure isomers (Valentine, 1984; Koizumi, 1978; Wu, 1994; 
Reddy, 2002).  
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4.3.1 Attempted Synthesis of Asymmetric Phosphonothioates via Alkaloid 
Resolution 
 Several prior studies showed that alkaloid resolution was an effective way to 
prepare enantioenriched phosphonothiolates (Valentine, 1984; Aaron, 1960).  In addition, 
our group also has experience in successfully separating phosphonothioic acids via 
alkaloid resolution (Berkman, 1993).  The general method for this type of resolution 
involves either conducting an acid-base reaction with a phosphonothioic acid and the 
alkaloid, or dealkylating a phosphonothioate methyl ester with the alkaloid to directly 
form the alkylated alkaloid/phosphonothioic acid diastereomer salts.   
Strychnine, brucine and quinine (Fig 4.3) are three widely known and used 
alkaloids in resolution of phosphorus compounds (Drabowicz, 1988; Michalski, 1963). 
 
strychnine
O
N
N H
OH
H
brucine
O
N
N H
H
OH
H3CO
H3CO
quinine
HO
N
H
H3CO
N  
Figure 4.3. Strychnine, brucine and quinine structures. 
 
Dealkylation of O,O-dimethyl (3-azopropyl) thiophosphonate 10 with strychnine, 
brucine and quinine was examined and 31P NMR was used to monitor the reaction.  
However only reaction with brucine occurred (Scheme 4.7).  Repeated dealkylations of 
10 with brucine were then performed followed by attempts at fractional crystallization of 
the resulting alkaloid salts.  Fractional crystallization of phosphonothioate-alkaloid salt is 
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commonly performed in methanol or ethanol followed by addition of ether or other non-
polar solvents.  However, the brucine salts of 10 failed to produce any crystals under 
these conditions.   
 
C2H5OH, 60 oC
strychnine
quinine
brucine
+
16a 16b
10
(CH2)3 N3
S
PH3CO
H3CO
(CH2)3N3
S
P
O
H3CO (CH2)3 N3
S
PO
H3CO
No reaction
No reaction
C2H5OH, 60 oC
C2H5OH, 60 oC
 
Scheme 4.7. Attempted dealkylation of phosphonothiolate with alkaloids. 
 
 Different solvent mixtures were examined and heat was also applied to effect a 
crystallization, which in most cases was subsequently stored at 0 ºC.  Despite this 
exploration of reactions, crystals of the brucine salt 16a/16b were only observed in 
chloroform/ethyl ether or chloroform/ethyl acetate/ethyl ether, and unfortunately, the 
crystals formed are not hard enough to be separated from solutions.  Examination of the 
reaction also showed that the two diastereomers 16a and 16b have overlapped peaks in 
31P NMR, making it difficult to examine the level of separation.  
 Acid-base reactions were next studied between proper phosphonothioic acid and 
the alkaloids.  These reactions occurred more easily and provided us more opportunities 
to develop fractional crystallization.  Strychnine, brucine and quinine were all able to 
form ionic parts with phosphonothioic acid 17 successfully (Scheme 4.8) and result in 
two distinct resonances (~ 0.05 ppm difference) for the diastereomers in the 31P NMR.  
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Scheme 4.8. Acid-base reactions between the phosphonothioic acid 17 and alkaloids. 
 
Various solvent mixtures were examined to form crystals.  A first crop of crystals 
was obtained for strychnine salts in ethanol/ethyl ether while brucine and quinine salts 
failed to produce any crystals.  These first crops were analyzed by 1H, 13C, and 31P NMR 
and enrichment of the diastereomers of strychnine salts (18a/18b) was easily observed in 
the 31P NMR spectrum as revealed by two resonances differing by about 0.05 ppm.  The 
most significant enrichment of the alkaloid salts from the first crop was observed for the 
strychnine/phosphonothioic acid salt in which 31P NMR revealed approximately 70% 
enrichment of the downfield diastereomer (Figure 4.4-A).  Further fractional 
crystallization of the downfield diastereomer was achieved stepwise, through repeated 
crystallization from ethanol-ethyl ether solutions.  However, the limit of diastereomeric 
purity achieved by repeated crystallization was approximately 90%.  To achieve higher 
resolution of the downfield diastereomer, several solvent mixtures for recrystallization 
were examined.  A mixture of isopropanol and ethyl ether eventually provided the 
downfield alkaloid salt in a maximum of 95% diastereomeric purity by 31P NMR (Figure 
4.4-B). 
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 ppm  
Figure 4.4. 31P NMR spectra of strychnine salts 18a and 18b: (A) crystallized in 
ethanol/ethyl ether, (B) recrystallized in isopropanol/ethyl ether, and (C) remaining 
mother liquor; integration included. 
 
The mother liquor from the first crystallization of the strychnine salts was 
concentrated to a smaller volume and crystallized repeatedly 4-5 times until no more 
crystals were formed.  The last mother liquor was concentrated to a glassy oil/solid that 
showed approximately 80% enrichment of the upfield diastereomer by 31P NMR (Figure 
4.4-C).  Several solvent mixtures were attempted to further enhance the diastereomeric 
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purity of this upfield diastereomer.  However, no further enrichment of the resulting salt 
was obtained.   
It’s worth noting that the phosphonothioic acid-strychnine salts are not stable in 
solution.  The possible reason for this is that it may be oxidized to the corresponding 
phosphonate compounds (loss of sulfur) after 1-2 days as determined by 31P NMR.  This 
observation severely limited the practicality of the fractional crystallization approach. 
 Fractional crystallization is largely dependent on the solvent system, physical and 
chemical properties of the target diastereomers, and other environmental uncertainties.  
With the method used above, it would not have allowed fully separating the two 
diastereomeric salts.  As a result, the synthesis of CLAP stereoisomers using a chiral 
auxiliary to form two diastereomers via a covalent chemical bond was proposed and 
chromatographic separation of the resulting diastereomers was attempted.   
 
4.3.2 Synthesis of Asymmetric Phosphonothioates Using a Chiral Auxiliary 
  A chiral auxiliary is an optically active compound that is temporarily 
incorporated into an organic synthesis so that the two diastereomers created from original 
enantiomers can be differentiated and separated from each other.  After the separation of 
the two original stereocenters the auxiliary will be removed. 
Previous experiments indicated that resolution of certain phosphonothioates could 
be achieved by the use of chiral auxiliaries (Valentine, 1984; Koizumi, 1978; Wu, 1994; 
Reddy, 2002).  With a second stereocenter added, the diastereomers synthesized from 
phosphonothionate enantiomers would be analyzed and differentiated by 31P NMR and 
separated.   
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Step 1: Adding a chiral auxiliary to phosphonothionate. 
Because it has been proved to be useful for the preparation of phosphonothionate 
diastereomers followed by successful HPLC separation (Wu, 1994; Lee, 1992; Purnanand, 
1994; Reddy, 2002), the enantiopure compound, (R)-methylbenzylamine was selected as 
the chiral auxiliary to resolve the diastereomeric phosphonamidothioates formed.  
Methanolysis of phosphonamidothioates with boron trifluoride would be attempted after 
diastereomeric resolution to replace the chiral auxiliary with a methoxyl group (Ryu, 
1991). 
To add the second chiral center to phosphorus, phosphonothionate 10 was 
converted to the amine-reactive phosphonochloridothionate 22 (Scheme 4.9).  There were 
many reported routes to achieve this.  The most convenient method to synthesize 
phosphonochloridothionates was reported by He (1998).  O,O-Dimethyl (3-azopropyl) 
phosphonothioate 10 was dealkylated with diethylamine to form O-methyl ammonium 
phosphonothioate 21,  followed by conversion to P-Cl using phosphorus oxychloride 
(POCl3) to give the corresponding O-methyl phosphonochloridothionate 22.  Reaction of 
22 with two equivalent of (R)-methylbenzylamine yielded the desired 
phosphonamidothionate diastereomers, 23a and 23b (1:1).   
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Scheme 4.9. Synthesis of phosphonamidothioate diastereomers. 
 
The diastereomers 23a and 23b differed approximately 0.2 ppm from each other 
in the 31P NMR spectrum but disappointingly were not separable to any great extent by 
flash chromatography.  Phosphonamidothionate 23 was next converted to a 
phosphonamidothiolate to achieve a better separation. 
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Step 2: Converting phosphonamidothionate to phosphonamidothiolate and 
separation. 
Hydrolysis or dealkylation of phosphonamidothionate, followed by desired 
alkylation, can afford corresponding phosphonamidothioate.  However, hydrolysis or 
dealkylation of phosphonamidothionate 23 was studied in various conditions without any 
success (Scheme 4.10).  In general, it was found that phosphonamidothionates such as 
compound 23, with a phosphonamide bond, were much more resistant to hydrolysis or 
dealkylation than the corresponding phosphonothionates. 
 
CH3ONa
LiOH
21
NaI
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CH3I
(CH2)3 N3
S
PH3CO
HN
PhH3C
(CH2)3 N3
S
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(C2H5)3N
(C2H5)2NH
 
Scheme 4.10. Attempted hydrolysis or dealkylation of phosphonamidothionate 23. 
 
With the difficulties of stepwise dealkylation-alkylation, reversing the sequence to 
alkylation first and dealkylation second was attempted.  This change ensured the success 
of the chemistry, however, the flexibility of the target compounds was restricted due to 
the availability of the alkylation reagents that would act in the first step.  Methyl triflate 
was known as a methylation reagent and used on phosphonothionates (Mikolajczyk, 
1988).  Alkylation of phosphonamidothionate 23 resulted in the derived phosphonium 
salt, which was treated with lithium chloride to make S-substituted 
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phosphonamidothiolate 24 (Scheme 4.11).   It was found later that the compound 24 
could also be synthesized by treating 23 with methyl iodide as solvent/reagent (Scheme 
4.11) under extreme conditions (heating and long time).  The methyl iodide reaction took 
a long time (6 days) under reflux to achieve 100% conversion.  Besides 31P NMR, TLC 
analysis staining with 2,6-dibromoquinone-4-chloroimide (DBQ) were also used to 
monitor the conversion reaction from P=S to P=O.  Visualization of the color change 
from orange to yellow provided a convenient way to identify the conversion progress.   
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Scheme 4.11. Synthesis of S-substituted phosphonamidothioate. 
 
 The phosphonamidothiolate 24 was confirmed by 1H, 13C, 31P NMR and 
elemental analysis.  Diastereomers 24a and 24b showed a 1.4 ppm difference in the 31P 
NMR spectrum and were effectively separated by flash chromatography using 1-2% 
 77 
methanol in chloroform.  The separation was reconfirmed by 31P NMR: 1) integration 
showed 50:50 of the two diastereomers 24a/24b after reaction (Figure 4.5-A); 2) the first 
fraction was collected and there is a single chemical shift at 48.6 ppm in 31P NMR 
analysis (Figure 4.5-B); and 3) the second fraction was collected and the chemical shift of 
the second diastereomer is 50.0 ppm (Figure 4.5-C).  The overlapped fractions were 
collected and separated once again with same chromatographic conditions. 
 
 ppm 
Figure 4.5. 31P NMR spectra of compound (A) 24a and 24b before chromatographic 
separation, (B) 24a, and (C) 24b.  
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Isomer 24a was further crystallized from ether and afforded needle-like crystals.  
Diastereomer 24b was dissolved in the necessary amount of methanol and crystallized as 
ether was added to afford needle-like crystals.  In addition to NMR analysis of the 
diastereomers 24a and 24b, specific rotations and melting points were also obtained 
(Table 4.5).  The diastereomers were identified as the levorotatory or dextrorotatory 
stereoisomer with respect to the phosphorus stereochemistry because the carbon 
configuration was known as 100% enantiopure.  The phosphorus and carbon 
configurations were later analyzed and confirmed by x-ray crystallography.   
 
Table 4.5: Physical data of the diastereomers 24a and 24b. 
 
compounds [α]D22 (conc.) a 31P NMR (δ) ppm mp(ºC) b 
24a (SpRc) +23.6 (1.40) 48.6 (4) 95.5-95.8 
24b (RpRc) +60.1 (1.04) 50.0 (3) 88.5-88.8 
 
a rotations performed in CHCl3; concentrations in g/100 mL; b melting point 
analysis calibrated with 4-nitrobenzyl chloride (mp 70.0 ºC). 
 
 
 Step 3: Identifying the absolute configurations of compounds 24a/24b. 
In an effort to assign the absolute configuration of the carbon and phosphorus 
stereocenters of the resolved diastereomers 24a/24b, x-ray crystallographic analysis was 
desired.  In order to prepare crystals for x-ray crystallography, recrystallization of the 
resolved diastereoisomers 24a and 24b was preformed in the respective solvent mixtures 
at a high dilution to afford crystals of high quality.   
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The structure of the crystal 24a was solved and revealed an orthorhombic unit cell 
with dimensions of 5 x 12 x 24 Å (Table 4.6).  As a result of this analysis, 
stereochemistry was assigned (Figure 4.6) as C9(R) P1(S) and the packing diagram was 
illustrated in Figure 4.7 for diastereomer 24a. 
 
 
Table 4.6: Crystal data for diastereomer 24a. 
Empirical formula  C12 H19 N4 O P S 
Formula weight  298.34 
Temperature  90(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 5.1896(2) Å α= 90° 
                                                                       b = 12.1755(4) Å               β= 90° 
                                                                       c = 23.6534(8) Å               γ = 90° 
Volume 1494.56(9) Å3 
Z 4 
Density (calculated) 1.326 mg/m3 
Absorption coefficient 0.322 mm-1 
F(000) 632 
Crystal size 0.39 x 0.19 x 0.17 mm3 
Crystal color and habit colorless needle 
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Figure 4.6. The structure of the diastereomer 24a as determined by x-ray crystallographic 
analysis. 
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Figure 4.7. Packing diagram of 24a (hydrogen atoms omitted for clarity and dashed lines 
indicate hydrogen bonding). 
 
 
 
The crystal structure of the crystal 24b was also solved and revealed an 
orthorhombic unit cell with smaller dimensions of 5 x 12 x 22 Å (Table 4.7) compared 
with 24a.  Stereochemistry of this crystal was assigned (Figure 4.8) as C9(R) P1(R) and 
the packing diagram was illustrated in Figure 4.9 for diastereomer 24b. 
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Table 4.7: Crystal data for diastereomer 24b. 
Empirical formula  C12 H19 N4 O P S 
Formula weight  298.34 
Temperature  90(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 5.4509(3) Å α= 90° 
 b = 12.0987(6) Å β= 90° 
 c = 22.2882(11) Å γ = 90° 
Volume 1469.88(13) Å3 
Z 4 
Density (calculated) 1.348 mg/m3 
Absorption coefficient 0.327 mm-1 
F(000) 632 
Crystal size 0.48 x 0.08 x 0.05 mm3 
Crystal color and habit colorless needle 
 
 
 
 
Figure 4.8. The structure of the diastereomer 24b as determined by x-ray 
crystallographic analysis. 
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Figure 4.9. Packing diagram of 24b (hydrogen atoms omitted for clarity and dashed lines 
indicate hydrogen bonding).  
 
 
Step 4: Removing the chiral auxiliary with  retention of configuration at 
phosphorus. 
With the two diastereomers resolved, removal of the chiral auxiliary group to 
form the respective enantiopure isomers was conducted.  Seungmin Ryu (1991) 
discovered an effective way to chemoselectively transform sulfur-containing 
phosphoramidates to the corresponding phosphonate methyl ester by using boron 
trifuoride-methanol (BF3-CH3OH) complex.  The reaction proceeds with net inversion of 
stereochemistry.  Reported higher yields, ease of reaction manipulation, the commercial 
availability of reagent, and the successful preparation of chiral phosphorus thiol ester 
made it the methanolysis method of choice in this study.  
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Reactions with each diastereomer (24a/24b) with BF3-CH3OH complex gave the 
corresponding chiral O,S-dimethyl 3-azidopropylphosphonothioate 25a (Sp, [α]22D = -48º) 
/25b (Rp, [α]22D = +48º) (Scheme 4.12).  It was observed that the methanolysis of 
phosphonothiolates 24a/24b took much longer time (5-6 d) to be completed than 
previously reported phosphorothiolate compounds (< 12 h). 
 
 
 
BF3-CH3OH O
PH3CS
H3CO
(CH2)3N3
25a: Sp
O
P
H3CS
H3CO (CH2)3N3
25b: Rp
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(CH2)3 N3
O
P
H3CS
(CH2)3 N3
O
PH3CS
HN
PhH3C
N
H
Ph
CH3
BF3-CH3OH
 
Scheme 4.12. Synthesis of phosphonamidothiolate diastereomers.  
   
  In summary, the azo-linked phosphonothiolates 24a/24b were successfully 
synthesized and separated using an auxiliary.  X-ray analysis showed the absolute 
configuration of phosphorus and chromophore-linked asymmetric phosphonothiolates 
(CLAPs) would be synthesized now. 
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4.4 Chromophore-linked Asymmetric Phosphonothiolates (CLAPs) 
 
The racemates of chromophore-linked phosphonothiolates were synthesized in 
section 4.2.4 with click chemistry.  However, whether click chemistry would work with 
the synthesized phosphonothiolates 25a/25b remains unclear.  Click chemistry with the 
phosphonothiolate as a racemate was studied first to ensure that Cu(I) used as the catalyst 
has no negative effect on the thiol-group (Scheme 4.13).   
 
t-BuOH/H2O
S
N(CH3)2
OO
NH
H2
C
sodium ascorbate
CuSO4.5H2O
+
3
SO2
N(CH3)2
H
N
N
N
N
(CH2)3
O
PH3CS
H3CO
25
(CH2)3 N3
O
PH3CS
H3CO
17
(CH2)3 N3
S
PHO
H3CO
13
CH3I
 
Scheme 4.13. Click reaction with phosphonothiolates.  
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 Racemic phosphonothiolate 25 was synthesized from phosphonothionate 17 by 
hydrolysis and methylation.  Click reaction occurred fabulously under 1% Cu(I) catalysis, 
which showed that chromophore-linked asymmetric phosphonothiolates (CLAPs) could 
be synthesized from 25a and 25b in this way (Scheme 4.14). 
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Scheme 4.14. Synthesis of chromophore-linked asymmetric phosphonamidothiolates.  
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4.5 Meta-Inhibitor (m-Trimethylaminophenyl Amine) Coupled to Sepharose Resin 
 
Meta-trimethylaminophenyl amine, also referred as meta-inhibitor, was 
synthesized and coupled to sepharose resin through a successively coupled succinic acid 
and diaminodipropylamine arm for purification purpose of recombinant mouse AChE.  
The expressed recombinant mouse AChE (rMAChE) in HEK 293 cells would be purified 
by an affinity chromatography packed with this modified resin (Taylor & Jacobs, 1974; 
Marchot, 1996; and Bourne, 1999).    
 
4.5.1 Meta-Inhibitor (m-trimethylaminophenyl amine) 
Meta-trimethylaminophenyl amine, also referred as meta-inhibitor (26) against 
recombinant mouse AChE, was synthesized as illustrated in Scheme 4.15.  
 
NH2
N(CH3)2
2HCl
HN
N(CH3)2
O
CH3
CH3I
HN
N(CH3)3
O
CH3
I
HCl
HCl
acetic 
anhydride
NH2
N(CH3)3 I
26  
Scheme 4.15. Synthesis of meta-inhibitor. 
 
 The free primary amino group of N,N-dimethyl-1,3-phenylenediamine was first 
protected by an acetyl group, followed by addition of methyl iodide to from the tertiary 
amine at meta-position.  Hydrochloric acid was used to deprotect and give the meta-
inhibitor (20-25% total yield).  Due to the salt form of the final compound containing 
iodide, it must be shielded from light. 
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4.5.2 Meta-Inhibitor Coupled Resin 
When the meta-inhibitor is coupled to the resin, a proper linker is necessary to  
ensure that the meta-inhibitor can reach the active site of rMAChE, so that the tertiary 
amine on the meta-inhibitor can reversibly interact with AChE.  The meta-inhibitor 
coupled resin with a proper linker length was illustrated in Scheme 4.16.   
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N
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O
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N
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N
O
C
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N(CH3)3
O
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Scheme 4.16. Synthesis of meta-inhibitor coupled resin. 
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 Sepharose CL-4B resin was activated by cyanogen bromide (CNBr), followed by 
reaction with 3, 3’- iminobispropylamine.  The success of reaction was examined by a 
bead testing using picryl sulfonic acid solution (3%), which would show an orange color 
for the resulting primary amine group.  The resulting amine coupled resin reacted with 
succinic anhydride through a peptide bond and offered a carboxylic acid coupled resin, 
which would not show color change in the bead testing.  These reactions were repeated 
once again to achieve appropriate length of the coupling linker.  The primary amine in the 
meta-inhibitor was added to the carboxylic acid coupled resin at last and offered a tertiary 
amine linked resin with appropriate linker length, which was used as affinity column for 
purification of rMAChE  
The total length of linker is approximately 25 Å, which is long enough to reach 
and interact with the active site at the bottom of the gorge of AChE.  The conjugated 
resin was stored as a 50% suspension in 100 mM NaCl, 40 mM MgC12, 10 mM NaHCO3, 
pH 8.0, containing NaN3, 0.02% (w/v) before packing an affinity column. 
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CHAPTER 5 
 
 
RESULTS AND DISCUSSIONS 
 
5.1 Solvent Effect on the Activity of AChE 
 
 The synthesized organophosphonate compounds with leaving groups (compound 
6, and 25) are reactive toward most solvents including water.  Any nucleophilic attack to 
phosphorus atom causes displacement of the leaving group of the OP inhibitors.  31P 
NMR analysis was used to investigate the stability of OP inhibitors and showed that most 
fluorophosphonate compounds (FPs) were hydrolyzed in water after 0.5 h, so all kinetic 
experiments in 0.1 M phosphate buffer solution (PBS) were designed to be completed in 
less than 0.5 h to ensure the purity of the OP inhibitors.  Meanwhile, organic solvent with 
the least effect on AChE was desired to store OP inhibitors and was selected to dissolve 
FPs and be mutually soluble with PBS. 
Acetylcholinesterase is sensitive to most organic solvents, so the amount of the 
solvent used in inhibition study was first examined.  Experiments with rMAChE and 
EEAChE demonstrated that rMAChE is particularly sensitive to the effect of solvents 
while EEAChE is more robust.  Solutions containing 0.5% (vol/vol) of acetone, methanol, 
DMSO, or DMF decreased the enzyme activity more than 20%.  In contrast, acetonitrile 
(ACN) was found to be the best solvent with least effect to both AChEs’ activity.  Less 
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than 10% reduction in activity was observed for solutions containing 0.5% (vol/vol) of 
ACN (Fig 5.1 and 5.2) for both enzymes, and subsequently, less than 0.5% of ACN 
would be used in all the following kinetic studies to ensure that more than 90% activity of 
AChE is retained. 
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Figure 5.1. Effect of composition of ACN in 0.1 M PBS 7.6 on rMAChE activity. 
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ACN effect for EEAChE
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Figure 5.2. Effect of composition of ACN in 0.1 M PBS 7.6 on EEAChE activity. 
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5.2 Inactivation of rMAChE and EEAChE by Chromophore-linked FPs 
 
All synthesized fluorophosphonate compounds are designed to inactivate AChE 
by covalently binding to the active site serine, which is an irreversible process.  Thus, the 
inhibition potencies of fluorophosphonates were determined in a concentration-dependent 
method and the kinetic parameters ki and KD were calculated.  The contributions to the 
inhibitory activity of the chromophore moiety and fluorophosphonate moiety were 
studied individually.  It is worth noting that the chromophore moiety by itself cannot 
irreversibly inhibit AChE and a different kinetic analysis was required.   
All data are expressed as mean ± S.E.M. from three or more replicate experiments. 
 
5.2.1 Inhibition of rMAChE and EEAChE by fluorophosphonoazides 8a and 8b 
The inhibitory action of fluorophosphonate portion of the target molecules was 
first studied to define its contribution to the overall inactivation process.  The FP 
compounds with no chromophore, (CH3O)(F)P(O)(CH2)3N3 (8a) and 
(CH3O)(F)P(O)(CH2)4N3 (8b), were examined as irreversible inhibitors in a 
concentration-dependent manner against rMAChE and EEAChE and the kinetic 
parameters (ki and KD) were determined in Table 5.1 and 5.2.   
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Table 5.1: Inhibition of rMAChE by 8a and 8b. 
compound ki (M-1min-1) KD (M) ik  (M
-1min-1) DK  (M) 
1.3 x 107 2.1 x 10-8 
1.4 x 107 2.1 x 10-8 8a 
1.3 x 107 3.8 x 10-8 
1.3 ± 0.1 x 107 2.7 ± 0.6 x 10-8
1.0 x 106 0.98 x 10-6 
0.93 x 106 1.7 x 10-6 8b 
1.2 x 106 2.4 x 10-6 
1.0 ± 0.1 x 106 1.7 ± 0.4 x 10-6
 
 
The bimolecular rate constant ki describes the overall interaction rate, which 
represents the potency of an inhibitor.  For fluorophosphonates 8a and 8b against 
rMAChE, it is determined that  ki(s) are 1.3 x 107 and 0.98 x 106 M-1min-1, respectively.  
Compared with a well-studied potent inhibitor, paraoxon, with ki of 4 x 105 M-1min-1 for 
rMAChE (Amitai, 1998; Kardos, 2000), compounds 8a and 8b both have larger ki values 
and therefore are more potent inhibitors for rMAChE than paraoxon, and are deemed 
extremely potent. 
The smaller fluorophosphonate 8a (with 3 CH2 groups) shows a ten-fold higher 
inhibitory activity than 8b (with 4 CH2 groups).  The fact that smaller FP inhibitor has 
stronger inhibition indicates the rigid structure of the active gorge of rMAChE.  A FP 
with a longer chain would have a harder time getting into the active gorge and inactivate 
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rMAChE.  The longer alkyl group also adds a slightly greater margin of electron donation 
thereby causing the phosphoryl to be less reactive toward nucleophilic attack. 
The dissociation constant KD  is generally considered a measure of an inhibitor’s 
affinity to the enzyme active site  (Fukuto, 1990).  A smaller KD indicates easier 
formation of reversible enzyme-inhibitor complex.  Comparing fluorophosphonates 8a 
and 8b, higher affinity of 8a (smaller KD) demonstrates that smaller inhibitors enter the 
active gorge and form the complex more easily than bigger ones. 
Similar trends were observed in the study of inactivation of EEAChE by 8a and 
8b.  The bimolecular rate constants ki for fluorophosphonates 8a and 8b were determined 
to be 7.7 x 106 and 0.96 x 106 M-1min-1, respectively.  Both are potent inhibitors against 
EEAChE as compared with paraoxon with ki of approximately 3 x 105 M-1min-1 
(Herzsprung, 1989; Mionetto, 1997).  The smaller fluorophosphonate 8a also exhibits 
roughly eight times stronger inhibitory potency than 8b, which is consistent with the 
observation in the study of rMAChE.  The dissociation constants (KD) also show 
agreement with the data for rMAChE:  a smaller molecule (fluorophosphonate 8a) has 
higher affinity (a smaller KD) for the enzyme than a larger molecule (8b). 
Comparing the kinetic results from the two sources of AChE, a higher ki was 
observed in rMAChE, indicating that it is more sensitive to the phosphonoazides 8a and 
8b than EEAChE. 
With the potency of these compounds established, the kinetic studies of the 
chromophore-linked FPs (section 5.2.2) containing the fragment can be compared to 
evaluate the effect of chromophores in inhibition of AChEs. 
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Table 5.2: Inhibition of EEAChE by 8a and 8b. 
compounds ki (M-1min-1) KD (M) ik  (M
-1min-1) DK  (M) 
7.8 x 106 1.2 x 10-7 
7.4 x 106 1.6 x 10-7 8a 
7.9 x 106 2.4 x 10-7 
7.7 ± 0.1 x 106 1.7 ± 0.4 x 10-7 
1.1 x 106 0.86 x 10-6 
0.89 x 106 2.9 x 10-6 8b 
0.86 x 106 4.8 x 10-6 
0.96 ± 0.08 x 106 2.9 ± 1.1 x 10-6 
 
 
5.2.2 Inhibition of rMAChE and EEAChE by Chromophore-linked FPs 
As described for experiments in the previous section, the inactivation of AChEs 
by chromophore-linked fluorophosphonates was also kinetically treated as an irreversible, 
pseudo-first order reaction.  The inhibition of AChEs by fourteen synthesized 
chromophore-linked FPs were determined in the concentration-dependent manner and 
examined more than three times to attain reproducible data.   
The kinetic parameters ki and KD were determined and presented in Table 5.3 and 
5.4.  The pyrene-linked FP with the four methylene (n = 4) linker showed poor solubility 
in ACN and thus no data was reported.  The precise kinetic data for Lissamine-linked FPs 
was not obtained due to the high concentration requirement of the inhibitor, which would 
cause strong color contamination from the inhibitor and swamp the UV signal in the 
assay, which is determined at 412 nm.   
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Table 5.3: Inhibition of rMAChE by chromophore-linked FPs. 
H
N
N
N
N
(CH2)n
O
PH3CO
F chromophore
(n = 3, 4)
 
chromophore n = 3 n = 4 
 ki (M-1min-1) KD (M) ki (M-1min-1) KD (M) 
dansyl 1.0 ± 0.1 x 106 4.6 ± 1.3 x 10-7 1.9 ± 0.5 x 105 3.2 ± 1.2 x 10-6
pyrene 4.0 ± 0.6 x 105 7.9 ± 0.4 x 10-7 N/A N/A 
dabsyl 7.5 ± 1.0 x 105 3.7 ± 0.5 x 10-7 6.5 ± 1.1 x 104 1.8 ± 0.1 x 10-6
diethylamino 
coumarin 2.1 ± 0.7 x 10
5 2.7 ± 1.2 x 10-6 1.4 ± 0.2 x 105 4.7 ± 0.8 x 10-7
methoxy 
coumarin 6.5 ± 0.6 x 10
5 2.4 ± 0.3 x 10-7 3.5 ± 0.6 x 104 4.8 ± 0.7 x 10-6
Lissamine 
rhodamine B ~ 1 x 10
4 N/A ~ 1 x 104 N/A 
Texas Red 8.4 ± 0.7 x 104 5.0 ± 0.9 x 10-6 3.1 ± 0.1 x 105 1.4 ± 0.2 x 10-6
N/A: not acquired. 
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Table 5.4: Inhibition of EEAChE by chromophore-linked FPs. 
H
N
N
N
N
(CH2)n
O
PH3CO
F chromophore
(n = 3, 4)
 
chromophore n = 3 n = 4 
 ki (M-1min-1) KD (M) ki (M-1min-1) KD (M) 
dansyl 1.3 ± 0.0 x 105 3.1 ± 0.6 x 10-5 6.2 ± 0.1 x 104 9.0 ± 0.4 x 10-6
pyrene 1.8 ± 0.3 x 105 1.1 ± 0.4 x 10-6 N/A N/A 
dabsyl 3.0 ± 0.3 x 105 1.9 ± 0.3 x 10-6 1.1 ± 0.0 x 105 1.7 ± 0.1 x 10-6
diethylamino 
coumarin 2.5 ± 0.4 x 10
5 1.4 ± 0.4 x 10-6 3.3 ± 0.8 x 104 6.8 ± 0.7 x 10-6
methoxy 
coumarin 1.8 ± 0.1 x 10
4 1.5 ± 0.4 x 10-4 2.7 ± 1.0 x 104 5.0 ± 2.1 x 10-5
Lissamine 
rhodamine B ~ 1 x 10
4 N/A ~ 1 x 104 N/A 
Texas Red 3.1 ± 0.2 x 104 6.7 ± 1.3 x 10-6 6.7 ± 0.4 x 104 1.6 ± 0.6 x 10-5
N/A: not acquired. 
 
All chromophore linked FPs but Lissamine were potent inhibitors against 
rMAChE (Table 5.3).  However, no chromophore-linked FP had a larger ki than the ki for 
phosphonoazides 8a and 8b (section 5.2.1), indicating that the attached chromophore 
decreases the overall inhibition potency.  This observation is consistent with the previous 
assumption that smaller molecules inactivate AChE more potently than larger ones. 
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It is also worth pointing out that both Texas Red-linked FPs exhibit relatively 
weak inhibition activity against rMAChE compared with other chromophores-linked FPs.  
The same trend was observed in Lissamine-linked FPs.  Texas Red and Lissamine are 
large polycyclic chromophores and it is likely that a different mechanism by which these 
two large size chromophores inactivate AChEs. 
For dansyl, dabsyl and methoxycoumarin, the ki(s) of their linked FPs with 3-CH2 
linker are roughly 10 times greater than the ki(s) of the corresponding FPs with 4-CH2 
linker (Fig 5.3).  This difference is the same as was observed for the phosphonoazides 8a 
and 8b (section 5.2.1).  In contrast, the ki of Texas Red-linked FP with 3-CH2 linker is 
less than that of corresponding FP with 4-CH2.  The two diethylamino coumarin-linked 
FPs showed similar inhibitory activity.   
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Figure 5.3. Comparison of inactivation potency of chromophore-linked FPs with n = 3, 4 
linker length against rMAChE. 
 
 
In terms of chemical structures, Lissamine and Texas Red are positively charged, 
larger and more complicated than dansyl, dabsyl and the other small chromophores.  It is 
suggested that these complex chromophores may have effect on binding to the peripheral 
active site (PAS) of rMAChE and the proper length is necessary for their FP moiety to 
access the enzyme active site and fit in the gorge. 
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Similar observations were also made for EEAChE (Table 5.4).  All chromophore-
linked FPs were less potent than the fluorophosphonates 8a and 8b, indicating that the 
attached chromophores decrease the inhibition potency.  For small chromophores such as 
dansyl and dabsyl, their linked FPs with shorter linker (3-CH2) also exhibit higher 
inhibition activities over ones with longer linker (4-CH2) against EEAChE.  In contrast, 
for Texas Red -linked FPs, 4-CH2 linker FP exhibits stronger inhibition activity 
compared with the 3-CH2 linker one (Fig 5. 4).   
 
da
ns
yl
py
re
ne
da
bs
yl
di
et
hy
la
m
in
o 
co
um
ar
in
m
et
ho
xy
 c
ou
m
ar
in
Li
ss
am
in
e 
rh
od
am
in
e 
B
Te
xa
s 
R
ed
n = 3
n = 4
0
50000
100000
150000
200000
250000
300000
EEAChE
n = 3
n = 4
k i (M-1min-1)
 
Figure 5.4. Comparison of inactivation potency of chromophore-linked FPs with n = 3, 4 
linker length against EEAChE. 
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It was also found that Texas Red-linked FPs have larger KD values compared to 
the other FPs, indicating that it is harder for these inhibitors to access the active site of 
AChEs and subsequently form the complex.  These observations suggest that the 
complicated structure of Texas Red interacts with the peripheral site of AChE and 
requires a minimum length of the linker to access the active site to irreversibly inactivate 
the enzyme. 
Comparing data against EEAChE and rMAChE, most chromophore-linked FPs 
showed similar inhibition activities.  However, the difference in kinetic data of EEAChE 
between shorter and longer linker FPs is less pronounced than that of rMAChE, which 
further illustrates that rMAChE has a more rigid structure in the active site.  
If a chromophore-linked FP can covalently modify the active site (using 
phosphorous moiety) and the peripheral active site (using the chromophore moiety) at the 
same time, the strength of its inhibition should be the sum of both parts, which is called 
‘double-site binding’.  The chromophore moiety of the chromophore-linked FPs is 
designed to be positioned at the PAS when the organophosphorus moiety reacts with the 
active site, however, all the chromophore-FPs have ki (s) smaller than that of the 
corresponding azo-FP compounds (8a or 8b).  These observations demonstrate that the 
length or the structure of our designed chromophore-linked FPs does not fit to allow for 
double-site binding on AChEs.  As a result, the chromophores attached on FPs do not 
increase the inhibition activities, on the contrary, they decrease the inactivation.  
Texas Red shows inhibition against both AChEs, however, the ki(s) of Texas Red-
linked FPs (3-CH2 or 4-CH2, 1 x 104 ~ 1 x 105 M-1min-1) demonstrate less inhibition 
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activity on either AChE compared to other chromophores-linked FPs, which indicates 
that the charge and/or the bulky structure of Texas Red hinders binding to AChE. 
In additional to the Texas Red-linked FPs, another relatively big chromophore-
linked FP, Lissamine-linked, displayed similar weak inhibitory potency (small ki).  The 
different inactivation behavior of these large chromophores linked FPs indicates a 
negative effect of chromophore moiety in binding to the enzyme.  This phenomenon was 
further examined by studying the effect of chromophore moiety without the covalently 
modification of the enzyme.  Specifically, we sought to determine the interaction of the 
chromophores (analogs of compound 3) with AChEs. 
 
5.2.3 Inhibition of rMAChE and EEAChE by Chromophore Groups 
The chromophore moiety may interact with AChE by binding to the active site, 
the peripheral active site, or non-competitively at other sites.  Without the 
fluorophosphonate moiety to form the covalent bond to the enzyme, the chromophore 
moiety only reversibly binds to the enzyme.  To elucidate how the chromophores interact 
with the enzyme and how much inhibition activity is resulted from this effect, the kinetic 
studies of chromophore moiety with no fluorophosphonate part (analogs of compound 3) 
against both AChEs were carried out.  The interaction between the chromophores and the 
enzyme is no longer a covalent modification, so a different data analysis method is 
required to characterize these compounds as reversible inhibitors.  
The chromophores with sulfonyl chloride or carboxylic chloride groups from 
Aldrich-sigma were first prepared by reacting with propargyl amine to obtain the 
corresponding propargyl amides (Table 5.5). 
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All chromophore-linked propargyl amides (3a - 3g) were first dissolved in 
acetonitrile (ACN) to make concentrated solutions with final concentrations of 20 µM 
and tested to see whether they were able to inactivate rMAChE.  Only diethylcoumarin, 
Lissamine and Texas Red showed apparent inhibition (more than 50%), while dansyl, 
dabsyl, methoxycoumarin and pyrene did not.  Higher concentrations of chromophores 
were not attempted due to solubility problem and interference with the assay. 
The effect of diethylcoumarin, Lissamine and Texas Red on the activity of 
rMAChE was further investigated in the concentration-dependent method.  As shown in 
Figure 5.5, the data were analyzed by Kaleidagraph 3.6 (Synergy Software, Reading, PA) 
and the concentration of the compound required to inhibit rMAChE and EEAChE by 
50% at 6 min incubation (IC50) was determined from the inhibition curve for each 
compound (Table 5.5).   
Lissamine (3f) showed an IC50 value of 50 nM range against rMAChE, indicating 
a strongest enzyme inactivation among all chromophores (3a - 3g).  Both Lissamine and 
Texas Red showed inhibition activity, suggesting that the positive charge on these 
molecules might contribute to the inactivation.  It is also possible for diethylcoumarin to 
obtain a proton and form a positive charge. 
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Table 5.5: rMAChE and EEAChE inhibitory activity (IC50) of chromophores. 
compound structure rMAChE EEAChE 
  IC50 ± SE (µM) 
3a  
(dansyl) 
SO2
N(CH3)2
N
H
 
N/A N/A 
3b  
(pyrene) 
SO2NH
 
N/A N/A 
3c  
(dabsyl) 
N N
N(CH3)2SO2
H
N
 
N/A N/A 
3d 
(diethylamino
coumarin) 
OO
N(C2H5)2
O
H
N
 
1.00 ± 0.47 N/A 
3e  
(methoxy 
coumarin) 
O
OO
OCH3
H
N
 
N/A N/A 
3f  
(Lissamine 
rhodamine B)
-O3S
O+(C2H5)2N N(C2H5)2
O2
S N
H
 0.05 ± 0.02 3.57 ± 1.45 
3g  
(Texas Red) 
O2
S
-O3S
ON+ N
N
H
 
0.70 ± 0.08 10.4 ± 2.1 
N/A: not acquired, indicating that less than 20% inhibition activity was observed 
when inhibitor concentration is 20 µM. 
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Figure 5.5. Concentration-dependence of rMAChE inhibition by diethylcoumarin (3d), 
Lissamine (3f), and Texas Red (3g); three chromophores that cause more than 20% 
inhibition at 10 µM. 
 
   
Similar studies were also performed for EEAChE (Table 5.5) and Lissamine and 
Texas Red were found to be inhibitors with IC50 of 3.57 and 10.4 µM, respectively (Fig 
5.6).  Previous reported studies on inactivation of EEAChE by polycyclic aromatic 
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hydrocarbons showed that pyrene was an inhibitor with IC50 of 5.22 µM (Kang, 1997).  
However, the inhibition potency of the pyrene-linked propargyl amide (3b) was not 
reported in this study.   
 
 
Figure 5.6. Concentration-dependence of EEAChE inhibition by Lissamine (3f) and 
Texas Red (3g); chromophores that cause more than 20% inhibition at 10 µM. 
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To further delineate the inhibitory mechanism of these chromophores against 
AChE, the compound with stronger inhibition potency (lower IC50), Lissamine, was 
further assayed against EEAChE at five substrate concentrations (duplicate experiments).  
Different concentrations of substrate were applied after 10 min of incubation with the 
inhibitor and the enzyme activity was recorded.  Lineweaver-Burk analysis in the 
presence of different substrate and inhibitor concentration was conducted with Lissamine 
(Fig 5.7).   
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Figure 5.7. Double reciprocal Lineweaver-Burk plot of Lissamine on the EEAChE 
activity. 
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Figure 5.7 shows both slopes and intercepts increase with higher inhibitor 
concentration.  This pattern indicates a mixed inhibition between competitive and 
noncompetitive inhibition, suggesting that Lissamine may interact with both the active 
site of free enzyme and some other site of the enzyme-substrate complex. 
The competitive inhibition constant Ki is obtained by secondary plot of the slope 
versus the inhibitor concentration (Fig 5.8).  The x axis intercept indicates a Ki = 11.7 µM 
of the inhibitor. 
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Figure 5.8. Replots of the reciprocal plots: slope versus inhibitor (Lissamine, 3f) 
concentration. 
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The noncompetitive inhibition constant Ki’ is obtained by secondary plot of the 
intercept versus the inhibitor concentration (Fig 5.9).  The x axis intercept represents Ki = 
24.9 µM of the inhibitor. 
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Figure 5.9. Replots of the reciprocal plots: intercept versus inhibitor (Lissamine, 3f) 
concentration. 
 
 
Kinetic data reveals the likely mechanism of EEAChE inactivation by Lissamine 
as an interaction with the entrance of the active gorge; namely, the peripheral active site 
(PAS).  When Lissamine interacts with the PAS of EEAChE, which is a noncompetitive 
process for both free enzyme and the substrate-enzyme complex.  When the EEAChE-
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Lissamine complex is formed, it prevents the substrate from entering the active site, 
making it a competitive inhibitor at the same time.  The mixed type property of the 
chromophores agrees with previous assumption and demonstrates that the bulky 
chromophores such as Lissamine and Texas Red inhibit AChEs by binding to the PAS 
and thereby blocking the gorge entrance. 
Chromophores with inhibition activity in this study are relatively weak reversible 
inhibitors against AChE compared with most well-known reversible inhibitors (e.g. 
E2020 with a mixed competitive Ki of 4.27 nM.  Saxena, 2003).  In the studies with 
chromophore-linked FPs, considering the fast phosphorylation step, the irreversibly 
binding by FP moiety is much more predominant than the reversible binding from the 
chromophore moiety and thus the whole ligand can still be treated as an irreversible OP 
inhibitor.   
 For both rMAChE and EEAChE, small chromophores such as dansyl and dabsyl 
show no inhibition activity, indicating no effect from small, uncharged chromophores on 
binding to AChEs.   
 
5.2.4 Molecular Modeling of Chromophore-linked FPs 
All kinetic analyses suggest that the large chromophores (Texas Red and 
Lissamine) interact with the peripheral active site of AChE.  To visualize this hypothesis 
and examine the orientation of the protein-ligand complexes, the smallest chromophore-
linked FP, dansyl-linked FP with 3-CH2, and the largest FP, Texas Red-FP with 3-CH2, 
were selected and compared using molecular modeling.  Both molecules were docked 
into the active gorge of AChE, followed by the comparison of the results. 
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Crystal structures of various types of AChE are available in the RCSB Protein  
Data Bank (PDB) (http://www.rcsb.org).  In order to be consistent with previous 
experiments, a crystal structure of rMAChE (1maa, resolution 2.90 Å) (Fig 3.1) (Bourne, 
1999) was chosen for simulation.  FlexX was used as the docking program because it 
offers specification of the tailored active site and customization of any kind of constraint 
between ligand and protein is allowed.  The phosphorus moiety of the inhibitor was first 
manually positioned into the active site to optimize the opportunity for phosphor-serine 
formation and then the docking program minimized the total energy of the protein-ligand 
complex to offer the possible docked configurations.   
 
 1) Dansyl-linked FP (3-CH2): 
  For dansyl-linked FP (3-CH2), four docking solutions were found when the 
constraint of distance from phosphorus to the hydroxyl of the active site serine was set up 
to be less than 2.5 Å, which is generally a distance for a chemical reaction to occur.  
FlexX provided various scoring for each of them (Table 5.6). 
 
Table 5.6: Docking solutions for dansyl-linked FP (3-CH2) in FlexX. 
 
1.Solution_Rank  2.Total_Score  3.Match_Score  4.Lipo_Score  5.Ambig_Score  
6.Clash_Score  7.Rot_Score  8.RMS  9.Similarity  10.Match  11.G_Score  
12.PMF_Acore  13.D_Score  14.CHEMSCORE  15.CScore 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
1 -5.5 -13.6 -9.5 -7.8 7.5 12.6 5.4 4.9 8 -169 -71 -133 -28 5
2 -4.9 -12.3 -10.9 -7.4 7.6 12.6 5.5 5.0 8 -156 -63 -132 -27 1
3 -4.6 -13.0 -9.2 -8.1 7.6 12.6 5.7 5.2 9 -161 -67 -130 -27 1
4 -4.5 -12.3 -10.8 -7.2 7.8 12.6 5.5 5.0 8 -164 -63 -133 -27 2
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The four docking solutions have high similarity.  The first one with the highest 
CScore (column 15, Table 5.6) represents the most reasonable structure of enzyme-OP 
complex (Fig 5.10).  
 
 
Figure 5.10. Best docking solution of dansyl-linked FP (3-CH2). 
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In this best docking solution, the distances were measured as (Fig 5.11): 
Phosphorus (ligand) – Oxygen (Ser203) = 2.5 Å; 
Phosphorus (P9) – Carbon (C19) = 14.6 Å; 
Phosphorus (P9) – Carbon (C13) = 11.6 Å. 
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Figure 5.11. Structure of dansyl-linked FP (3-CH2). 
 
The distance of 2.5 Å from the Ser203-O and the phosphorus atom P is close 
enough for a chemical reaction to occur in assistance of small changes of protein 
structure.  Meanwhile, the whole dansyl-linked FP is smoothly placed along the active 
gorge in this structure. 
 
2) Texas Red-linked FP (3-CH2): 
Texas Red was the largest chromophore molecule used in the study.  The 
compound obtained from Invitrogen, Inc is a mixture of ortho- and para- isomers that 
relate to the position of amide link to propargyl amine.   
2a) (o-)Texas Red-linked FP (3-CH2): 
 116 
SO2
-O3S
O
N+
NHNN
N
NO
PH3CO
F
 
Figure 5.12. Structure of (o-) Texas Red-linked FP (3-CH2). 
The structure of (o-)Texas Red-linked FP (3-CH2) was drawn in SYBYL.  After 
minimizing the free energy of this ligand, the most stable structure was bent and the 
length of the molecule in this configuration is approximate 13.1 Å, which is much shorter 
than the length of the gorge. 
No docking solution was found when the distance between phosphorus of the 
inhibitor and the hydroxyl of Ser203 was constrained to 3.0 Å or less.  The docking 
results indicate that the possibility for fluorophosphonate moiety to access the hydroxyl 
serine is relatively low for (o-)Texas Red-linked FP (3-CH2). 
The constraint was later set to be “optional” to show all possible docking 
solutions.  Among the first 30 docking solutions produced (about 200 solutions 
generated), most of them showed that the docked ligand was outside of the enzyme, 
which is not desired.  The best docking solution with highest scores is shown in Fig 5.13. 
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Figure 5.13. Best docking solution of (o-)Texas Red-linked FP (3-CH2). 
 
In the docking solution, the chromophore moiety is placed outside of the gorge 
entrance (Fig 5.14), either because the size of the chromophore is bigger than the 
entrance or because the interaction between the chromophore and the entrance is strong.  
Considering the ligand length about 13.1 Å, it is unsurprising that the linker is not long 
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enough for the phosphorus to access the bottom of the gorge if its big chromophore 
moiety cannot pass through the gorge entrance.  
 
Figure 5.14. A docking solution for (o-)Texas Red-linked FP (3-CH2) in rMAChE 
(surface view), showing that the chromophore portion remains external to the enzyme. 
 
 
  In the solution, the distances were: 
Phosphorus (ligand) – Oxygen (Ser203) = 4.5 Å; 
Phosphorus (ligand) – Oxygen (ligand, in the ring) = 15.5 Å. 
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The 4.5 Å distance from the phosphorus of the ligand to the hydroxyl serine, is 
too far for a chemical reaction to take place, unless the protein structure changes 
dramatically to help the reaction.  It is proposed that (o-)Texas Red-linked FP (3-CH2) 
can not slide into the active gorge completely due to its big chromophore moiety.  Both 
the big size and the charge of the Teas Red could be the reasons for this unfavorable 
configuration. 
 
 
2b) (p-)Texas Red-linked FP (3-CH2): 
 
O3S
SO2
O
N+
N
HNN
N
NO
PH3CO
F
 
Figure 5.15. Structure of (p-) Texas Red-linked FP (3-CH2). 
 
Compared with (o-)Texas Red-linked FP (3-CH2), the other isomer, (p-)Texas 
Red-linked FP (3-CH2) (Fig 5.15), has a longer linker.  The most stable structure after 
minimizing free energy showed that the direct molecule length is 14.8 Å, which provides 
a better chance for the FP moiety to access the hydroxyl serine at the bottom of the gorge. 
Two similar solutions were produced by the docking program when the distance 
between phosphorus of the ligand and the hydroxyl Ser203 is less than 2.5 Å.  The one 
with better scores was shown in Figure 5.16 and 5.17. 
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Figure 5.16. Best docking solution of (p-)Texas Red-linked FP (3-CH2). 
 
The distances were: 
Phosphorus (ligand) – Oxygen (Ser203) = 2.5 Å; 
Phosphorus (ligand) – Oxygen (on the ring of the ligand) = 17.8 Å. 
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Figure 5.17. A docking solution for (p-)Texas Red-linked FP (3-CH2) in rMAChE 
(surface view), showing that the chromophore portion remains external to the enzyme. 
 
As shown in figure 5.17, the chromophore moiety was again placed outside of the 
gorge entrance.  For (p-)Texas Red-linked FP (3-CH2), the phosphorylation step is easier 
to take place than the ortho- isomer because of the longer molecular length, although the 
chromophore group is positioned out of the gorge entrance in both cases.   
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Based upon all the docking experiments, it is proposed that (o-)Texas Red-linked 
FP (3-CH2) is not able to covalently modify the enzyme while the (p-)Texas Red-linked 
FP (3-CH2) possibly can.  The mixture of isomers of Texas Red makes the interaction 
with enzyme complicated and unpredictable.  However, it is clear that Texas Red moiety 
interacts with the enzyme by blocking the entrance of the active site.  
 
5.2.5 Summary 
In summary, large chromophores such as Texas Red and Lissamine interact with 
AChE by blocking its gorge entrance, which further block the enzyme activity.  On the 
other hand, small chromophores such as dansyl and dabsyl, do not have much interaction 
with the enzyme by themselves and their linked FPs demonstrate similar inhibition 
potency.  Both docking observations and kinetic data show agreement on this conclusion.   
In the docking studies, Texas Red moiety restricts the FP moiety from reacting 
with Ser203, either by sterically hindering the entrance, or by strongly binding to the PAS 
on the entrance with their cations.  Either mechanism prevents this type of chromophore-
linked FPs from phosphorylating the active site unless long enough linker is attached.  
This explains why the big chromophore linked FPs show relatively low inhibition activity.  
Longer linker FP inhibitors with these chromophores are better than shorter linker ones 
because the longer linker provides a better chance for the FP moiety to access the active 
site on the bottom of the gorge.   
Texas Red and Lissamine linked propargyl amide behave as reversible inhibitors 
against AChE, both competitively and noncompetitively, indicating that the big 
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chromophores inactivate the enzyme by both binding to the PAS and blocking the gorge 
entrance.  
To avoid the binding from the chromophore moiety, smaller, uncharged 
chromophores are preferred for investigating the stereoselectivity of the gorge in the 
future.  It is also possible to increase the chain length of big chromophore-linked FPs to 
decrease the effect.  The big chromophores with complicated interactions with the 
enzyme can be used in the future to study the PAS of AChE or build the double-site 
binding inhibitors by optimizing the length of the molecule.  
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5.3 Post-inhibition Analysis of Inactivated EEAChE by Chromophore-linked FPs 
 
The post-inhibition phases of inhibited acetylcholinesterase by irreversible 
fluorophosphonate inhibitors are illustrated in Figure 5.18.   
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Figure 5.18.  Inhibition of AChE and post-inhibitory mechanism. 
 
The post-inhibition phases of inhibited acetylcholinesterase are supposed to be the 
same for all fluorophosphonate inhibitors because the fluorophosphonate moiety is the 
only target involved in these processes.  Preliminary study of reactivation process was 
made and fluorophosphonate inhibitors with different inhibition potency were examined. 
Because the reactivation experiments require a high concentration of enzyme, 
only EEAChE was studied.  Spontaneous reactivation was studied for fluorophosphonate 
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8a, which is the strongest inhibitor among all FPs.  Following the method described in 
section 7.4.3, more than 90% inactivated EEAChE by inhibitor 8a was diluted 100-fold, 
and the reactivation rate was studied.  At a 100-fold dilution, the inhibitor concentration 
is no longer a factor in further inactivating the enzyme and only reactivation, aging or 
inhibited species exist.  No reactivation of inhibited EEAChE was observed.  
Spontaneous reactivation was also analyzed for dansyl-linked FP (4-CH2), an inhibitor 
with average inhibition strength and no reactivation was observed.  A weaker inhibitor, 
Texas Red-linked FP (3-CH2) was studied under the same conditions and no reactivation 
was observed.   
The activity of the control aliquot started decreasing after 3 h inhibition, thus no 
study was attempted more than 3 h.  To get more than 90% inhibition of AChE in 3 h, 
excess amount of inhibitors was used.  The amount of inhibitors should be better 
controlled to investigate the reactivation process more precisely in the future.   
2-PAM solution (0.1 mM) was used in mediated reactivation of EEAChE 
inhibited by Texas Red-linked FP (3-CH2) and dansyl-linked FP (3-CH2).  Again, no 
reactivation was found.  Further study with more concentrated 2-PAM is desired to study 
this process in more details. 
 Current observations showed that EEAChE inhibited by FPs was not reactivated, 
implying that the aging is the dominant post-inhibitory process or that the chromophore 
moiety around the gorge entrance prevents the nucleophile (oxime) from accessing the 
active site.  The fact that no reactivation was observed is beneficial to the purpose of 
separation and purification of protein-inhibitor complex in the future. 
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5.4 Inactivation of rMAChE and EEAChE by Dansyl-linked Phosphonothiolates 
 
The inhibition activities of the synthesized dansyl-linked phosphonothiolates 13 
and 15 are the average activities of its chromophore-linked asymmetric 
phosphonothiolates (CLAPs) (Fig 5.19).   
 
SO2
N(CH3)2
H
N
N
N
N
(CH2)3
O
PH3CO
RS
13: R = SCH3
15: R = SCH2CH2N+(CH3)3  
Figure 5.19. Structures of dansyl-linked phosphonothiolates 13 and 15 (racemate). 
 
To evaluate the inhibitory potency of the CLAPs, the inhibition abilities of 
racemic dansyl-linked phosphonothiolates (compound 13 and 15) were examined.  
Phosphonothiolates were examined as phosphorylated inhibitors in a concentration 
dependent manner and the ki and KD values were presented in Table 5.7.  Each compound 
was tested more than three times and data were only included when R2 of the plot is over 
0.95.   
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Table 5.7: Inhibition of rMAChE and EEAChE by phosphonothiolates 13 and 15 
(racemate). 
 
compound rMAChE EEAChE 
 ki (M-1min-1) KD (M) ki (M-1min-1) KD (M) 
13 < 103 NA < 103 NA 
15 2.0 ± 0.4 x 105 2.5 ± 0.7 x 10-6 3.3 ± 0.4 x 103 1.2 ± 0.5 x 10-5
N/A: not acquired. 
 
 
Compared with dansyl-linked FP compounds, dansyl -linked phosphonothiolates 
have lower inhibition potency against rMAChE and EEAChE.  The phosphonothiolate 15 
is more potent than compound 13.  Considering the structure difference in the two 
compounds, the thiocholine group of compound 15 makes the phosphorus moiety bind to 
the active site better and thus increases the inhibition ability. 
Modest inhibition ability of phosphonothiolates may provide longer time course 
in studying the stereoselectivity of AChE later, however, the low inhibition potency of 
compound 13 may add difficulty in obtaining the kinetic data at the same time.   
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5.5 Inactivation of rHuAChE and EEAChE by Asymmetric Phosphonothiolates 
 
Asymmetric phosphonothiolates 25a and 25b were prepared in chapter 4 and used 
to determine the stereospecific inhibition of recombinant human and electric eel AChE.  
Recombinant human AChE selected in this section has comparable properties as 
rMAChE but more practical application due to its human source.  
 
5.2.1 Stereoselective Inactivation of rHuAChE by Asymmetric Phosphonothiolates 
The racemate O, S-dimethyl (3-azopropyl) phosphonothiolate 25 and the 
corresponding enantiopure isomers 25a and 25b were studied against rHuAChE as 
irreversible inhibitors, respectively.  The inhibition rates (ki) and dissociation constants 
(KD) were determined in the concentration-dependent manner and presented in Table 5.8. 
 
Table 5.8: Inhibition of rHuAChE by phosphonothiolates 25, 25a and 25b. 
 
compound ki (M-1min-1) KD (M) ik  (M
-1min-1) DK  (M) 
8.1 x 103 6.1 x 10-5 
8.2 x 103 7.3 x 10-5 25 
7.2 x 103 12.1 x 10-5 
7.9 ± 0.3 x 103 8.5 ± 1.8 x 10-5 
1.7 x 103 9.8 x 10-5 
1.7 x 103 9.8 x 10-5 25a (S) (-) 
1.9 x 103 11.2 x 10-5 
1.7 ± 0.1 x 103 10.3 ± 0.5  x 10-5 
9.4 x 103 2.4 x 10-5 
9.7 x 103 2.8 x 10-5 25b (R) (+) 
7.8 x 103 4.7 x 10-5 
9.0 ± 0.6 x 103 3.1 ± 0.8 x 10-5 
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The extent of stereoselective inhibition is revealed by the kinetic rate constants 
(ki).  (S)-Phosphonothiolate 25a exhibits five times less inhibitory potency than (R)- 
phosphonothiolate 25b on recombinant human AChE, showing that the enzyme is (R)-
selectively inactivated.    
The dissociation constant KD, which describes the formation of the OP-AChE 
complex, is restricted by the steric hindrance, possibly suggesting a selective 
configuration favored by the active site of rHuAChE.  (R)-Phosphonothiolate 25b has 
three times higher affinity (lower KD) than (S)-25a, indicating that the first inhibition step 
of complex formation is largely dependent on the chirality of the inhibitor due to the 
configuration refinement.  In contrast, phosphorylation step proceeds rapidly and the rate 
constant (kp = ki x KD) is less dependent of the chirality of the inhibitor. 
 
5.5.2 Inhibition of EEAChE by Asymmetric Phosphonothiolates 
Similar stereoselective inactivation of EEAChE was observed with the 
asymmetric phosphonothiolates 25a and 25b.  However, the racemate compound 25 
shows a small ki of 5.3 x 102 M-1Min-1 against EEAChE, indicating that the inhibition 
potency of this inhibitor is too weak to study the stereoselectivity.    
Both 25a and 25b slightly inactivated EEAChE however the kinetic parameter 
ki(s) were not determined and only estimated to be less than 103 M-1Min-1.  It is hard to 
obtain data of a weak inhibitor (ki < 103 M-1Min-1) in the kinetic studies because either 
longer incubation time or more concentrated sample is required.  However, a longer 
incubation time induces the decrease of the enzyme activity according to the control 
 130 
study, and a more concentrated sample is not applicable in most cases due to solubility 
problem.  It was decided that only ki larger than 103 (M-1Min-1) is attempted.  
In contrast to EEAChE, recombinant Human AChE is more sensitive to 
phosphonothiolate inhibitors.  Recombinant acetylcholinesterases from different sources 
are desired to examine the stereoselectivity in the future.     
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5.6 Attempted Analysis of Inactivation of rHuAChE by CLAPs 
 
 Before attempting inactivation analysis with CLAPs, dansyl-linked racemic 
phosphonothiolate 13 was studied first.   Previous data in section 5.4 have already 
demonstrated the weak inhibitory activity of this compound against rMAChE and 
EEAChE.  Current kinetic study on rHuAChE showed that the ki of compound 13 is 
approximately 0.8 x 103 M-1Min-1.  Considering the larger effect added by other 
chromophores than dansyl, study of two different chromophores-linked asymmetric 
phosphonothiolate compounds was not attempted.   
In order to increase the inhibition potency of the asymmetric phosphonothiolate 
inhibitors, chromophore-linked O-methyl, S-choline phosphonates (analog of compound 
15) are desired in the future study.  Based on studies in section 5.4, S-choline group 
increases the inhibition activity by binding to the active site with its tertiary amine.  O-
methyl, S-choline (3-azopropyl) phosphonate is to be synthesized as an asymmetric 
inhibitor and more stereoselectivity is expected due to the structural bulkiness.   
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CHAPTER 6 
 
 
CONCLUSIONS 
 
1. A flexible and reliable synthetic route for the generation of an array of chromophore-
linked fluorophosphonate (FPs) was found to be successful and a panel of 
chromophore-linked FPs with different chromophore and length was synthesized via 
click chemistry.   
 
2. The chromophore-linked FPs showed potent inhibitory activity against both 
recombinant mouse AChE (rMAChE) and electric eel AChE (EEAChE).  Compared 
with the inhibitory activity for the FP moiety without chromophore, a decrease in 
inhibition potency demonstrated a negative effect of the chromophore in the 
inactivation of AChEs.  This negative effect is especially evident when the 
chromophore is bulky and positively charged.   
 
3. Detailed analysis of one chromophore (Lissamine) as a reversible inhibitor that 
transiently binds to AChE confirmed the inhibition effect of the chromophore.  A 
mixed inhibitory activity (both competitive and non-competitive) of Lissamine was 
observed, indicating the steric blockage effect of bulky chromophore.   
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4. Molecular modeling of chromophore-linked FPs in AChE verified that bulky 
chromophores were positioned outside the gorge entrance and small chromophores 
were seated within the gorge.  The blockage of the gorge entrance by big 
chromophores in docking observations verified their kinetic inhibition activity. 
   
5. A new synthetic route for preparation of the phosphonothiolate analogs of 
chromophore-OPs was proposed and the synthesized chromophore-linked 
phosphonothiolates showed inhibitory activity on both rMAChE and EEAChE. 
 
6. The asymmetric synthesis of the phosphonothiolate building block of chromophore-
linked phosphonothiolates was accomplished by using a chiral auxiliary to form 
separable phosphorus diastereomers. X-ray analysis assigned the absolute 
configuration at phosphorus for both stereoisomers. 
   
7. Anti-AChE potency of phosphonothiolate enantiomers demonstrated a 4-fold 
favoring of Rp–isomer over Sp–isomer by the recombinant human acetylcholinesterase 
(rHuAChE). 
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CHAPTER 7 
 
 
EXPERIMENTAL 
 
7.1 General 
 
Commercially available reagents were purchased from Aldrich Chemical Co., 
Millwaukee, WI.  All solvents and reagents were purified when necessary by standard 
literature methods.  Melting points were determined on a Fisher-Johns melting point 
apparatus with calibration in an appropriate temperature range.  Analytical thin-layer 
chromatography (TLC) was conducted on E. Merck aluminum-backed, 0.2 mm silica gel, 
TLC plates.  Flash chromatography was performed with Kieselgel 60, 230-400 mesh 
(Merck).  Elemental analyses were performed by Midwest Microlab Ltd., Indianapolis, 
IN.  High resolution mass spectra (HRMS) were obtained by electrospray ionization (ESI) 
on a Micromass LCT using caffeine as a mass standard at m/z 195.0882. 
All proton (1H), carbon (13C) and phosphorus (31P) nuclear magnetic resonance 
spectra were recorded on a Varian VXR 400-NMR instrument (400 MHz, 100 MHz and 
162 MHz, respectively) in deuterated chloroform (CDCl3) unless specified otherwise.  
Pertinent proton NMR frequencies are tabulated in the following order: chemical shift (in 
ppm), multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet), coupling 
constant (J in hertz) and the number of hydrogens.  Proton and carbon frequencies of 
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spectra obtained are relative to chloroform (1H, 7.26 ppm; 13C, 77.0 ppm) as an internal 
standard unless specified otherwise.  Phosphorus chemical shifts are relative to 
phosphoric acid (H3PO4) in CDCl3 as an external standard.  
Caution: The OP chemicals synthesized and used in this study are hazardous 
anticholinesterases and should be handled only by trained personnel in a well-ventilated 
hood.  The OP chemicals described are hydrolyzed by 5N NaOH to render them inactive 
as phosphorylating agents. 
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7.2 Synthesis 
 
Br (CH2)3 Br P(OCH3)3+
160oC
1a
(CH2)3 Br
O
PH3CO
H3CO
 
 
O,O-Dimethyl (3-bromopropyl) phosphonate (1a).  This compound has been 
described previously (Maguire, 2001).  Slight modifications in the reaction conditions are 
presented here to prevent double addition by-product.  Trimethylphosphite (3.55 mL, 
30 mmol) and 1,3-dibromopropane (12.2 mL, 120 mmol) were placed in a round bottom 
flask fitted with a reflux condenser and heated to 150 °C (external temperature) in an oil-
bath for 1 h.  Once cooled to rt, the excess dibromopropane was removed by distillation 
at 60–62 °C under reduced pressure (1 mmHg).  Purification by Kugelrohr distillation at 
120 °C at 0.1 mmHg gave a clear, colorless oil (3.28 g, 47%).   
 
1H NMR (CDCl3): δ 1.86 (m, 2 H), 2.09 (m, 2 H), 3.42 (t, J = 6.0 Hz, 2 H), 3.69 
(d, 3JHP = 8.2 Hz, 6 H).   
13C NMR (CDCl3): δ 23.5 (d, 1JCP = 143.0 Hz), 25.9 (d, 2JCP = 4.8 Hz), 33.6 (d, 
3JCP = 18.4 Hz), 52.6 (d, 2JCP = 6.4 Hz).   
31P NMR (CDCl3): δ 34.2 (s). 
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Br (CH2)4 Br P(OCH3)3+
160oC
1b
(CH2)4 Br
O
PH3CO
H3CO
 
 
O,O-Dimethyl (4-bromobutyl) phosphonate (1b).  This procedure is identical to 
that described in 1a except that it started with1,4-dibromobutane. 
 
1H NMR (CDCl3): δ 1.57 (m, 2 H), 1.60(m, 2 H), 1.78 (m, 2 H), 3.24 (t, J = 6.6 
Hz, 2 H), 3.56 (d, 3JHP = 10.7 Hz, 6 H).   
13C NMR (CDCl3): δ 20.7 (d, 2JCP = 6.0 Hz), 23.3 (d, 1JCP = 141.9 Hz), 32.4, 32.6 
(d, 3JCP = 15.0 Hz), 51.9 (d, 2JCP = 7.6 Hz).   
31P NMR (CDCl3): δ 34.8 (s). 
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Figure 7.1. (A) 1H, (B) 13C and (C) 31P NMR spectra of O,O-dimethyl (4-bromobutyl) 
phosphonate (1b). 
(B) 
(C) 
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(CH2)3 N3
O
PH3CO
H3CO
2a
70oC
1a
(CH2)3 Br
O
PH3CO
H3CO
+ NaN3
DMF, H2O
 
 
O,O-Dimethyl (3-azopropyl) phosphonate (2a).  A reaction mixture of 
compound 1a (2.00 g, 8.67 mmol) and sodium azide (1.13 g, 17.00 mmol) in a 10:1 
mixture of acetonitrile-water (15 mL) was heated at 70 °C for 12 h.  After cooling to rt, 
ethyl acetate was added and the organic layer was washed with water, collected and dried 
over anhydrous MgSO4.  Evaporation under reduced pressure gave 1.20 g (72%) of the 
title compound as light yellow oil.   
 
1H NMR (CDCl3): δ 1.77 (m, 2 H), 1.86 (m, 2 H), 3.36 (t, J = 4.3 Hz, 2 H), 3.73 
(d, 3JHP = 11.0 Hz, 6 H).   
13C NMR (CDCl3): δ 21.3 (d, 1JCP = 142.9 Hz), 22.6 (d, 2JCP = 4.1 Hz), 51.6 (d, 
3JCP = 16.4 Hz), 52.6 (d, 2JCP = 6.8 Hz).   
31P NMR (CDCl3): δ 34.5 (s). 
MS (ESI-TOF): Calcd for C5H12N3O3P (M+H) 194.0695; found 194.0615.  
IR (NaCl, CHCl3): ν 3464, 2954, 2852, 2099, 1459, 1248, 1031, 818 cm–1. 
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Figure 7.2. (A) 1H, (B) 13C and (C) 31P NMR spectra of O,O-dimethyl (3-azopropyl) 
phosphonate (2a). 
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(CH2)4 N3
O
PH3CO
H3CO
2b
70oC
1b
(CH2)4 Br
O
PH3CO
H3CO
+ NaN3
DMF, H2O
 
 
O,O-Dimethyl (4-azobutyl) phosphonate (2b).  This procedure is identical to 
that described in 2a except that it started with O,O-dimethyl (4-bromobutyl) phosphonate 
1b. 
 
1H NMR (CDCl3): δ 1.66(m, 4 H), 1.77 (m, 2 H), 3.28 (t, J = 6.5 Hz, 2 H), 3.72 (d, 
3JHP = 11.0 Hz, 6 H).   
13C NMR (CDCl3): δ 19.5 (d, 2JCP = 6.1 Hz), 23.8 (d, 1JCP = 141.9 Hz), 29.2 (d, 
3JCP = 16.2 Hz), 50.5, 52.1 (d, 2JCP = 7.6 Hz).   
31P NMR (CDCl3): δ 34.6 (s). 
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Figure 7.3. (A) 1H, (B) 13C and (C) 31P NMR spectra of O,O-dimethyl (4-azobutyl) 
phosphonate (2b). 
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S
(H3C)2N
OO
Cl
H2N+
CH2Cl2
3
SO2NH
N(CH3)2
 
 
5-(Dimethylamino)-N-(2-propynyl)-1-naphthalenesulfonamide (3) (Bolletta, 
1996).  To a solution of 5-(dimethylamino)naphthalene-1-sulfonyl chloride (1.00 g, 3.70 
mmol) in anhydrous dichloromethane (CH2Cl2, 10 mL) were added triethylamine (0.55 
mL, 4.00 mmol) and propargylamine (0.28 mL, 4.00 mmol).  The solution immediately 
turned from bright yellow to fluorescent.  After quenching with 0.1 M phosphate buffer 
(pH 7.0, 20 mL) and extraction with CH2Cl2 (25 mL), the organic layer was collected and 
dried over anhydrous MgSO4.  Further purification by flash chromatography using silica 
(5:95 methanol-chloroform) gave a yellow solid (0.95 g, 89%) of pure compound 3.   
 
1H NMR (CDCl3): δ 1.90 (t, J = 2.5 Hz, 1 H), 2.88 (s, 6 H), 3.76 (dd, J = 6.0, 2.5 
Hz, 2 H), 4.81 (t, J = 6.0 Hz, 1 H), 7.19 (d, J = 7.8 Hz, 1 H), 7.55 (q, J = 7.8 Hz, 2 H), 
8.25 (t, J = 7.8 Hz, 2 H), 8.55 (d, J = 7.8 Hz, 1 H).   
13C NMR (CDCl3): δ 158.0, 152.2, 134.5, 131.0, 130.1, 130.0, 128.8, 123.4, 118.8, 
115.4, 78.1, 72.9, 45.6, 33.2. 
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3
sodium ascorbate
CuSO4.5H2O
t-BuOH/H2O
SO2
N(CH3)2
H
N
N
N
N
(CH2)3 N3
(CH2)3
O
PH3CO
H3CO
O
PH3CO
H3CO
2a
SO2NH
(H3C)2N
+
4a  
 
Dansyl-linked phosphonate (4a).  Dimethyl (3-azopropyl) phosphonate (2a) 
(0.33 g, 1.70 mmol) and dansyl sulfonamide 3 (0.49 g, 1.70 mmol) were suspended in a 
1:1 mixture of water and tert-butyl alcohol (8 mL).  Sodium ascorbate solution (0.17 
mmol; 0.17 mL of freshly prepared 1 M solution in water) was added, followed by 
copper (II) sulfate pentahydrate solution (7.50 mg, 0.10 mmol, in 0.20 mL of water).  The 
heterogeneous mixture was stirred vigorously overnight, at which point it cleared and 
TLC analysis indicated complete consumption of the reactants.  Ethyl acetate (30 mL) 
was added and washed with water twice.  The organic layer was collected and dried over 
anhydrous MgSO4.  Evaporation under reduced pressure and purification by flash 
chromatography using silica (5:95 methanol-chloroform) gave 0.63 g (78%) of pure 
product as a yellow powder. 
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1H NMR (CDCl3): δ 1.57 (m, 2 H), 1.99 (m, 2 H), 2.77 (s, 6 H), 3.59 (d, 3JHP = 
10.8 Hz, 6 H), 4.11 (dd, J = 6.9, 5.1 Hz, 2 H), 4.16 (t, J = 6.9 Hz, 2 H), 6.87 (t, J = 5.1 Hz, 
1 H), 7.04 (d, J = 7.6 Hz, 1 H), 7.33 (s, 1 H), 7.39 (q, J = 7.6 Hz, 2 H), 8.14 (d, J = 7.6 Hz, 
1 H), 8.22 (d, J = 9.0 Hz, 1 H), 8.41 (d, J = 7.6 Hz, 1 H).   
13C NMR (CDCl3): δ 20.5 (d, 1JCP = 142.3 Hz), 23.1 (d, 2JCP = 4.5 Hz), 38.3, 45.1, 
49.5 (d, 3JCP = 17.5 Hz), 52.2 (d, 2JCP = 6.0 Hz), 77.2, 114.9, 118.7, 122.5, 122.9, 128.5, 
129.3, 130.0, 134.6, 144.0, 151.5.   
31P NMR (CDCl3): δ 33.9 (s). 
MS (ESI-TOF): Calcd for C20H29N5O5PS (M+H) 482.1627; found 482.1633; 
Calcd for C20H28N5O5PSNa (M+Na) 504.1446; found 504.1433. 
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Figure 7.4. (A) 1H, (B) 13C and (C) 31P NMR spectra of dansyl-linked phosphonate (4a). 
(C) 
(B) 
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3
sodium ascorbate
CuSO4.5H2O
t-BuOH/H2O
SO2
N(CH3)2
H
N
N
N
N
(CH2)4 N3
(CH2)4
O
PH3CO
H3CO
O
PH3CO
H3CO
2b
SO2NH
(H3C)2N
+
4a'  
 
Dansyl-linked phosphonate (4a’).  This procedure is identical to that described 
in 4a except that it started with O,O-dimethyl (4-azobutyl) phosphonate 2b. 
 
1H NMR (CDCl3): δ 1.50 (m, 2 H), 1.69 (m, 2 H), 1.83 (m, 2 H), 2.84 (s, 6 H), 
3.66 (d, 3JHP = 11.2 Hz, 6 H), 4.15 (t, J = 7.2 Hz, 2 H), 4.16 (dd, J = 6.9, 3.5 Hz, 2 H),  
6.52 (t, J = 5.1 Hz, 1 H), 7.13 (d, J = 7.8 Hz, 1 H), 7.28 (s, 1 H), 7.47 (q, J = 7.3 Hz, 2 H),  
8.21 (d, J = 7.3 Hz, 1 H), 8.25 (d, J = 8.8 Hz, 1 H), 8.49 (d, J = 8.1 Hz, 1 H).   
13C NMR (CDCl3): δ 22.2 (d, 1JCP = 143.5 Hz), 23.6 (d, 2JCP = 4.5 Hz), 31.5 (d, 
3JCP = 16.5 Hz), 38.4, 45.6, 50.0 (d, 4JCP = 15.1 Hz), 51.8 (d, 2JCP = 6.2 Hz), 76.8, 115.7, 
119.8, 122.8, 123.5, 128.3, 129.3, 129.5, 130.0, 135.1, 143.9, 150.3.   
31P NMR (CDCl3): δ 34.7 (s). 
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Figure 7.5. (A) 1H and (B) 31P NMR spectra of dansyl-linked phosphonate (4a’). 
(A) 
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N(CH3)2
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N
N
N
N
(CH2)3
O
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N(CH3)2
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1. NaOH,70oC
2. H+
 
 
Dansyl-linked phosphonic acid (5a).  Hydrolysis of dansyl-linked phosphonate 
4a was achieved by dissolving 4a (0.52 g, 1.10 mmol) into isopropanol (20 mL) with 1 N 
NaOH (3 mL).  The mixture was heated at 70 °C for 12 h while refluxing.  After cooling 
to rt, the solution mixture was diluted with water (20 mL) and washed with ethyl acetate 
(2 x 20 mL).  The aqueous part was acidified by 1 N HCl to adjust to pH 2.  A mixture of 
chloroform and isopropanol (30 mL, 1:3) was added and the extracted product was 
collected and dried over anhydrous MgSO4.  Evaporation under reduced pressure gave 
0.32 g (62%) of pure product 5a as light yellow oil.  
 
1H NMR (CDCl3): δ 1.54 (m, 2 H), 1.93 (m, 2 H), 2.89 (s, 6 H), 3.55 (d, 3JHP = 9.5 
Hz, 3 H), 4.10 (dd, J = 6.9, 2.1 Hz, 2 H), 4.18 (t, J = 6.9 Hz, 2 H), 5.98 (t, J = 5.1 Hz, 1 
H), 7.21 (d, J = 7.2 Hz, 1 H), 7.41 (s, 1 H), 7.45 (q, J = 7.6 Hz, 2 H), 8.25 (t, J = 8.1 Hz, 2 
H), 8.45 (d, J = 8.1 Hz, 1 H).    
13C NMR (CD3OD): δ 22.2 (d, 1JCP = 138.1 Hz), 23.0 (d, 2JCP = 3.3 Hz), 37.7, 
45.0, 50.0 (d, 3JCP = 16.1 Hz), 51.0 (d, 2JCP = 6.1 Hz), 75.7, 116.3, 121.3, 123.1, 124.1, 
127.9, 128.8, 129.1, 129.5, 136.3, 148.6.   
31P NMR (CDCl3): δ 30.1 (s). 
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MS (ESI-TOF): Calcd for C19H27N5O5PS (M+H) 468.1471; found 468.1499; 
Calcd for C19H26N5O5PSNa (M+Na) 490.1290; found 490.1394. 
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Figure 7.6. 31P NMR spectrum of dansyl-linked phosphonic acid (5a). 
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Dansyl-linked phosphonic acid (5a’).  This procedure is identical to that 
described in 5a except that it started with dansyl-linked phosphonate 4a’. 
 
1H NMR (CDCl3): δ 1.47 (m, 4 H), 1.85 (m, 2 H), 2.83 (s, 6 H), 3.46 (d, 3JHP = 7.2 
Hz, 3 H), 4.08 (t, J = 6.9 Hz, 2 H), 4.12 (dd, J = 6.9, 2.1 Hz, 2 H), 6.55 (s, 1 H), 7.03 (d, J 
= 7.4 Hz, 1 H), 7.21 (s, 1 H), 7.46 (q, J = 7.6 Hz, 2 H), 8.06 (d, J = 7.3 Hz, 1 H), 8.21 (d, 
J = 8.5 Hz, 1 H), 8.39 (d, J = 9.0 Hz, 1 H).    
13C NMR (CD3OD): δ 22.5 (d, 1JCP = 141.1 Hz), 23.7 (d, 2JCP = 3.3 Hz), 29.2, 
38.6, 45.8, 50.0 (d, 3JCP = 15.2 Hz), 52.0 (d, 2JCP = 6.1 Hz), 75.7, 115.9, 120.1, 123.8, 
128.6, 129.5, 129.7(2), 129.8, 130.3, 135.4, 144.2.   
31P NMR (CDCl3): δ 32.2 (s). 
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Figure 7.7. 31P NMR spectrum of dansyl-linked phosphonic acid (5a’). 
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Dansyl-linked fluorophosphonate (6a).  To a solution of compound 5a (0.060 g, 
0.13 mmol) in CH2Cl2 (5 mL) was added cyanuric fluoride (0.018 g, 0.13 mmol).  The 
reaction mixture was stirred at rt for 0.5 h until 31P NMR showed a complete conversion 
from P-OH to P-F.  After evaporation under vacuum, compound 6a (0.060 g, 0.13 mmol) 
was isolated as a yellow solid. 
 
1H NMR (CDCl3): δ 1.69 (m, 2 H), 1.87 (m, 2 H), 2.87 (s, 6 H), 3.78 (d, 3JHP = 9.0 
Hz, 3 H), 4.21 (dd, J = 4.9, 2.1 Hz, 2 H), 4.27 (t, J = 6.6 Hz, 2 H), 5.78 (t, J = 5.1 Hz, 1 
H), 7.24 (d, J = 8.1 Hz, 1 H), 7.34 (s, 1 H), 7.55 (q, J = 8.0 Hz, 2 H), 8.38 (t, J = 8.2 Hz, 2 
H), 8.45 (d, J = 8.1 Hz, 1 H).    
31P NMR (CDCl3) δ 31.6 (d, J = 1072 Hz). 
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Figure 7.8. 31P NMR spectrum of dansyl-linked fluorophosphonate (6a). 
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Dansyl-linked fluorophosphonate (6a’).  This procedure is identical to that 
described in 6a except that it started with dansyl-linked phosphonic acid 5a’. 
 
1H NMR (CDCl3): δ 1.65 (m, 4 H), 2.00 (m, 2 H), 2.90 (s, 6 H), 3.67 (d, 3JHP = 8.2 
Hz, 3 H), 4.23 (dd, J = 6.9, 2.1 Hz, 2 H), 4.25 (t, J = 6.9 Hz, 2 H), 6.55 (s, 1 H), 7.20 (d, J 
= 7.4 Hz, 1 H), 7.37 (s, 1 H), 7.48 (q, J = 7.6 Hz, 2 H), 8.23 (d, J = 7.3 Hz, 1 H), 8.31 (d, 
J = 8.5 Hz, 1 H), 8.50 (d, J = 9.0 Hz, 1 H).    
31P NMR (CDCl3) δ 32.2 (d, J = 1070 Hz). 
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O-Methyl (3-azopropyl) phosphonic acid (7a).  Hydrolysis of O,O-dimethyl (3-
azopropyl) phosphonate 2a was accomplished by dissolving 2a (0.33 g, 1.71 mmol) into 
isopropanol (10 mL), followed by adding 1 N NaOH solution (3 mL).  The mixture was 
heated at 70 °C for 12 h while refluxing until 31P NMR showed a complete conversion 
(PONa, δ = 27.7 ppm).  After cooling to rt, the solution mixture was diluted by water (15 
mL) and washed with ethyl acetate (2 x 15 mL).  The aqueous part was acidified by 1 N 
HCl to adjust to pH 1.  A mixture of chloroform and isopropanol (15 mL, 1:3) was added 
and the extracted product was collected and dried over anhydrous MgSO4.  Evaporation 
under reduced pressure gave 0.23 g (75%) of pure product 7a as light yellow oil.  
 
1H NMR (CDCl3): δ 1.76 (m, 2 H), 1.83 (m, 2 H), 3.32 (t, J = 6.6 Hz, 2 H), 3.66 
(d, 3JHP = 10.4 Hz, 3 H).   
13C NMR (CDCl3): δ 22.0 (d, 2JCP = 4.4 Hz), 22.3 (d, 1JCP = 144.9 Hz), 51.1 (d, 
3JCP = 16.7 Hz), 51.6 (d, 2JCP = 6.1 Hz).   
31P NMR (CDCl3): δ 33.7 (s). 
MS (ESI-TOF): Calcd for C4H10N3O3P (M+H) 180.0493; found 180.0671.  
IR (NaCl, CHCl3): ν 2954, 2852, 2100, 1248, 1031 cm–1. 
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Figure 7.9. (A) 1H, (B) 13C and (C) 31P NMR spectra of O-methyl (3-azopropyl) 
phosphonic acid (7a).   
(C) 
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O-Methyl (4-azobutyl) phosphonic acid (7b).  This procedure is identical to that 
described in 7a except that it started with O,O-dimethyl (4-azobutyl) phosphonate 2b. 
 
1H NMR (CDCl3): δ 1.64 (m, 4 H), 1.76 (m, 2 H), 3.25 (t, J = 6.7 Hz, 2 H), 3.67 
(d, 3JHP = 11.1 Hz, 3 H).   
13C NMR (CDCl3): δ 19.5 (d, 2JCP = 6.2 Hz), 23.8 (d, 1JCP = 141.9 Hz), 29.3 (d, 
3JCP = 16.9 Hz), 51.1, 51.4 (d, 2JCP = 7.7 Hz).   
31P NMR (CDCl3): δ 33.7 (s). 
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Figure 7.10. (A) 1H, (B) 13C and (C) 31P NMR spectra of O-methyl (4-azobutyl) 
phosphonic acid (7b).   
(C) 
(B) 
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O-Methyl (3-azopropyl) fluorophosphonate (8a).  To a solution of compound 
7a (0.060 g, 0.34 mmol) in dichloromethane (5 mL), cyanuric fluoride (0.050 g, 0.34 
mmol) was added.  The reaction mixture was stirred at rt for 0.5 h until 31P NMR showed 
a complete conversion from P-OH to P-F.  After evaporation under vacuum, compound 
6a (0.060 g, 0.33 mmol) was isolated as a yellow oil. 
 
1H NMR (CDCl3): δ 1.88 (m, 2 H), 1.95 (m, 2 H), 3.41 (t, J = 6.4 Hz, 2 H), 3.86 
(d, 3JHP = 11.1 Hz, 3 H).   
13C NMR (CDCl3): δ 21.0 (d, 1JCP = 146.3 Hz), 21.7 (d, 2JCP = 4.6 Hz), 51.3 (d, 
3JCP = 16.4 Hz), 51.6 (d, 2JCP = 7.3 Hz).  
31P NMR (CDCl3): δ 31.9 (d, J = 1071 Hz). 
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O-Methyl (4-azobutyl) fluorophosphonate (8b).  This procedure is identical to 
that described in 8a except that it started with O-methyl (4-azobutyl) phosphonic acid 7b. 
 
1H NMR (CDCl3): δ 1.68 (m, 4 H), 1.89 (m, 2 H), 3.30 (t, J = 6.0 Hz, 2 H), 3.82 
(d, 3JHP = 10.6 Hz, 3 H).   
13C NMR (CDCl3): δ 19.3 (d, 2JCP = 4.6 Hz), 23.2 (d, 1JCP = 144.5 Hz), 29.2 (d, 
3JCP = 15.1 Hz), 50.6, 53.0 (d, 2JCP = 8.2 Hz).   
31P NMR (CDCl3): δ 32.9 (d, J = 1074 Hz). 
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Dimethyl thiophosphonate (DMTP, 28) (Tongcharoensirikul, 2004).  
Although dimethyl thiophosphonate is commercially available, it always contains 
dimethyl phosphonate (according to 31P NMR).  We synthesized and distilled it in the lab 
to improve purity and subsequently reactivity.  
A solution of 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-
disulfide (Lawesson reagent; 22.7 g, 0.056 mol) and freshly distilled dimethyl 
phosphonate (10 mL, 12.0 g, 0.11 mol) in benzene (80 mL) was heated at 90-100 ºC for 2 
h until the reaction was complete indicated by 31P NMR (from 11.5 ppm to 74.9 ppm in 
benzene).  The reaction mixture was cooled to room temperature, and hexane (80 mL) 
was added to precipitate sulfur- and phosphorus-containing by-products.  The reaction 
mixture was passed through filter paper, and the solution was concentrated to oil under 
reduced pressure.  The product, dimethyl thiophosphonate, distilled bulb-to-bulb as a 
colorless liquid (8.45 g, 0.067 mol, 61%).  
 
1H NMR (CDCl3): δ 3.72 (d, J = 15.0 Hz, 6 H), 7.68 (m, 1 H).   
13C NMR (CDCl3): δ 52.7 (d, JCP = 6.2 Hz).   
31P NMR (CDCl3): δ 74.9 (s). 
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O,O-Dimethyl (3-bromopropyl) phosphonothionate (9).  The synthesis of O,O-
diethyl (3-chloropropyl) thiophosphonate from diethyl thiophosphonate has been reported 
(Reznik, 2001). By a similar way, O,O-dimethyl (3-bromopropyl) thiophosphonate can 
be obtained. 
A solution of sodium dimethyl thiophosphonate was prepared from dimethyl 
thiophosphonate (1.30 g, 10.00 mmol) and sodium (0.24 g, 10.00 mmol) in anhydrous 
methanol (6 mL).  The sodium dimethyl thiophosphonate solution was added dropwise 
with stirring at 30-35 ºC to a solution of 1,3-dibromopropane (3.00 mL, 24.00 mmol) in 4 
mL of anhydrous methanol.  The reaction mixture was refluxed for 5 h until the 31P NMR 
showed that loss of the starting material was complete.  The sodium bromide precipitate 
(NaBr) was filtered off, and the filtrate was concentrated under reduced pressure.  The 
product was extracted with ethyl ether, washed with water, and dried over MgSO4.  Ethyl 
ether was then removed, and the residue was distilled in vacuo to give compound 9 as a 
light yellow oil (1.28 g, 5.00 mmol, 50%). 
 
1H NMR (CDCl3): δ 2.02 (m, 4 H), 3.36 (t, J = 5.2 Hz, 2 H), 3.58 (d, J = 8.3 Hz, 6 
H).   
13C NMR (CDCl3): δ 26.5 (d, 3JCP = 3.1 Hz), 31.3 (d, 1JCP = 115.0 Hz), 33.6 (d, 
2JCP = 19.2 Hz), 53.2 (d, 2JCP = 7.6 Hz).   
31P NMR (CDCl3): δ 102.7 (s). 
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Figure 7.11. (A) 1H, (B) 13C and (C) 31P NMR spectra of O,O-dimethyl (3-bromopropyl) 
phosphonothionate (9). 
 
(C) 
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O,O-Dimethyl (3-azopropyl) phosphonothionate (10).  A solution of compound 
phosphonothionate 9 (0.73 g, 2.95 mmol) in dimethylformamide (DMF, 5 mL) was 
stirred at rt under argon.  Sodium azide (0.38 g, 5.85 mmol) was added, followed with 
several drops of deionized water (0.5 mL) to help sodium azide dissolve.  Using a 31P 
NMR shift from 102.7 ppm to 103.2 ppm to assess reaction progress, the reaction was 
completed in 24 h.  The reaction mixture was concentrated under reduced pressure.  Ethyl 
acetate (30 mL) was added and washed with water (15 mL) twice.  The organic layer was 
collected and dried over anhydrous MgSO4.  Evaporation under reduced pressure and 
purification by flash chromatography using silica (6:94 ethyl acetate-hexane) gave 0.31 g 
(1.48 mmol, 50%) of pure product as a light yellow oil.  
 
1H NMR (CDCl3): δ 1.76-1.83 (m, 2 H), 1.89-1.97 (m, 2 H), 3.28 (t, J = 6.6 Hz, 2 
H), 3.61 (d, J = 12.8 Hz, 6 H).   
13C NMR (CDCl3): δ 22.9 (d, 3JCP = 3.5 Hz), 30.7 (d, 1JCP = 112.8 Hz), 51.4 (d, 
2JCP = 18.3 Hz), 53.2 (d, 2JCP = 6.1 Hz).   
31P NMR (CDCl3): δ 103.2 (s). 
 
 
 170 
1.82.02.22.42.62.83.03.23.43.63.84.04.24.44.64.8
 2
.1
 
 1
.9
 
 2
.0
 
 6
.0
 
 
 
 
102030405060708090  
 
 
 
(A) 
(B) 
 171 
0102030405060708090100110120130140150160
102.80103.00103.20103.40103.60103.80
 
 
Figure 7.12. (A) 1H, (B) 13C and (C) 31P NMR spectra of O,O-dimethyl (3-azopropyl) 
phosphonothionate (10). 
(C) 
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Dansyl-linked phosphonothionate (11).  Phosphonothionate 10 (0.43 g, 2.06 
mmol) and dansyl sulfonamide 3 (0.59 g, 2.05 mmol) were suspended in a 1:1 mixture of 
water and tert-butyl alcohol (8 mL total) under argon.  Sodium ascorbate (0.50 mmol, 
0.30 mL of freshly prepared 1 M solution in water) was added, followed by copper (II) 
sulfate pentahydrate solution (0.10 mmol, 0.20 mL of 0.5 M solution in water).  The 
heterogeneous mixture was stirred vigorously overnight, at which point the mixture 
cleared and TLC analysis indicated complete consumption of the reactants.  A mixture of 
chloroform-isopropanol (30 mL, 3:1) was added and the organic layer was washed with 
water, collected and dried over anhydrous MgSO4.  Evaporation under reduced pressure 
and purification by flash chromatography using silica (2:1 ethyl acetate-hexane) gave 
0.92 g (1.86 mmol, 90%) of pure product as a yellow oil.  
 
1H NMR (CDCl3): δ 1.86 (m, 2 H), 2.13 (m, 2 H), 2.87 (s, 6 H), 3.68 (d, J = 13.8 
Hz, 6 H), 4.18 (dd, J = 6.1, 5.7 Hz, 2 H), 4.26 (t, J = 7.0 Hz, 2 H), 5.79 (t, J = 6.1 Hz, 1 
H), 7.17 (d, J = 8.1 Hz, 1 H), 7.30 (s, 1 H), 7.39 (q, J = 8.1 Hz, 2 H), 8.24 (t, J = 8.1 Hz, 2 
H), 8.53 (d, J = 8.3 Hz, 1 H).   
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13C NMR (CDCl3): δ 24.8 (d, 1JCP = 140.4 Hz), 29.8, 31.2 (d, 3JCP = 4.5 Hz), 38.9, 
45.7, 50.0 (d, 2JCP = 16.8 Hz), 53.3, 64.6, 79.6, 115.6, 122.6, 123.4, 128.8, 129.7, 129.8, 
130.0, 130.8, 144.2.   
31P NMR (CDCl3): δ 102.1 (s). 
 
 
2.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 5
.8
 
 6
.0
 
 2
.0
 
 1
.9
 
 2
.0
 
 2
.0
 
 1
.0
 
6.87.07.27.47.67.88.08.28.48.68.8
 1
.1
 
 2
.0
  2
.0
 
 0
.9
 
 1
.1
 
 
 
(A) 
 174 
 
2030405060708090100110120130140150  
 
0102030405060708090100110120130140150
101.60101.80102.00102.20102.40102.60
 
 
Figure 7.13. (A) 1H, (B) 13C and (C) 31P NMR spectra of dansyl-linked 
phosphonothionate (11). 
(B) 
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Dansyl-linked phosphonothioic acid (12).  Dealkylation of dansyl-linked 
phosphonothionate 11 was achieved by dissolving it (0.30 g, 0.60 mmol) into acetone 
(1.5 mL) and adding triethylamine (TEA, 1 mL).  The mixture was stirred under argon at 
35 °C for 48 h while refluxing until the solution did not contain any 31P NMR peak of the 
starting material.  After cooling to rt, chloroform and water were added to extract by-
products out.  Hydrochloric acid (HCl, 1 N) was used to adjust to pH 1, and then a 
mixture of chloroform and isopropanol (3:1) was added to extract desired product from 
water.  The organic layer was collected and dried over anhydrous MgSO4.  Evaporation 
under vacuum gave 0.17 g (0.35 mmol, 58%) of pure product 12 as light yellow oil.  
 
1H NMR (d-DMSO): δ 1.74 (m, 2 H), 1.97 (m, 2 H), 3.07 (s, 6 H), 3.68 (d, J = 
13.1 Hz, 3 H), 4.22 (dd, J = 15.7, 6.6 Hz, 2 H), 4.31 (t, J = 5.2 Hz, 2 H), 6.62 (t, J = 5.8 
Hz, 1 H), 7.13 (d, J = 7.1 Hz, 1 H), 7.39 (d, J = 7.8 Hz, 1 H),7.57 (q, J = 4.3 Hz, 2 H), 
8.22 (d, J = 7.3 Hz, 1 H), 8.49 (d, J = 8.9 Hz, 1 H), 8.63 (d, J = 8.1 Hz, 1 H).   
31P NMR (d-DMSO): δ 93.1 (s). 
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Compound 12 was found to undergo a proton oxo-thio shift under certain 
conditions as revealed by a second 31P NMR shift at 49.7 ppm. 
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Figure 7.14. (A) 1H and (B) 31P NMR spectra of dansyl-linked phosphonothionic acid 
(12).  
(B) 
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Dansyl-linked O, S-dimethyl phosphonate (13).  To a solution of compound 12 
(0.020 g, 0.041 mmol) in dichloromethane, triethylamine (TEA, 0.050 mL) and methyl 
iodide (0.014 g, 0.10 mmol) were added.  The reaction mixture was stirred under argon at 
rt for 0.5 h until 31P NMR showed a complete consumption of starting material.  Water (1 
mL) was added and then extracted with ethyl acetate (2 x 1 mL).  The organic layer was 
collected and dried over anhydrous MgSO4.  Evaporation under reduced pressure gave 
0.019 g (87%) of final compound 13 as a yellow oil. 
 
1H NMR (CDCl3): δ 1.90 (m, 2 H), 2.21 (m, 2 H), 2.25 (d, 3JPH = 12.6 Hz, 3 H), 
2.88 (s, 6 H), 3.75 (d, 3JPH = 12.5 Hz, 3 H), 4.20 (d, J = 6.3 Hz, 2 H), 4.34 (t, J = 6.4 Hz, 
2 H), 5.66 (t, J = 4.5 Hz, 1 H), 7.17 (d, J = 8.1 Hz, 1 H), 7.37 (s, 1 H), 7.53 (q, J = 8.2 Hz, 
2 H), 8.26 (t, J = 8.5 Hz, 2 H), 8.54 (d, J = 8.7 Hz, 1 H). 
13C NMR (CDCl3): δ 12.1 (d, 2JCP = 3.1 Hz), 23.2 (d, 2JCP = 4.7 Hz), 28.0 (d, 1JCP 
= 108.3 Hz), 38.7, 45.4, 49.7 (d, 3JCP = 16.8 Hz), 51.6 (d, 2JCP = 6.2 Hz), 77.2, 115.3, 
118.6, 122.5, 123.1, 128.5, 129.5, 129.6, 129.8, 130.6, 134.4, 144.0.     
31P NMR (CDCl3): δ 58.9 (s). 
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Figure 7.15. (A) 1H, (B) 13C and (C) 31P NMR spectra of dansyl-linked O, S-dimethyl 
phosphonate (13). 
(C) 
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Dansyl-linked O-methyl, S-2-(dimethylamino)ethyl phosphonate (14).  To a 
solution of compound 12 (0.040 g, 0.083 mmol) in dimethylsulfoxide (DMSO), 
potassium carbonate (K2CO3, 0.012 g, 0.083 mmol) and 2 drops of deionized water were 
added, followed with  2-chloro-N,N-dimethylethylamine (0.012 g, 0.083 mmol).  The 
reaction mixture was stirred under argon at rt for 0.5 h until 31P NMR showed a complete 
consumption of starting material.  Water (1 mL) was added and washed with a 1:3 
mixture of CHCl3 - isopropanol.  The organic layer was collected and dried over 
anhydrous MgSO4.  Evaporation under reduced pressure and purification by flash 
chromatography using silica (1:9 chloroform-methanol) gave 0.036 g (78%) of the final 
compound 14 as a yellow oil. 
 
1H NMR (CDCl3): δ 1.89 (m, 2 H), 2.20 (m, 2 H), 2.32 (s, 6 H), 2.60 (m, 2 H), 
2.88 (s, 6 H), 3.46 (t, J = 2.0 Hz, 2 H), 3.74 (d, 3JPH = 12.5 Hz, 3 H), 4.19 (d, J = 4.5 Hz, 
2 H), 4.34 (t, J = 3.8 Hz, 2 H), 6.14 (t, J = 4.5 Hz, 1 H), 7.17 (d, J = 7.5 Hz, 1 H), 7.40 (s, 
1 H), 7.53 (q, J = 8.0 Hz, 2 H), 8.26 (t, J = 8.5 Hz, 2 H), 8.53 (d, J = 8.9 Hz, 1 H).   
13C NMR (CDCl3): δ 23.6, 28.5 (d, 1JCP = 158.8 Hz), 30.2 (d, 3JCP = 43.2 Hz), 
39.0, 45.0, 45.6, 49.9 (d, 2JCP = 18.5 Hz), 51.0, 51.9, 59.7, 115.5, 119.0, 122.9, 123.4, 
128.7, 129.7, 130.0, 134.9, 152.2.   
31P NMR (CDCl3): δ 58.9 (s). 
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Figure 7.16. (A) 1H, (B) 13C and (C) 31P NMR spectra of dansyl-linked O-methyl, S-2-
(dimethylamino)ethyl phosphonate (14). 
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Dansyl-linked O-methyl, S-choline phosphonate (15).  To a solution of 
compound 14 (0.036 g, 0.065 mmol) in chloroform, methyl iodide (2 equiv) was added.  
The reaction mixture was stirred at rt for 1 h until 31P NMR spectral did not contain the 
peak of the starting material.  After evaporation under vacuum, compound 15 was 
obtained as a yellow solid (quantitative yield). 
 
1H NMR (CDCl3): δ 1.69 (m, 2 H), 2.04 (m, 2 H), 2.16 (s, 9 H), 2.70 (m, 2 H), 
2.86 (s, 6 H), 3.46 (t, J = 2.0 Hz, 2 H), 3.45 (d, 3JPH = 14.5 Hz, 3 H), 3.90 (t, J = 5.7 Hz, 2 
H), 4.14 (d, J = 5.9 Hz, 2 H), 7.08 (t, J = 6.0 Hz, 1 H), 7.15 (d, J = 7.5 Hz, 1 H), 7.53 (q, 
J = 7.8 Hz, 2 H), 7.78 (s, 1 H), 8.22 (d, J = 7.2 Hz, 1 H), 8.34 (d, J = 8.2 Hz, 1 H), 8.51 (d, 
J = 9.0 Hz, 1 H).   
31P NMR (CDCl3): δ 58.8 (s). 
MS (ESI-TOF): Calcd for C24H38N6O4PS2 (M+H) 569.2134; found 569.2148. 
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Figure 7.17. 31P NMR spectrum of dansyl-linked O-methyl, S-choline phosphonate (15). 
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O-Methyl (3-azopropyl) phosphonothioic acid, brucines salt (16).  Brucine 
(1.65 g, 4.18 mmol) was added to a stirring solution of O,O-dimethyl (3-azopropyl) 
phosphonothionate 10 (0.96 g, 4.59 mmol) in ethanol (10 mL).  The reaction mixture was 
brought to reflux at 50 ºC for six days until 31P NMR showed a complete conversion.  
Ethanol was removed by rotary evaporation under reduced pressure and ethyl ether was 
added to wash off the starting material and give the crude brucine salt 16.  
The separation of 16a/16b was attempted.  This separation was not able to be 
monitored by 31P NMR since the two peaks are largely overlapped. 
 
1H NMR (CDCl3): δ 
Brucine part: 1.21 (dt, J = 10.1, 4.2 Hz, 1 H), 1.53 (d, J = 15.3 Hz, 1 H), 1.69 (m, 
2 H), 2.53 (dd, J = 20.4, 2.8 Hz, 1 H), 2.87 (d, J = 15.4 Hz, 1 H), 2.96 (m, 1 H), 3.59 (d, J 
= 14.0 Hz, 1 H), 3.67 (s, 3 H), 3.70 (d, J = 13.7 Hz, 2 H), 3.77 (d, J = 27.3 Hz, 6 H), 3.85 
(d, J = 20.4 Hz, 2 H), 4.04 (d, J = 13.7 Hz, 1 H), 4.11 (m, 1 H), 4.22 (t, J =  10.7 Hz, 2 H), 
4.45 (s, 1 H), 6.37 (t, J = 8.7 Hz, 1 H), 7.11 (s, 1 H), 7.61 (s, 1 H). 
Phosphonothionate part: 1.77 (m, 2 H), 2.10 (m, 2 H), 3.18 (t, J = 6.4 Hz, 2 H), 
3.41 (d, J = 12.4 Hz, 3 H).  
31P NMR (CDCl3): δ 76.1 (s) (2 single peaks for 16a and 16b). 
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Figure 7.18. (A) 1H and (B) 31P NMR spectra of O-methyl (3-azopropyl) 
phosphonothioic acid, brucines salt (16). 
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O-methyl (3-azopropyl) phosphonothioic acid (17).  Hydrolysis of 
phosphonothionate 10 was performed by dissolving 10 (5.00 g, 23.92 mmol) into 20 mL 
methanol with 5 mL NaOH (5 M).  The mixture was stirred at 55 °C under argon for 48 h 
while refluxing until 31P NMR showed completion of the reaction.  After cooling to rt, 
dichloromethane and water were added to extract the remaining starting material.  
Hydrochloric acid (HCl, 3 N) was used to adjust to pH 1, and then a mixture of 
chloroform and isopropanol (3:1) was added to extract the desired product from water.  
The organic layer was collected and dried over anhydrous MgSO4.  Evaporation under 
vacuum gave 3.19 g (16.36 mmol, 68%) of pure product 17 as light yellow oil.   
 
1H NMR (CDCl3): δ 1.91-1.98 (m, 2 H), 2.04-2.12 (m, 2 H), 3.40 (t, J = 6.6 Hz, 2 
H), 3.74 (d, J = 13.7 Hz, 3 H).   
13C NMR (CDCl3): δ 22.9 (d, 3JCP = 3.5 Hz), 31.6 (d, 1JCP = 111.3 Hz), 51.3 (d, 
2JCP = 18.4 Hz), 51.9 (d, 2JCP = 6.3 Hz).   
31P NMR (CDCl3): δ 95.2 (s). 
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Figure 7.19. (A) 1H and (B) 31P NMR spectra of O-methyl (3-azopropyl) 
phosphonothioic acid (17). 
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O-methyl (3-azopropyl) phosphonothioic acid – alkaloid salts (18, 19, 20).  
One of three alkaloids (strychnine, brucine or quinine, 6.00 mmol) was added to a stirring 
solution of 17 (1.17 g, 6.00 mmol) in 10 mL ethanol. The reaction mixture was brought to 
65 ºC while refluxing.  31P NMR showed a complete conversion after 3 h.  
 
Strychnine 18a/18b: 31P NMR (CDCl3): δ 84.02 (s), 83.97 (s). 
Brucine 19a/19b: 31P NMR (CDCl3): δ 83.77 (s), 83.66 (s). 
Quinine 20a/20b: 31P NMR (CDCl3): δ 82.07 (s), 82.00 (s). 
 
The strychnine salts 18a/18b were selected for more detailed analysis.  See 
subsequent experimental. 
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Figure 7.20. 31P NMR spectra of (A) O-methyl (3-azopropyl) phosphonothioic acid – 
strychnine salts (18a and 18b), (B) O-methyl (3-azopropyl) phosphonothioic acid – 
brucine salts (19a and 19b) and (C) O-methyl (3-azopropyl) phosphonothioic acid – 
quinine salts (20a and 20b). 
(C) 
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Experimental continued from general procedure to phosphonothioic acid – 
alkaloid salts.  18a: Ethyl ether was added to effect cloudiness.  Upon cooling, crystals 
precipitated a strychnine salt (18).  The first crop of crystals was filtered, and washed 
with a small portion of ethanol.  The resulting crystals were dissolved into isopropanol 
under heat and recrystallized twice. 31P NMR of the first crop of crystal showed > 90% of 
one diastereomer (18a). 
 
1H NMR (CDCl3): δ 
Strychnine part: 1.34 (dt, J = 10.4, 3.1 Hz, 1 H), 1.61 (d, J = 15.5 Hz, 1 H), 1.94 
(d, J = 4.4 Hz, 2 H), 2.56 (dt, J = 15.4, 3.3 Hz, 1 H), 2.62 (dd, J = 18.2, 3.5 Hz, 1 H), 3.08 
(d, J = 8.3 Hz, 1 H), 3.13 (d, J = 8.3 Hz, 1 H), 3.17 (d, J = 13.9 Hz, 1 H), 3.85 (dd, J = 
11.3, 7.1 Hz, 1 H), 3.91 (s, 1 H), 3.95 (t, J = 6.0 Hz, 1 H), 4.02 (d, J = 6.0 Hz, 0.5 H), 
4.06 (d, J = 5.8 Hz, 0.5 H), 4.12 (s, 1 H), 4.18 (m, 2 H), 4.29 (dt, J =  18.8, 3.2 Hz, 1 H), 
4.69 (s, 1 H), 6.25 (t, J = 7.5 Hz, 1 H), 7.10 (t, J = 7.3 Hz, 1 H), 7.25 (t, J = 7.4 Hz, 1 H), 
7.42 (d, J = 7.5 Hz, 1 H), 8.02 (d, J = 8.1 Hz, 1 H). 
Phosphonothionate part: 1.88-1.93 (m, 2 H), 1.95-2.10 (m, 2 H), 3.34 (t, J = 6.4 
Hz, 2 H), 3.64 (d, J = 13.2 Hz, 3 H).  
31P NMR (CDCl3): δ 84.02 (s). 
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Figure 7.21. (A) 1H and (B) 31P NMR spectra of crystals (18a) formed from O-methyl 
(3-azopropyl) phosphonothioic acid – strychnine salts. 
(A) 
(B) 
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18b: 18b was in the mother liquor with approximate 20% 18a.   
 
Data for 18b is same as 18a except:  
1H NMR (CDCl3): δ in phosphonothionate part: 3.62 (d, J = 13.2 Hz, 3 H), 3.33 (t, 
J = 6.4 Hz, 2 H). 
31P NMR (CDCl3): δ 83.97 (s). 
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Figure 7.22. (A) 1H and (B) 31P NMR spectra of mother liquor (18b) formed from O-
methyl (3-azopropyl) phosphonothioic acid – strychnine salts. 
(B) 
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21
Me
NH(C2H5)2
NH(C2H5)2
10
(CH2)3 N3
S
PH3CO
H3CO
(CH2)3 N3
S
PH3CO
O
CH3OH
40oC
+
 
 
O-Methyl (3-azopropyl) ammonium phosphonothioic acid, ammonium salt 
(21).  The mixture of 10 (0.53 g, 2.50 mmol) and diethylamine (1.04 mL, 10.00 mmol) in 
methanol (2 mL) was refluxed vigorously at 50-60 ºC for 4 h with stirring until 10 
disappeared in 31P NMR.  The excess diethylamine together with solvent was removed by 
rotary evaporation under reduced pressure to give the crude ammonium salt 21 as a 
viscous oil in a quantitative yield.  The ammonium salt can be directly used without 
further purification.  
 
31P NMR (CH3OH): δ 80.4 (s). 
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Figure 7.23. 31P NMR spectrum (unlocked in methanol) of ammonium 
phosphonothionate 21. 
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21
Me
NH(C2H5)2
POCl3
toluene
22
(CH2)3 N3
S
PH3CO
O
(CH2)3 N3
S
PH3CO
Cl
 
 
O-Methyl (3-azopropyl) phosphonochloridothionate (22).  To a solution of 
phosphorus oxychloride (0.23 mL, 2.50 mmol) and toluene (1 mL) was added dropwise a 
suspension of the crude ammonium salt 21 (2.50 mmol) and toluene (1.5 mL) at rt under 
argon with rapid stirring.  After addition, the reaction mixture was stirred at 40 ºC for 4 h, 
then cooled to rt and poured into cold water to consume excess phosphorous oxychloride.  
The organic layer was collected and dried over MgSO4.  Toluene was removed under 
reduced pressure to give the crude product 22 (0.49 g, 2.30 mmol, 92%).  Further 
purification was performed in next step after synthesizing the stable 
phosphonamidothionates. 
 
1H NMR (CDCl3): δ 2.01 (m, 2 H), 2.42-2.50 (m, 2 H), 3.43 (t, J = 6.1 Hz, 2 H), 
3.83 (d, J = 12.8 Hz, 3 H).   
31P NMR (CDCl3): δ 105.4 (s). 
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Figure 7.24. (A) 1H and (B) 31P NMR spectra of O-methyl (3-azopropyl) 
phosphonochloridothionate (22). 
(A) 
(B) 
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23a: RPRC 23b: SPRC
+
(CH2)3 N3
S
P
H3CO
N
H
(CH2)3 N3
S
PH3CO
HNPh
CH3
PhH3C
22
(CH2)3 N3
S
PH3CO
Cl
NH2(R)Ph
CH3
CH2Cl2
 
  
N-(1-Phenylethyl), O-methyl (3-azopropyl) phosphonamidothionate (23).  
Phosphonochloridothionate 22 (0.49 g, 2.30 mmol) and (R)-(+)-methylbenzylamine (1.20 
mL, 9.20 mmol) were mixed in dichloromethane (10 mL).  31P NMR showed completion 
of the reaction after 12 h.  The excess amine and solvent were removed under reduced 
pressure and the crude diastereomeric products 23a/23b were purified by 
chromatography (1:4 ethyl ether-hexane) to give a light yellow oil (0.48 g, 1.60 mmol, 
70%). 
 
23a + 23b (1:1): 
1H NMR (CDCl3): δ 1.46 (d, J = 2.3 Hz, 3 H), 1.47 (d, J = 2.1 Hz, 3 H), 1.53-1.64 
(m, 2 H), 1.72-1.81 (m, 2 H), 1.89-1.96 (m, 2 H), 2.00-2.07 (m, 2 H), 3.06 (q, J = 3.9 Hz, 
2 H), 3.25 (d, J = 13.7 Hz, 3 H), 3.37 (q, J = 8.0 Hz, 2 H), 3.60 (d, J = 13.7 Hz, 3 H), 
4.25-4.40 (m, 2 H), 7.35-7.23 (m, 10 H). 
13C NMR (CDCl3): δ 22.7 (d, 2JCP = 4.2 Hz), 23.1, 25.5 (d, 2JCP = 7.6 Hz), 26.0(d, 
2JCP = 4.5 Hz), 51.8 (d, 1JCP = 64.1 Hz), 50.4 (d, 2JCP = 4.8 Hz), 50.5 (d, 2JCP = 4.8 Hz), 
51.2 (d, 2JCP = 3.0 Hz), 51.3 (d, 2JCP = 3.0 Hz), 51.8 (d, 2JCP = 3.0 Hz), 52.0 (d, 2JCP = 3.0 
Hz), 125.7, 127.4, 127.5, 128.6, 128.7, 144.6 (d, 3JCP = 3.0 Hz).  
31P NMR (CDCl3): δ 88.93 (s), 88.76 (s). 
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Figure 7.25. (A) 1H, (B) 13C and (C) 31P NMR spectra of N-(1-phenylethyl), O-methyl 
(3-azopropyl) phosphonamidothionate (23). 
 
 
 
Attempted separation of 23a and 23b: Separation of phosphonamidothionates 23a 
and 23b was attempted by a flash chromatography, however, separation was not obtained.  
The first fraction collected after chromatography showed approximately 24a:24b = 3:1 
and the last fraction collected contained approximately 24a:24b = 1:4.  As a result, 
diastereomers’ separation would be attempted after dealkylation in the next step because 
the S-alkylated phosphonamidothiolates would be expected to differ on silica gel more 
easily than phosphonamidothionates because of greater bonding between the P=O and the 
silica surface.    
(C) 
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2423
(CH2)3 N3
S
P
H3CO
HN
PhH3C
(CH2)3 N3
O
P
H3CS
HN
PhH3C
1. CF3SO3CH3
2. LiCl
 
 
S-methyl-P-(3-azopropyl)-N-[(1R)-1-phenylethyl] phosphonamidothiolate 
(24).  Method A. 
N-(1-Phenylethyl), O-methyl (3-azopropyl) phosphonamidothionate 23 (0.11 g, 
0.37 mmol) and methyl triflate (0.050 mL, 0.37 mmol) were mixed in dichloromethane (2 
mL) under argon at rt.  31P NMR showed completion of reaction after 12 h.  The reaction 
mixture was dried under reduced pressure and the resulting salt was dissolved in acetone 
(2 mL), followed with lithium chloride (0.015 g, 0.37 mmol).  The reaction was complete 
in 12 h according to TLC (10% methanol in chloroform) with DBQ staining.  The 
solution was concentrated and purified by chromatography (1:20 methanol-chloroform) 
to give a crude diastereomeric mixture of 24 (0.10 g, 0.33 mmol) in 91% yield and a 
diastereomeric ratio of 50:50.  
 
For spectral data, see Method B. 
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(CH2)3 N3
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H3CO
HN
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O
P
H3CS
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S-methyl-P-(3-azopropyl)-N-[(1R)-1-phenylethyl] phosphonamidothiolate 
(24).  Method B.   
Phosphonamidothiolate (24) was also prepared by alkylation-dealkylation.  
Methyl iodide (2 mL, 32.00 mmol) was added to phosphonamidothiolate 23 (0.30 g, 1.00 
mmol).  The reaction mixture was refluxed for 4 d until the TLC analysis or 31P NMR 
showed a complete conversion.  The solution was concentrated under reduced pressure 
and the crude product was purified by chromatography (1:50 methanol-chloroform) to 
give a diastereomeric mixture of 24a and 24b (0.23 g, 0.77 mmol) in 77% yield as an 
equal population of diastereomers, 50:50.  
 
1H NMR (CDCl3): δ 1.50 (d, J = 6.7 Hz, 1.5 H), 1.52 (d, J = 6.7 Hz, 1.5 H), 1.75 
(m, 2 H), 1.89 (m, 2 H), 2.15 (d, J = 12.6 Hz, 3 H), 3.20 (t, J = 9.1 Hz, 1 H), 3.32 (t, J = 
6.5 Hz, 2 H), 4.46-4.56 (m, 1 H), 7.23-7.33 (m, 5 H).  
31P NMR (CDCl3): δ 49.5 (s), 50.9 (s). 
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Figure 7.26. (A) 1H and (B) 31P NMR spectra of phosphonamidothiolate (24). 
(A) 
(B) 
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24
1. chromatography
2. recrystallization 24a: SpRc
24b: RpRc
(CH2)3 N3
O
P
H3CS
(CH2)3 N3
O
PH3CS
(CH2)3 N3
O
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Diastereomers of phosphonamidothiolate 24: SpRc (24a) and RpRc (24b).  
The diastereomeric mixture of 24a and 24b was separated by a gradient chromatography 
(from 1:100 to 1:40 methanol-chloroform) and pure fractions of the two diastereomers 
were collected and concentrated.  The first diastereomer after chromatography (24a) was 
dissolved in warm ethyl ether and crystallized as needle-like crystals.  The second 
diastereomer after chromatography (24b) was dissolved in methanol-ethyl ether (1:20) 
and crystallized as a colorless needle-like crystals.  Both crystals were subsequently 
recrystallized prior to diffraction analysis.   
High resolution MS (ESI-TOF): Calcd for C12H20N4OPS (M+H) 299.1095; found 
299.1093. 
Anal. Calcd for C12H19N4OPS: C 48.31, H 6.42, N 18.78; found: C 48.30, H 6.44, 
N 18.68. 
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SpRc (24a):  
mp: 95.5 - 95.8 ºC. 
[α]D20  = +23.6º (c = 1.40 g/100 mL, CHCl3).   
1H NMR (CDCl3): δ 1.53 (d, J = 6.7 Hz, 3 H), 1.85 (m, 2 H), 1.94 (m, 2 H), 2.17 
(d, J = 12.6 Hz, 3 H), 3.22 (t, J = 9.1 Hz, 1 H), 3.32 (t, J = 6.5 Hz, 2 H), 4.46-4.56 (m, 1 
H), 7.23-7.33 (m, 5 H). 
13C NMR (CDCl3): δ 11.2 (d, 2JCP = 3.1 Hz), 22.5 (d, 2JCP = 4.6 Hz), 25.2 (d, 2JCP 
= 4.6 Hz), 30.3 (d, 1JCP = 96.1 Hz), 50.6, 51.4 (d, 3JCP = 18.4 Hz), 126.0, 127.3, 128.6, 
144.6 (d, 3JCP = 4.6 Hz).  
31P NMR (CDCl3): δ 49.5 (s).   
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Figure 7.27. (A) 1H, (B) 13C and (C) 31P NMR spectra of phosphonamidothiolate 24a.
(B) 
(C) 
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RpRc (24b): 
mp 88.5 - 88.8 ºC. 
[α]D20 = +60.1º (c = 1.04 g/100 mL, CHCl3). 
1H NMR (CDCl3): δ 1.54 (d, J = 6.7 Hz, 3 H), 1.75 (m, 2 H), 1.86 (m, 2 H), 2.18 
(d, J = 12.6 Hz, 3 H), 3.25 (t, J = 9.1 Hz, 1 H), 3.33 (t, J = 6.5 Hz, 2 H), 4.48-4.58 (m, 1 
H), 7.24-7.35 (m, 5 H). 
13C NMR (CDCl3): δ 11.0 (d, 2JCP = 3.0 Hz), 22.1 (d, 2JCP = 4.6 Hz), 25.8 (d, 2JCP 
= 6.1 Hz), 30.2 (d, 1JCP = 94.6 Hz), 51.2, 51.4 (d, 3JCP = 16.8 Hz), 126.0, 127.5, 128.7, 
144.5 (d, 3JCP = 4.6 Hz).     
31P NMR (CDCl3): δ 50.9 (s). 
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Figure 7.28. (A) 1H, (B) 13C and (C) 31P NMR spectra of phosphonamidothiolate 24b. 
(C) 
(B) 
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O,S-Dimethyl (3-azopropyl) phosphonothiolate (25a/25b).  
Methanolysis of phosphonamidothiolates 24a/24b was achieved by boron 
trifluoride-methanol complex (Ryu, 1991).  To an oven-dried flask under an argon 
atmosphere was added 0.50 mmol of phosphonamidothioate (24a or 24b, 0.15 g) in 1 mL 
of anhydrous methanol.  The solution was stirred at 0 ºC for 20 min, at which point BF3-
MeOH complex (5.00 mmol) was added dropwise over 5 min.  The temperature was 
maintained for 1 h and then stirred at rt overnight.  The reaction mixture was added 
dropwise to a saturated solution of sodium bicarbonate (10 mL) and extracted twice with 
ethyl ether (2 x 10 mL).  The ethyl ether extracts were combined, washed with saturated 
sodium bicarbonate and brine, and dried over sodium sulfate.  Filtration, evaporation, and 
chromatography (1:40 methanol-chloroform) afforded the product (0.052 g, 0.25 mmol). 
 
25a: [α]D20 = -48.4º (c = 0.95 g/100 mL, CHCl3). 
25b: [α]D20 = +48.4º (c = 0.62 g/100 mL, CHCl3). 
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1H NMR (CDCl3): δ 1.92 (m, 2 H), 2.02 (m, 2 H), 2.26 (d, 3JPH = 12.5 Hz, 3 H), 
3.38 (t, J = 6.5 Hz, 2 H), 3.73 (d, 3JPH = 12.5 Hz, 3 H). 
13C NMR (CDCl3): δ 12.0 (d, 2JCP = 3.1 Hz), 22.0 (d, 2JCP = 4.7 Hz), 28.9 (d, 1JCP 
= 110.1 Hz), 51.2 (d, 3JCP = 7.8 Hz), 51.4 (d, 2JCP = 6.4 Hz). 
31P NMR (CDCl3): δ 59.5 (s). 
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Figure 7.29. (A) 1H, (B) 13C and (C) 31P NMR spectra of O,S-dimethyl (3-azopropyl) 
phosphonothiolate (25). 
(B) 
(C) 
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25
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The racemate of O,S-dimethyl (3-azopropyl) phosphonothiolate (25) from O-
methyl (3-azopropyl) phosphonothioic acid (17).   
To a solution of compound 17 (0.19 g, 1.00 mmol) in dichloromethane (2 mL), 
triethylamine (TEA, 0.20 mL) was added, followed with methyl iodide (0.10 mL).  The 
reaction mixture was stirred at rt under argon for 1 h until the 31P NMR spectrum did not 
contain the peak of the starting material.  After evaporation under vacuum, compound 25 
was obtained as a yellow oil (quantitative yield). 
 
The spectral data of compound 25 is same as enantiopure isomers, 25a and 25b. 
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The racemate of dansyl-linked O, S-dimethyl phosphonate (13) synthesized 
by click chemistry from the racemate of O,S-dimethyl (3-azopropyl) 
phosphonothiolate (25).  
Phosphonothiolate 25 (0.14 g, 0.67 mmol) and dansyl sulfonamide 3 (0.20 g, 0.67 
mmol) were suspended in a 1:1 mixture of water and tert-butyl alcohol (5 mL total) under 
argon.  Sodium ascorbate (0.067 mmol, 0.67 mL of freshly prepared 0.1 M solution in 
water) was added, followed by copper (II) sulfate pentahydrate solution (0.0067 mmol, 
0.67 mL of 0.01 M solution in water).  The heterogeneous mixture was stirred vigorously 
for 4 h, at which point it cleared and TLC analysis indicated complete consumption of the 
reactants.  Water (3 mL) and ethyl acetate (6 mL) were added and the organic layer was 
washed with water, collected and dried over anhydrous MgSO4.  Evaporation under 
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reduced pressure and purification by flash chromatography using silica (1:40 methanol-
chloroform) gave 0.22 g (0.44 mmol, 66%) of pure product as a yellow oil.  
 
For NMR spectral, see the synthesis of compound 13 from compound 12. 
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7.3 X-ray Crystallography Analysis  
 
In an effort to assign the absolute configuration of the carbon and phosphorus 
stereocenters of the resolved diastereomers 24a/24b, x-ray crystallographic analysis was 
desired.   
X-ray analysis of 24a: The suitable crystal was selected, attached to a glass fiber 
and data were collected at 90(2) K using a Bruker/Siemens SMART APEX instrument 
(Mo Kα radiation, λ = 0.71073 Å) equipped with a Cryocool NeverIce low temperature 
device (performed by Prof. Twamley in the University of Idaho).  Data were measured 
using omega scans 0.3 ° per frame for 5 seconds, and a full sphere of data was collected.  
A total of 2400 frames were collected with a final resolution of 0.77 Å.  Cell parameters 
were retrieved using SMART (v. 5.632, Bruker AXS, Madison, WI, 2005) software and 
refined using SAINTPlus (v. 7.23a, Data Reduction and Correction Program, Bruker 
AXS, Madison, WI, 2004) on all observed reflections.  Data reduction and correction for 
Lp and decay were performed using the SAINTPlus software. Absorption corrections 
were applied using SADABS (v.2007/4, an empirical absorption correction program, 
Bruker AXS Inc., Madison, WI, 2007).  The structure was solved by direct methods and 
refined by least squares method on F2 using the SHELXTL program package (v. 6.14, 
Structure Determination Software Suite, Sheldrick, G.M., Bruker AXS Inc., Madison, WI, 
2004).  The structure was solved in the space group P2(1)2(1)2(1) (# 19) by analysis of 
systematic absences.  All non-hydrogen atoms were refined anisotropically.  
Stereochemistry assignment: C9, R; P1, S. No decomposition was observed during data 
collection. 
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X-ray analysis of 24b: Similar experimental procedures for 24b showed stereochemistry 
assignment: C9, R; P1, R. 
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7.4 Kinetic Analysis 
 
Each organophosphorus compound synthesized as irreversible inhibitor of the 
active site of acetylcholinesterases was studied and the kinetic parameter was determined.  
As previously described (Section 2.5), a concentration-dependent method was primarily 
used for measuring the bimolecular inhibition constant ki, KD and kp: 
D
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i
1
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1
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∆
∆
=  (7.1) 
in which ν represents the relative velocity.  In the concentration-dependent method, ν is 
the relative activity of AChE with no inhibitor to AChE with an inhibitor under same 
conditions.   
The potency of chromophores prepared as potential reversible inhibitors of 
AChEs was also determined.  By measuring the inactivation percentage with a 
concentration-dependent method, IC50 of each chromophore was determined by plotting 
with Kaleidagraph 3.6 (Synergy Software, Reading, PA) and the inhibition constant Ki 
was deduced from Lineweaver-Burk plot. 
In order to measure the activity of AChE (A), a colorimetric assay originally 
developed by Ellman et al. (Ellman, 1961) was utilized.  In this method, acetylthiocholine 
iodide (ATCh-I) is used as the substrate for AChE instead of ACh.  The determination of 
AChE activity is dependent upon the enzyme-catalyzed hydrolysis of ATCh-I and the 
subsequent thiocholine-mediated reaction with 5,5’-dithiobis-2-nitrobenzoic acid 
(DTNB), a chromogen, to yield a chromophore whose absorbance is measured 
spectrophotometrically at 412 nm.  The rate at which the absorbance is generated is 
proportional to the enzyme’s rate of hydrolysis. 
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7.4.1 Materials 
Chemicals in the enzyme assay were commercially obtained as follows: 
Acetylthiocholine iodide (ATCh-I), 5,5’-dithio(2-nitrobenzoic acid) (DTNB), paraoxon, 
pyridine-2-aldoxime methiodide (2-PAM), EEAChE type V-S, and recombinant human 
AChE, Aldrich and Sigma Chemical Company (Milwaukee, WI).  Soluble recombinant 
mouse AChE was expressed in HEK 293 cells and purified by affinity chromatography as 
described in Section 7.2 (Marchot, 1996). 
Phosphate buffer solution (0.1 M, pH7.6) was prepared in distilled deionized 
water.  
A Beckman DU-7500 diode-array spectrophotometer was used to measure rates, 
which is the changes in absorbance against real time.  
 
7.4.2 Enzyme and Tissue Preparation 
Recombinant Mouse AChE.  rMAChE was truncated at its carboxyl-terminal end 
by the insertion of an early stop codon at position 549.  This modification allowed the 
enzyme to be expressed into the extra-cellular medium as the deleted residues undergo 
post-translational modifications, including glycosylation, which dictated their association 
with the cell membrane.  Soluble recombinant mouse AChE was expressed in HEK 293 
cells and purified by a meta-inhibitor resin chromatography (Marchot, 1996; Bourne, 
1999).   
The modifications on the enzyme have been demonstrated to have a negligible 
effect on the enzymes activity and specificity relative to the native enzyme.  It has been 
shown that this lack of glycosylation decreases the stability of the expressed AChE 
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(Velan, 1993).  Our experiments with rMAChE verified these observations of thermal 
and organic solvent stability.   
Consequently, prior to use of rMAChE was stored at -20 ºC with concentration of 
1 mg/mL and data collecting time of all kinetic analysis was controlled within less than 
30 min.  Studies that required an incubation period greater than 30 min were conducted at 
0-4 ºC.  The highest final concentration of organic solvent used to dissolve inhibitors 
present in all experiments was less than 0.5%, and the control experiment in each assay 
contained the same amount of solvent as was present in the inhibited samples. 
Stock solutions of rMAChE were prepared by diluting 0.1 mL of the purified 
enzyme (1 mg/mL) to a final volume of 10 mL in 0.1 M Phosphate Buffer Solution (PBS, 
pH = 7.6) and were stored at 4 ºC.  Working solutions were prepared as needed by 
diluting the necessary amount of stock solution in 0.1 M PBS (pH = 7.6) to achieve 
desired activity.  In most cases in our study, the working concentration of rMAChE is 
approximately 0.25 µg/mL.  Activity of the working solution might be attenuated from 
time to time such that the optical density of the experiment is suitable for the detection of 
the spectroscopic device used to monitor the inhibition course. 
 
Electric Eel AChE.  EEAChE (type V-S, lyophilized powder) was obtained from 
Sigma-Aldrich without any further purification.  Gel electrophoresis and Western blotting 
experiments demonstrated the presence of contaminants in the commercially available 
preparations of EEAChE.  Despite these observations, it was found that this enzyme is 
relatively robust to both thermal extremes and solvent effects and consistently provides 
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reproducible results.  These factors combined with the availability of this source have 
made it the enzyme of choice for conducting most preliminary studies.   
Stock solutions of EEAChE were prepared by dissolving 5 mg (5000 units) in 10 
mL of 0.1 M PBS with pH 7.6 and kept on ice.  Working solutions of EEAChE were 
prepared by diluting a certain amount of stock solution to about 1 unit/mL in most cases.  
All studies were conducted in 0.1 M PBS with pH 7.6 at 20 ºC.  These pH and 
temperature conditions were chosen for all assays to facilitate comparisons with work on 
various types of AChEs. 
 
Human Recombinant AChE.  rHAChE was obtained from Aldrich without any 
further purification.  Stock solutions of rHAChE were prepared by dissolving 1 mg (2000 
units) in 1 mL of 0.1 M PBS with pH 7.6 and kept on ice.  Working solutions of rHAChE 
were prepared by diluting a certain amount of stock solution to about 1 unit/mL in most 
cases.  All studies were conducted in 0.1 M PBS with pH 7.6 at 20 ºC.   
 
7.4.3 Methods for Irreversible OP Inhibitors 
As discussed in section 2.5, the inhibition potency of organophosphorus 
compounds is generally evaluated by kinetic parameters, ki, KD, and kp, in which ki is the 
bimolecular reaction constant, KD is dissociation constant, and kp is phosphorylation 
constant. 
Method 1: Concentration-dependent determination of ki, KD, and kp. 
Since the concentration-dependent method (Ellman, 1961) affords ki, KD, and kp 
all together, this more rigorous method was primarily used and reported. 
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Six cuvettes containing 480 µL of DTNB solution (1.32 mM DTNB, 59 mM 
NaHCO3, PBS pH 7.6) 150 µL of working solution of AChE, and 1340 µL of PBS (pH 
7.6) were placed in a Beckman DU-7500 diode-array spectrophotometer and maintained 
at 20 ºC.  The first cuvette treated with 10 µL of the solvent to dilute the inhibitors served 
as the control (Ano); the other 5 cuvettes were treated with 10 µL of five gradient inhibitor 
concentrations (Ai).  All six experiments were incubated for same period of time, 6 mins.  
The remaining enzyme activity (v) was determined by adding 20 µL aliquots of the 
ATCh-I solutions to the cuvette and the rate of ATCh-I hydrolysis was monitored at 412 
nm over a period of 10 min (22 sec intervals).  The final concentrations of the reactants 
during enzyme assay were: 0.33 mM DTNB, 0.59 mM ATCh-I, and 0.58 mM NaHCO3. 
The bimolecular reaction constant (ki), dissociation constant (KD), and phosphorylation 
constant (kp) were determined using equation 7.1: 
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Where: t = the time of inhibition (6 min), 
  lnν = ln(Ano/Ai), 
 kp = ki x KD. 
 
Method 2: Time-dependent determination of ki. 
Where appropriate, a time-dependent method of analysis was also applied: 
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The time-dependent analysis was performed to verify the accuracy of the kinetic 
parameters obtained from the concentration-dependent method. 
Ten cuvettes containing 480 µL of DTNB solution (1.32 mM DTNB, 59 mM 
NaHCO3, PBS 7.6), 150 µL of working solution of AChE, and 1340 µL of PBS 7.6 were 
prepared and maintained at 20 ºC.  The first five cuvettes treated with 10 µL of the 
solvent used to dilute the inhibitors served as the control (A0).  At t = 0, 10 µL of the 
inhibitor solution was added to the other five cuvettes and stirred gently.  At select time 
points (t), a control solution and an inhibited solution were placed in a Beckman DU-
7500 diode-array spectrophotometer and the residual activity of each solution was 
determined by adding 20 µL of ATCh-I and the hydrolysis was monitored at 412 nm (10 
sec intervals) for 3 min.    The bimolecular rate constant (ki) was determined as the 
average of 5 runs by plotting ln(A0/At) versus the incubation time.  The resulting slopes 
were determined by linear regression based on the equation: 
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where: 
 A0 is the activity of the uninhibited enzyme at time = t without adding the 
inhibitor, 
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 At is the activity of the uninhibited enzyme at time = t following addition of a 
specific concentration of the inhibitor ([i]).  
 
Method 3: Determination of k3, the rate constant of spontaneous reactivation. 
0.2 mL of working enzyme solutions containing inhibitor that had caused 90% 
loss of enzyme activity after 20 min incubation were isolated.  The inhibition reaction 
was stopped by diluting the mixture 100 fold with 0.1 M PBS 7.6.  Immediately 
following dilution (t = 0), and at discrete time points thereafter (t), 1 mL aliquots of 
diluted solution were added to cuvettes containing DTNB solution and the residual 
enzyme activity (A0 and At, respectively) was determined using Beckman DU-7500 as 
detailed in Method 2.   In parallel, a second set of aliquots from working enzyme solution 
that had been exposed to the same amount of solvent as used to dilute the inhibitor in the 
first sample were diluted with PBS 7.6 100 fold and their residual enzyme activity and 
served as a control for the reaction (A). 
The rate constant for spontaneous reactivation, k3spon, was calculated from the 
linear portion of the graph using the following equation (Clothier 1981; Berkman 1993): 
 
ln(100 / %inhibition) = k3t (7.5) 
 
where: 
  % inhibition = (A - At)/(A - A0) x 100. 
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Enzyme activity was assayed periodically to determine the total percentage of 
reactivation of enzyme activity after 60 min.  Total percentage of reactivation was 
calculated by using the following equation:  
  % reactivation = 100 - (% inhibition at 60 min). 
 
Method 4: Determination of k3 (2-PAM), the rate constant of oxime-mediated 
reactivation. 
This procedure is identical to that described in Method 3 except that the buffer 
solution used to dilute the samples also contains 2-PAM (final concentration of 50 mM). 
The rate constant for oxime-mediated reactivation k3 (2-PAM) and the amount of total 
percentage of reactivation was calculated using the procedures detailed in method 3. 
 
7.4.4 Methods for Reversible Inhibitors 
Reversible inhibitors bind to the enzyme by different mechanisms, so it is difficult 
to use a single kinetic parameter as a measure of inhibition potency for all types of 
reversible inhibitors.  Here, a general estimation by using IC50 and a detailed method to 
calculate Ki were utilized. 
 
Method 1: Concentration-dependent screening to determine IC50. 
This procedure is identical to that described in concentration-dependent method 
for irreversible OP inhibitors (Method 1 in 7.4.3).  Six cuvettes containing 480 µL of 
DTNB solution (1.32 mM DTNB, 59 mM NaHCO3, PBS pH 7.6) 150 µL of working 
solution of AChE, and 1340 µL of PBS (pH 7.6) were placed in a Beckman DU-7500 
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diode-array spectrophotometer and maintained at 20 ºC.  The first cuvette treated with 10 
µL of the solvent to dilute the inhibitors served as the control (Ano); the other 5 cuvettes 
were treated with 10 µL of five gradient inhibitor concentrations (Ai).  All six 
experiments were incubated for same period of time, 6 mins.  The remaining enzyme 
activity (v) was determined by adding 20 µL aliquots of the ATCh-I solutions to the 
cuvette and the rate of ATCh-I hydrolysis was monitored at 412 nm over a period of 10 
min (22 sec intervals).  The final concentrations of the reactants during enzyme assay 
were: 0.33 mM DTNB, 0.59 mM ATCh-I, and 0.58 mM NaHCO3.  In order to get a good 
estimation of IC50, the inhibitor concentration range was chosen to ensure the AChE 
inactivation from 20% to 80%.  
The remaining enzyme activity (v) was determined for five solutions containing 
different inhibitor concentrations.   
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where: 
 Ano is the activity of the uninhibited enzyme without adding the inhibitor, 
 Ai is the activity of the uninhibited enzyme following addition of a specific 
concentration of the inhibitor ([i]).  
Plotting remaining activity v vs. log[i] in Kaleidagraph 3.6 (Synergy Software, 
Reading, PA), IC50 can be determined by curve fitting using the following equation: 
 
Y = F (M0; 1 - M1 * (M0/(M2 + M0)); M1 = 1; M2 = 50) (7.7) 
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in which IC50 is determined as the M2 value. 
 
Method 2: Concentration-dependent pharmacological analysis of Ki. 
Six cuvettes containing 480 µL of DTNB solution (1.32 mM DTNB, 59 mM 
NaHCO3, PBS pH 7.6) 150 µL of working solution of AChE, 10 µL inhibitor, and 1340 
µL of PBS (pH 7.6) were placed in a Beckman DU-7500 diode-array spectrophotometer 
and maintained at 20 ºC.  After 10 mins incubation, 20 µL of six gradient concentrations 
of the ATCh-I solutions ([S]) was added and the substrate hydrolysis (A) was monitored 
at 412 nm over a period of 10 min (22 sec intervals). 
According to Michaelis–Menten equation (Henri, 1903): 
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A linear relationship was observed by plotting 1/A vs. 1/[S] (Lineweaver, 1934).  All 
other parameters are constants when inhibitor concentration is specified. 
The above experiment was repeated five times with five inhibitor concentrations, 
including one with no inhibitor ([i] = 0).  All five equations were plotted on the same 
graph to determine the mechanism of inhibitor’s inactivation. 
The competitive inhibition constant Ki is determined by secondary plot of the 
slope versus the inhibitor concentration and the resulting x axis intercept represents -Ki of 
the inhibitor.  The noncompetitive inhibition constant -Ki’ is determined by secondary 
plot of the intercept versus the inhibitor concentration and the resulting x axis intercept 
represents Ki’. 
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7.4.5 Data Analysis 
Experiments were repeated at least 3 times for every single inhibitor to acquire 
duplicate data sets, and only plots with R2 > 0.95 were accepted to ensure the accuracy of 
the data.   
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7.5 Molecular Modeling 
 
In order to elucidate the configuration of protein-ligand complex and explain the 
kinetic analysis data, the OP compounds synthesized as inhibitors have been docked into 
the active gorge of rMAChE, followed by the comparison of the results. 
Organophosphorus inhibitors can chemically react with Ser203 of AChE.  There 
are three main steps in this binding process: 1) The ligand (OP inhibitor) gets into the 
gorge of AChE and the phosphorus on the ligand is placed close to Ser203 so that the 
distance between phosphorus and Ser203 allows a chemical reaction to happen.  2) The 
chemical reaction takes place. The conformation of the ligand and protein change at the 
same time to assist the reaction.  3) The ligand-protein complex is stabilized by 
conformational changes, followed by aging, reactivation or any other post-inhibitory 
processes.  The second and third steps are too complicated to simulate in modeling 
program, thus the first step is the focus of this study.  How close the ligand can reach the 
active site or how well the chemical bond can be formed is visualized by docking the 
ligand into the protein.      
FlexX was chosen as the docking program because it offers specification of the 
active site and customization of any kind of constraint between the ligand and protein, 
which satisfied the requirement of OP-AChE interaction.  
 
7.5.1 Structure Preparation 
 According to the FlexX requirement, structures of reference ligand, ligand, and 
protein were prepared before docking.   
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1) Protein file preparation 
Crystal structures of various sources of AChE are available in the RCSB Protein  
Data Bank (PDB) (http://www.rcsb.org).  Recombinant mouse AChE (1maa, resolution 
2.90 Å) (Fig 7.30) (Bourne, 1999), used in kinetic analysis, was chosen for simulation. 
 
 
Figure 7.30. Structure of 1maa A) tetramer and B) monomer (ser203 colored in green). 
 
Monomer AChE structure file (Fig 7.28.B) was created by extracting one chain 
from 1maa as the original 1maa PDB file contains a tetramer.  Serine 203, the reaction 
site of the gorge, was colored in green and shown as spheres.  
  
2) Ligand file preparation 
The structure of ligand inhibitor, for example, dansyl-linked fluorophosphonate 
(6a), was first constructed in SYBYL 7.0 (Fig 7.31).  Then atom and bond types were 
carefully checked, and formal charges were properly assigned (FlexX only reads formal 
charges) to the ligand.  
A) B) 
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Figure 7.31. Structure of dansyl-linked fluorophosphonate (6a) in SYBYL. 
 
After making sure that the ligand was defined appropriately, hydrogen atoms were 
added to the ligand and the whole structure was minimized energy-wise.  After 1000 
minimizations, the structure of ligand was optimized (Fig 7.32) and saved as a ligand 
file (.mol2 file).  In this optimized structure, the distance between phosphorus and 
carbon (attached with dimethylamino group) is 14.4 Å.  
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Figure 7.32. Structure of dansyl-linked fluorophosphonate (6a) after energy 
minimization. 
 
3) Reference ligand file 
Inserting the ligand file into protein space can be achieved by either “JOINing” 
the ligand file into the protein file, or “MERGEing” the ligand file and protein file 
together.  “JOINing” was used in this study by creating a bond between the phosphorus 
 235 
on the ligand and the hydroxyl oxygen on Ser203 of the active site.  By this way, the 
ligand molecule was dragged into the active site of the protein.  
Torsion angles of the ligand structure were adjusted to make the ligand fit for the 
gorge best.  Also, minimizing the residues in the sphere centered at the ligand with a 
certain radius (including the ligand) provided a most favorable conformation of ligand-
protein complex without significantly changing the protein.  After adjustments of torsions 
and minimization of substructure, new PDB file containing both reference ligand and 
protein was saved as a reference file (pdb file) (Fig 7.33).   
 
 
Figure 7.33.  Reference file of dansyl-linked fluorophosphonate (compound 6a): The 
reference ligand lying along the gorge colored in red, and Ser203 colored in green 
spheres. The distance between phosphorus on the ligand and hydroxyl oxygen on Ser203 
is 1.6 Å. 
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After extracting the reference ligand file from the reference file, the ligand 
structure was checked again by “FIXing SYBYL atom types in ligand” because the 
molecule information might be misrepresented when it was transferred from a pdb file.  
The reference file was used to define the active site and compare with the docking results.   
 
7.5.2 Docking with FlexX 
 Docking a single ligand with FlexX and optional FlexX-Pharm requires finishing 
following steps: 
1) Creating FlexX Receptor Definition File (RDF) 
The RDF contains the information about the protein, its amino acids, the 
definition of the active site, and the specific torsion angles.   
 First, the protein structure was loaded.  By default, FlexX ignores all HETATM 
records in the PDB file.  The included HETATM (reference ligand) was only for defining 
the active site.  The active site was defined as a sphere containing all residues of protein 
within 8.5 Å around HETATM (ligand), including Ser203.  It has been shown that all 
residues along the gorge have been selected as the active site with this radius.  The RDF 
was also customized by changing the torsion angle of Ser203 on AChE from 180° to 0.0°, 
thus the nucleophilic oxygen on Ser203 was exposed to the ligand. 
 
2) Creating Constraint Description File (CDF) 
The CDF consists of the FlexX-Pharm interaction, spatial and partial 
pharmacophore constraints.  In this study of docking OP inhibitors, a spatial constraint is 
preferred to define the distance between Ser203-OH to OP-phosphorus where a chemical 
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reaction can occur.  For dansyl-linked fluorophosphonate (6a), the distance between the 
hydroxyl group on Ser203 and the phosphorus atom of OP was constrained at less than 
2.5 Å and this constraint was set to be “required” (Fig 7.34). 
 
 
 
Figure 7.34. CDF of dansyl-linked fluorophosphonate (6a). 
 
3) Reading in ligand file and reference ligand file 
The ligand file and reference ligand file previously created were opened. 
 
4) Other options 
CSscore calculation was used, so that we would have additional scoring functions 
to evaluate the interaction between the ligand and the receptor. 
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FlexX works with formal charges rather than partial atomic charges, thus  
 “Formal charges” was set to be “Assign”. 
 
 
5) Running FlexX 
 After running FlexX, only solutions with RMS < 1.5 were generated.  Each 
solution contains various scoring information and some important factors used to 
evaluate the solutions are listed below (Tripos Inc., 2004): 
• Rank = ranking of the conformation by decreasing FlexX total score 
• Total Score = the total FlexX docking score 
• Match Score = contribution of the matched interacting groups 
• Lipo Score = contribution of the lipophilic contact area 
• Ambig Score = contribution of the lipophilic-hydrophilic contact area 
• Clash Score = contribution of the clash penalty (a bump check) 
• Rot Score = ligand rotational entropy score 
• RMS = the RMS difference of coordinates against the reference 
structure or against the highest ranking structure if the reference is 
omitted 
• Similarity = a measure of similarity between solution coordinates and 
reference coordinates. If there are no reference coordinates, all entries of 
this column are -1.0. 
• CSCORE = the consensus score computed from these additional and the FlexX 
scoring functions. 
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For dansyl-linked fluorophosphonate (6a), the docking solution with highest score 
is illustrated in Figure 7.35. 
 
 
Figure 7.35. Best docking solution of dansyl-linked fluorophosphonate (6a). 
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7.6 Preparation of Meta-inhibitor Coupled Resin 
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Meta-trimethylaminophenyl amine (meta-inhibitor, 26) (Bourne, 1999).  N,N-
Dimethyl-1,3-phenylenediamine dihydrochloride (10.00 g, 47.80 mmol) was dissolved in 
acetic anhydride (45 mL).  Seven drops of sulfuric acid (H2SO4) was added and the 
solution mixture was brought to reflux with stirring (around 75 ºC).  After 30 min 
refluxing, the reaction was cooled to rt and water (184 mL) was added very slowly.  The 
entire solution was treated with 5N NaOH (1380 mL) and cooled overnight at 4 ºC to 
afford brownish crystals (7.90 g, 93%).  The crystals were collected and dissolved in 
acetone (40 mL), methyl iodide (3.30 mL) was added with stirring.  The reaction was 
refluxed for 30 min and a precipitate was formed and collected.  The filtrate was refluxed 
for one more hour with adding more methyl iodide (2.20 mL).  Precipitates were 
combined and rinsed with cold acetone (40 mL) to afford a beige powder.  The beige 
powder was dissolved in ethanol (35 mL) and hydrochloric acid (35 mL, 12 N) was 
added.  The reaction was stirred and refluxed for 2 h until the deprotection process was 
complete.  Acetone (600 mL) was added after the solution was cooled to rt to form a 
precipitate (4.82 g, 20% yield).  This meta-inhibitor was shielded from light. 
 
 241 
1H NMR (CDCl3): δ 3.67 (s, 9 H), 7.60 (dd, J = 8.0, 2.3 Hz, 1 H), 7.77 (t, J = 8.5 
Hz, 1 H), 7.85 (t, J = 2.3 Hz, 1 H), 7.93 (dd, J = 8.8, 3.0 Hz, 1 H). 
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Figure 7.36. 1H NMR spectrum (D2O) of meta-trimethylaminophenyl amine (meta-
inhibitor, 26).
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Meta-inhibitor coupled resin (27) (Bourne, 1999).   Sepharose resin (CL-4B, 
100 mL) was activated by cyanogen bromide (13.00 g) and NaOH (5 N) was used to 
maintain pH11.  3,3’-Iminobispropylamine (4.30 mL) was added to the activated resin 
and the mixture was stirred at 0 ºC overnight.  Succinic anhydride (10.00 g) was added 
and NaOH (5 N) was used to maintain pH at 6.  The coupling reaction was complete after 
stirring overnight at 0 ºC.  Another portion of 3,3’-iminobispropylamine (18.00 mL) was 
added to the resin, followed by the slow addition of 1-cyclohexyl-3-(2-morpholino-
ethyl)carbodiimide metho-p-toluene sulfonate (7.00 g). The pH was maintained at 5 using 
HCl (12 N) and the resin solution was kept at 0 ºC overnight.  One more portion of 
succinic anhydride (8.00 g) was added to the resin while maintaining the pH at 6 and the 
solution was stirred overnight.  Meta-inhibitor (compound 26, 2.00 g) was added, 
followed with 1-cyclohexyl-3-(2-morpholino-ethyl)carbodiimide metho-p-toluene 
sulfonate (7.00 g).  The pH was maintained at 5 before stirring overnight at 0 ºC.  The 
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resin coupled with the meta-inhibitor was assayed with wild type AChE to ensure the 
activity. 
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